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Historically, relatively little regulation has been in place to safeguard the health and 
well-being of related HPC donors (RDs), and retrospective studies have suggested an 
increased incidence of adverse events in comparison to unrelated donors. Although in 
recent years, FACT-JACIE Standards have introduced specific requirements aiming to 
address this gap, accreditation is not mandatory in many countries, and the influence of 
such changes has never been evaluated.  
This thesis provides insight into current procedures for managing RDs in transplant 
centres internationally, examines the impact of regulatory guidance to date, and 
explores potential pathways to improvement.  
Studies in this thesis provide a detailed analysis of RD care pathways in the USA and 
Europe, and I am able to clearly demonstrate the potential for regulation to drive 
change in this field. Improvements are shown over time in aspects of care that have 
been addressed by regulatory standards, and management of RDs in accredited 
centres is shown to be more consistent with accepted best practice than that in non-
accredited centres. These studies also reveal heterogeneity in donor care at each 
stage of the pathway with the result that RDs who would be deemed suitable by some 
transplant centres would be deferred by others.  
In an effort to align care standards for RDs, I assessed the feasibility of alternative care 
pathways and showed considerable logistical and financial difficulties for care models 
where the entire RD pathway is managed outside the transplant centre setting. 
However I was able to establish a model of RD follow-up by an unrelated donor 
registry, which was evaluated through a successful pilot study.  
After I demonstrated enthusiasm for clear guidelines and medical criteria in related 
donor care, I led the development of national RD care guidelines and including an 
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Adverse event Any unintended or unfavorable sign, symptom, abnormality, or 
condition temporally associated with an intervention that may or 
may not have a causal relationship with the intervention, 
medical treatment, or procedure. An adverse reaction is a type 
of adverse event.  
Adverse reaction A noxious and unintended response suspected or demonstrated 
to be caused by the collection or infusion of a cellular therapy 
product or by the product itself.  
Anthony Nolan A UK charity that is the largest unrelated HPC donor registry in 
the UK, and carries out research in the field of HPC 
transplantation.   
Apheresis A procedure using a cell separator to separate the blood of a 
donor into its component parts, the desired component is 
removed, and the remaining components are returned to the 
donor. 
BM  Bone marrow 
BSBMT The British Society of Blood and Marrow Transplantation. 
CD34 A cell surface glycoprotein, expressed by 1-2% of normal bone 
marrow mononuclear cells, that is defined by a specific 
monoclonal antibody (anti-CD34) using the standardised cluster 






This organisation is a research collaboration between the 
National Marrow Donor Program and the Medical College of 
Wisconsin that facilitates observational and interventional 
research in the field of blood and marrow transplantation.  
Collection centre A facility affiliated with an unrelated donor registry, equipped to 
carry out collection of haematopoietic progenitor cells, In most 
cases, the same centre will be responsible for medical 
assessment of donors to determine suitability to donate.  
Conditioning The administration of chemotherapy, radiotherapy or 
immunotherapy to modulate the recipient haematopoietic 
system prior to haematopoietic progenitor cell infusion to allow 
engraftment +/- to control disease in the recipient.  
Cord blood unit Cord blood, which is rich in HPCs can be collected from 
placental and umbilical cord blood vessels after the umbilical 
cord has been clamped. Cord blood units are then 





Donor A person who is the source of cells organs or tissue for a 
transplant or transfusion of a cellular therapy product. For the 
purpose of this thesis, a donor is an individual providing 
haematopoietic progenitor cells or lymphocytes for allogeneic 
transplantation.  
Donor advocate An individual distinct from the recipient’s main physician whose 
obligation is to protect the interests, well-being, and safety of the 
donor. The donor advocate may help the donor to understand 
the procedures, and the potential risks and benefits of donation. 
Donor lymphocyte 
infusion 
The process of giving lymphocytes, to a recipient who has 
already received an allogeneic hematopoietic progenitor cell 
transplant from the same donor. Typical indications for DLI 
include correction of mixed chimerism, or treatment/prevention 
of relapse. Lymphocytes may be stored from the original 
donation, or collected during a subsequent apheresis procedure.  
EBMT The European Group for Blood and Marrow Transplantation. 
Europdonor The unrelated HPC donor registry in the Netherlands.  




An organisation founded by the ISCT and the American Society 
of Blood and Marrow Transplantation (ASBMT) to provide 
inspection and accreditation in the field of cellular therapy. 
FACT produces international standards in the field, in 




A haematopoietic cytokine glycoprotein which regulates 
production, differentiation and functional activation of 
neutrophils. GCSF can be administered at higher 
pharmacological doses to stimulate production of HPCs and 
their subsequent release into the circulation.  
Graft versus host 
disease (GvHD) 
A reaction that occurs when cells from the transplanted donor 
immune system recognise the genetically disparate host tissues 




A multipotent cell capable of self-renewal and of differentiation 
into any of the hematopoietic lineages.  
 
Haploidentical donor A related donor who shares a single HLA haplotype with the 
intended recipient.  
Haplo-identical 
donor 
An HPC donor who matches the intended recipient at a single 
haplotype. Since haplotypes are inherited in a mendelian 
fashion, individuals will inherit one haplotype from each of their 
parents. Thus any parents or offspring of an individual will be 
potential haploidentical donors, and any siblings have a 50% 
chance of being haploidentical.  
HLA The system that encodes the cell surface proteins that are 
responsible for recognition of ‘self’.  
HPC mobilisation The process of administering GCSF (or an alternative 
mobilisation agent) to stimulate production of excess HPCs and 




HPC transplantation Haematopoietic progenitor cell transplantation, which comprises 
transplantation of the recipients own HPCs (autograft) or donor 
HPCs (allograft). Allogeneic transplantation includes the use of 
an HLA matched or mismatched family donor, a volunteer 
unrelated donor or an umbilical cord blood unit 
Human Tissue 
Authority (HTA) 
The competent authority responsible for regulation of human 
cells, tissues and organs in the UK.  




A collaborative global organisation which provides inspection-
based accreditation in HPC transplantation against established 
international standards. The standards are produced in 
collaboration with FACT.  
National Marrow 
Donor Program  
(NMDP) 
The largest unrelated HPC donor registry in the United States of 
America.  
Peripheral blood 
stem cells (PBSC) 
Haematopoietic progenitor cells that have been mobilised into 
the peripheral circulation and collected by apheresis.  
Related donor (RD) A tissue donor who is a blood relative of the transplant recipient. 
For the purposes of this thesis this term refers to a related HPC 
donor unless otherwise specified.   
Swiss Blood Stem 
Cells (SBSC) 
The unrelated donor registry in Switzerland.  
Transplant centre A unit (usually within a hospital) capable of carrying out 
haematopoietic stem cell transplantation. For the purposes of 
this thesis, this term refers to centres that carry out allogeneic 
HPC transplantation.  
HLA Typing The process of establishing the HLA phenotype, for the purpose 
of determining a match for allogeneic transplantation  
Verification Typing HLA typing performed on a second independent sample from a 
patient or donor to confirm identity and verify concordance with 
the initial HLA typing result.  
Volunteer Unrelated 
Donor 
A haematopoietic progenitor cell donor who is not related to the 
intended transplant recipient and has been identified through an 
unrelated donor registry.  
The World Marrow 
Donor Association 
(WMDA) 
A global organisation providing accreditation for unrelated donor 
registries and a forum for global collaboration to improve the 
care of haematopoietic progenitor cell donors.  
Worldwide Network 
for Blood & Marrow 
Transplantation 
(WBMT) 
An international organisation aiming to promote excellence in 
HPC donation, transplantation and cellular therapy. WBMT 
undertakes global activity surveys and develops consensus 






THESIS	  AIMS	  	  
PRIMARY AIMS 
To provide an in-depth analysis of current practice patterns in related donor care, in the 
UK and worldwide, focusing in particular on the influence of regulatory standards and 
consensus recommendations in the field. 
To explore alternative models of related donor care and test the acceptability to 
transplant teams, the logistics and financial impact, and the acceptability to donors.  
SECONDARY AIMS 
To investigate the influence of donor characteristics on the safety and efficacy of HPC 
donation in the related donor setting.  
To explore the experience of related donors and to determine areas in which current 
care pathways could be improved.  
To use the results of the studies in this thesis as a basis for development of national 









Chapter 1 provides an overview of current knowledge regarding related donor care 
pathways. The factors known to influence the safety of HPC donation are described 
and the legislation and guidance in this field is discussed.  
Chapter 2 describes the methodology behind the studies described in chapters 3,4 5, 6 
and 7. 
Chapter 3 details the findings of a study of 207 RDs who donated in a single centre 
between 2004 and 2013, and examines the impact of changes to regulatory guidance 
during this time period on the management of these donors. The influence of donor 
characteristics on the incidence of SARs is also described.  
Chapter 4 provides a detailed analysis of related donor care in UK transplant centres, 
with a survey that examines compliance with FACT-JACIE Standards and consensus 
recommendations. The views of UK transplant physicians regarding current care 
pathways and potential initiatives for improvement are also discussed.  
Chapter 5 builds on the findings of Chapter 4 describing a study that provides an 
international perspective on related donor care. Comparison with an earlier study in the 
USA allows interpretation of the influence of regulatory changes in that region, while in 
Europe differences between care in accredited and non-accredited centres are 
examined.  
Chapter 6 provides an analysis of the feasibility of alternative pathways of RD care, 
where aspects of the care pathway are provided by an organisation other than the 




Chapter 7 reports a retrospective study of 53 related donors, examining donor 
experience in the setting of a transplant centre where FACT-JACIE Standards and 
international recommendations have been adopted.  
Chapter 8 describes the development of national guidelines for related donor 
management, based on the results of the studies outlined in earlier chapters of this 
thesis.  
Chapter 9 summarises the findings of this thesis and describes some of challenges 
encountered, and future plans to expand on this work.  
  




CHAPTER	  1.	  	  BACKGROUND	  	  
1.1 INTRODUCTION 
1.1.1 HISTORY OF HAEMATOPOIETIC PROGENITOR CELL 
TRANSPLANTATION 
Allogeneic haematopoietic progenitor cell (HPC) transplants in humans were first 
successfully reported in 1957 by Thomas et al who treated leukaemic patients with 
lethal doses of chemotherapy or irradiation followed by an infusion of bone marrow 
(BM) (Thomas et al, 1957). At this early time, the only successful transplants were 
seen in recipients of BM from an identical twin donor, and were followed by a brief 
remission period before patients succumbed to their original disease (Copelan, 2006; 
Thomas et al, 1959). Subsequent discovery and characterisation of antibodies reacting 
with antigens on the cell surface of leukocytes led to the understanding of the 
importance of matching donors and recipients at specific HLA loci in HPC 
transplantation (Dausset, 1958). Development of early serological typing techniques in 
the 1960s enabled identification of matched sibling donor-recipient pairs, which 
resulted, for the first time, in prolonged successful engraftment and remission in 
patients receiving HCTs for aplastic anaemia and advanced leukaemia (Buckner et al, 
1970).  
The 1970s saw HPC transplantation become established as a treatment option for 
previously incurable patients with matched sibling donors, and rapidly led to efforts to 
increase knowledge around HLA, and to improve serological typing techniques. These 
efforts resulted in the first successful unrelated donor transplant in 1973, (Copelan, 
2006; O'Reilly et al, 1977), and to the set up of the first unrelated donor stem cell 
registries shortly afterwards (Cleaver, 1993).  
To meet the needs of the two thirds of  patients with such diseases who lack a matched 
sibling donor, unrelated donor registers have rapidly expanded, and there are now over 




25 million unrelated donors listed internationally (source www.bmdw.org, accessed 14th 
October 2015). Despite this,  there remain patients for whom an acceptable unrelated 
donor cannot be found, and thus over the last 20 years investigators have explored the  
the use of alternative donor stem cell sources.  Following sucessful results from HPC 
transplants using umbilical cord blood, cord blood banks were established worldwide. 
However, despite several advantages of this cell source, the use of cord blood has 
been limited by expense and relatively low HPC doses.  More recently, attention has 
turned to the use of mismatched related donors. Since HLA haplotypes are inherited in 
a medelian fashion, only one in four siblings will match both haplotypes,  but one in two 
will be haploidentical  (sharing a single haplotype), as will both an individual’s parents, 
and any offspring. Advances in outcomes for recipients of haplo-identical transplants 
have been greeted with much enthusiasm, and some countries have seen a rapid rise 
in utilisation of  this donor source.  
Figure 1.1 Trends in donor source for recipients of Allogeneic HPC transplant aged >20 years in 
the USA. CIBMTR summary slides (Pasquini & Zhu)  
 
While the above progress has changed the landscape of transplantation dramatically 
and has led to a continued rise in the number of patients receiving an allogeneic HPC 
transplant, a matched sibling remains the ideal donor for most patients. 




1.1.2 PATIENT ACCESS TO ALLOGENEIC HPC TRANSPLANTATION 
In addition to the increase in available donors, another major reason for the continued 
increase in patients undergoing allogeneic HPC transplantation lies in the development 
of reduced intensity transplant conditioning regimens. In the initial years of  HPC 
transplantation, it was believed that engraftment of a donor haematopoietic system 
could only occur if that of the  recipient had been completely ablated. Since 
myeloablation requires the use of very high doses of irradiation or chemotherapy 
conditioning prior to stem cell infusion, the associated toxicity precluded this treatment 
in older or less fit patients. The subsequent discovery that engraftment was possible, 
providing sufficient immunosuppressive therapy was administered without the need for 
complete myeloablation, led to development of less toxic conditioning regimens, 
opening up transplant as an option for older patients and those with comorbidities. 
Accordingly, many transplant centres will now accept patients into their early 70s for 
this procedure, providing they are otherwise fit, which has resulted in a parallel 
increase in the age of HLA-matched siblings undergoing donation. 
1.1.3 PRINCIPLES OF HPC TRANSPLANTATION  
For patients receiving an allogeneic HPC transplant for non-malignant haematological 
disease the purpose of this treatment is to replace a non-functioning haematopoietic 
system with a healthy system. In these patients, the  aim of the pre-transplant 
conditioning is purely to allow sustained engraftment of the donor stem cells, and, since 
there is no advantage to a genetic disparity between the donor and recipient, the HLA 
match should ideally be as close as possible.  
For patients receiving HPC transplantation for malignant disease, this treatment serves 
two functions. Firstly, it allows delivery of very high intensity anti-tumour 
chemo/radiotherapy, which would be lethal if not followed by a stem cell infusion. 
Secondly, the engraftment of a genetically disparate donor haematopoietic system 
confers a graft-versus-tumour effect which is crucial in maintaining disease remission in 




these high-risk patients.  For patients receiving reduced intensity conditioned 
transplants, this latter effect provides the majority of the treatment efficacy.   
When it became apparent in the early 1990s that the graft-versus-tumour effect is 
mediated by T cells, researchers investigated methods of enhancing this effect using 
therapeutic lymphocyte infusions. These were initially used as treatment for patients 
with relapsed disease, and more recently, for patients where evidence of recipient 
haematopoiesis remains after reduced intensity transplants. Donor lymphocytes 
infusions are now administered to almost 10% of patients receiving reduced intensity 
transplants, and consequently the number of donors undergoing more than one 
donation procedure is increasing.   
1.1.4 COMPLICATIONS OF HPC TRANSPLANTATION  
Despite the multitude of advances in transplantation over the last 30 years, the long-
term overall survival of adults transplanted for malignancy is still as low as 
approximately 50%. Outcomes in children and patients with non-malignant disease are 
somewhat better, but all patients remain at risk of a number of severe complications 
with the potential for long-term morbidity.  
1.1.4.1 Disease relapse  
Relapse of primary disease remains the major cause of treatment failure.  In selected 
patients, further treatment aiming to enhance the graft-versus-tumour effect can be 
successfully initiated.  
1.1.4.2 Graft-versus-host-disease  
Graft-versus-host disease (GvHD) occurs when donor-derived T cells initiate immune 
responses against unshared recipient tissue antigens. The risk of GvHD is thus 
dependent on genetic disparity between the donor and recipient, and is greatest in 




recipients of HLA mismatched transplants. GvHD can be classified according to 
National Institute of Health (NIH) criteria depending on distinct clinical features and the 
timing of onset. In brief, GvHD is a multisystem disease which can occur at any time 
post transplant and has a clinical picture, ranging from mild symptoms requiring no 
treatment, to severe disease requiring multiple immunosuppressive agents and causing 
severe morbidity or mortality.   
1.1.4.3 Infectious complications  
All recipients of HPC transplants will develop profound immune suppression as a result 
of the conditioning treatment and GvHD prophylaxis. Immune reconstitution occurs 
over a period of a year or more and is further delayed in patients with chronic GvHD. 
During this time patients remain at risk of infection from a wide range of organisms 
including bacteria, fungi, and viruses.  
1.1.4.4 Organ toxicity and late effects  
Many patients will have already undergone intensive treatment for their primary 
disease before reaching the point of HPC transplantation. The cumulative effects of this 
previous treatment, the pre-transplant conditioning and post-transplant complications 
can lead to long-term organ dysfunction and also confers an increased risk of 
secondary malignancies.  
1.1.5 FACTORS KNOWN TO INFLUENCE TRANSPLANT OUTCOME  
The incidence of the complications described above is, to an extent, dependent on 
several known patient and donor factors. 
1.1.5.1 Patient factors 
1.1.5.1.1 Disease 
The nature of the primary disease and, for malignant disease, its inherent susceptibility 
to the graft-versus-tumour effect, is arguably the most important factor in determining 




transplant outcome. Several groups have been able to a show stepwise reduction in 
overall survival following allogeneic transplantation in recipients with good risk, 
intermediate risk and poor risk markers of disease (Cornelissen et al, 2007; Koreth et 
al, 2009)  
1.1.5.1.2 Comorbidities 
Although the advent of reduced intensity conditioning has expanded the pool of 
patients that can undergo this therapy, outcomes for patients with pre-existing medical 
issues, or organ dysfunction acquired during primary treatment for their disease, are 
nevertheless inferior to those of fitter patients. Research in this area has led to 
development of a specific co-morbidity index for patients undergoing HPC 
transplantation to aid clinician decision-making regarding the relative risks and benefits 
of this procedure and to allow adjustment for this risk factor in transplant trials.  
1.1.5.2 Donor factors 
1.1.5.2.1 HLA matching 
HLA matching is the most important determinant of transplant outcome with higher 
rates of GvHD seen in UD versus matched sibling transplant and in mismatched 
(<10/10) versus matched (10/10) unrelated donor transplants (Shaw, 2008; Lee et al, 
2007).  
1.1.5.2.2 Cytomegalovirus (CMV) 
CMV serostatus is the second most important donor factor, with recipients of a graft 
from a CMV matched donor demonstrating significantly more favourable outcomes 
than those who are CMV mismatched (Ljungman et al, 2014).  
1.1.5.2.3 Donor age 
In the unrelated donor context a survival advantage has been shown for recipients of 
HPC transplants from younger donors (<30 years)  (Bertani et al, 2014; Kollman et al, 




2001). This finding has led to debate regarding the optimal donor for a patient with an 
elderly HLA matched sibling; whether the sibling or a well matched young unrelated 
donor should be used (Ringdén et al, 2014). 
1.2 COLLECTION OF HPCS AND THE RELATED DONOR 
PATHWAY 
1.2.1 COLLECTION OF HPCS  
1.2.1.1 Bone marrow 
As described, the earliest stem cell transplants were all conducted using BM as the cell 
source.  The procedure for harvesting BM involves extraction of marrow directly from 
bilateral posterior iliac crests under general anaesthetic. To avoid haemodilution of the 
product, operators must make multiple small volume aspirations, re-siting the harvest 
needle between each one (Bacigalupo et al, 1992; Batinić et al, 1990).   Some centres 
perform a midway cell count to ensure marrow quality and to guide the required harvest 
volume (Wang et al, 2011), however generally no more than 20mls/kg donor weight is 
harvested, to prevent anaemia. It is usually possible to complete this procedure within 
30-45 minutes and, depending on centre practice, BM donors are either discharged the 
same or the following day. The harvested marrow is heparinised and filtered before 
being infused to the patient. Achievement of a harvest containing a high concentration 
of HPCs requires considerable operator expertise and there are concerns that centre 
experience is diminishing (Remberger et al, 2015) over time.  
1.2.1.2 Peripheral blood stem cells 
While BM is rich in the HPCs required for transplantation, these cells are present in low 
concentration in the peripheral blood. In order to collect HPCs from the peripheral blood 
a two-stage process is necessary. Firstly HPCs are ‘mobilised’ using granulocyte 
colony stimulating factor (GCSF) injections for 4-5 days, and then collected from the 
peripheral blood using leukapheresis.  This procedure entails connecting the donor to a 




cell separator using bilateral peripheral cannulae, or a central venous catheter (CVC) 
for the small minority with inadequate venous access. Blood from the donor is 
circulated through the apheresis circuit, and mononuclear cells are removed by 
centrifugation, and the remaining blood components are returned to the donor. The 
apheresis circuit is primed using ACD anticoagulant. This procedure typically takes 
approximately 4 hours. In 80-90% of healthy adult donors a single collection is 
necessary to collect adequate HPCs for an allogeneic transplant while the other 10-
20% of donors will return the following day for a second collection.  
1.2.2 MOBILISATION OF HPCS 
GCSF is a haematopoietic cytokine glycoprotein, endogenously produced by 
monocytes, fibroblasts, and endothelial cells. Under normal circumstances GCSF 
regulates the production, differentiation, and functional activation of neutrophils. In the 
early 1990s two chemically different recombinant GCSFs lenograstim and filgrastim 
were launched, and are now routinely used in treatment of a variety of haematological 
conditions. When given at high pharmacological doses, GCSF stimulates the 
development of primitive HPCs, which are then released into the peripheral blood 
(Pamphilon et al., 2008).  The summary of product characteristics of lenograstim and 
filgrastim recommend doses of 10mcg/kg/day for mobilisation of allogeneic HPC 
donors for 4-5 days with leukapheresis on the fifth day.  Once daily and split twice daily 
doses are both common administration schedules, although there is no convincing 
evidence of an improvement in yield using 5mcg/12hours versus 10mcg/24hours 
(Anderlini et al, 2000; Martino et al, 2015). 
More recently, other mobilisation agents have been developed.  Three biosimilar 
GCSFs are now approved for all the registered indications of their originator filgrastim, 
including stem cell mobilisation. Plerixafor, a CXCR4 antagonist, was developed to 
enhance HPC mobilisation in patients who failed autologous HPC collection using 
standard mobilisation procedures. Neither biosimilar GCSF nor plerixafor have been 
extensively studied in healthy donors and are not used by unrelated donor registries.  




1.2.3 COLLECTION OF DONOR LYMPHOCYTES 
Collection of lymphocytes for therapeutic T cell infusion is also performed using the 
leukapheresis procedure. Since adequate numbers of lymphocytes are present in the 
peripheral blood, no prior mobilisation is necessary and a single apheresis procedure 
suffices for multiple doses of therapeutic T cells.  
1.2.4 TRENDS IN THE SOURCE OF HPCS 
Over the last twenty years there has been a significant shift from BM to PBSC as the 
requested cell source in both related and unrelated donors (Passweg et al, 2013). 
Studies have consistently demonstrated faster hematopoietic recovery in recipients of 
PBSC (Anasetti et al, 2012; Bensinger et al, 2001) as well as lower rates of graft failure 
(Blaise et al, 2000; Pavletic et al, 1997; Champlin et al, 2000) due to an increased 
number of haematopoietic stem cells infused. HPC source also influences other 
transplant outcomes, with evidence of a reduced incidence of relapse in patients with 
advanced haematological malignancies using PBSC (Champlin et al, 2000). However, 
this occurs at the expense of higher rates of chronic GvHD than recipients of BM. Other 
groups have shown more favourable outcomes, including a survival advantage, in 
paediatric patients who receive BM rather than PBSC (Eapen et al, 2004). These 
effects have been attributed to a difference in product cell composition between the two 
sources, with PBSC containing a ten times greater number of T cells, monocytes and 
NK cells (Ottinger et al, 1996) than BM. For these reasons the preferred cell source 








Figure 1.2 Changes in source of HPCs between eras. CIBMTR summary slides (Pasquini	  &	  
Zhu) 
 
1.2.5 FACTORS INFLUENCING THE STEM CELL YIELD FROM HEALTHY 
DONORS  
The total nucleated cell count (TNC) has traditionally been used to calculate the yield of 
bone marrow grafts and is still used for this purpose today. The TNC is divided by the 
patient’s weight to give a TNC dose received per kilogram. Doses of 3-5x108 TNC/kg 
recipient weight are generally considered optimal, while cell doses of <2x108 are widely 
considered to be inadequate. Higher cell doses have been associated with faster 
neutrophil engraftment and improved graft function, as well as improved survival in 
some studies (Bittencourt et al, 2002; Spitzer et al, 1994; Barrett et al, 2000). The 










Table 1.1 Factors known to influence BM harvest yield 
Factors Effect References 
Donor factors   
Donor weight Increase TNC yield and 
increased quality of harvest 
in some studies  
(Kao et al, 2009; Wang et al, 
2011)  
Donor BMI Higher BMI associated with 
higher CD34 yield 
(Favre et al, 2003) 
Procedure factors   
Aspiration techniques Multiple small aspirations 
(<5mls) are superior to 
larger volume aspirations 
(Spitzer et al, 1994; 
Bacigalupo et al, 1992; 
Batinić et al, 1990) 
BM stimulation with 
GCSF 
Improves TNC yield per kg 
donor weight 
 (Ji et al, 2002) 
Operator expertise Difference in quality 
between collection centres. 
Difference in quality 
between operators 
(Remberger et al, 2015)  
Harvest volume Inversely associated with 
BM harvest quality 
(Wang et al, 2011) 
 
PBSC HPC calculations are always based on CD34+ cell dose. CD34 is a 
transmembrane glycoprotein that is expressed on undifferentiated haematopoietic 
progenitor cells but is lost as maturation occurs and therefore provides a robust 
measurement of the HPC content.  Determination of the CD34 cell dose is performed 
using immunophenotyping. Typically, 4x106/kg recipient weight is considered optimal, 









Table 1.2 Factors known to influence PBSC harvest yield 






Lower CD34 yield in some studies  (Martino et al, 2006; Billen 
et al, 2014; Fischer et al, 
2005; Wang et al, 2013) 
Donor 
weight 
Higher weight associated with higher 
yield 
(Ings et al, 2006; Billen et 
al, 2014) 
Donor BMI  Higher BMI associated with higher yield 
in some but not all studies 
(Favre et al, 2003) 
Donor age Lower CD34 yield in older donors (Martino et al, 2006; la 
Rubia et al, 2001; Lysák et 










No difference in the majority of studies 
providing the same total daily dose used. 
(Anderlini et al, 2000; 




Higher in vitro efficacy with lenograstim 
in early studies. Subsequent studies 
suggest equal efficacy. 
(Ings et al, 2006; Martino 
et al, 2006) 
 
1.3 THE PATHWAY OF DONOR CARE 
1.3.1 RELATED DONORS  
Potential related donors are always identified by their sick relatives, who put them in 
touch with the healthcare worker(s) responsible for arranging tissue typing within the 
transplant centre or referring hospital. Due to the fact that most countries do not have a 
central organisation accountable for related donor management, this work has 
traditionally been undertaken by the same transplant centre caring for their intended 
recipient, and often by the same medical professionals.  
 
After being identified as an HLA match, related donors undergo a formal donor medical 
evaluation, the aim of which is to identify any medical condition that might pose a risk 
to the donor during donation (medical suitability) and to identify any conditions that 




might pose a risk to their intended recipient (medical eligibility). Typically this evaluation 
occurs within a few weeks of the planned donation, with consent for the procedure 
taken at the same appointment. Since transplant teams in many centres are limited to a 
small number of physicians, this has historically led to a physician frequently being 
simultaneously responsible for the care of a RD and their intended recipient.      
 
RDs donate by apheresis or bone marrow at the transplant centre caring for their 
recipient and the harvested cells are infused fresh the day of or day following the 
donation.  
 
This donor pathway has developed independently in each transplant centre with 
protocols largely determined at a local level. As a result, little is known about the 
process each donor undergoes and how this varies between centres nationally and 
internationally. 
Figure 1.3 The related donor care pathway
 
1.3.2 UNRELATED DONORS  
Volunteer unrelated donors are recruited to donor registries through a variety of 
methods, including national blood donation programmes, university organisations, 
patient appeals, and specific campaigns to improve registry diversity. At the point of 
recruitment, all donors are provided with information about the stem cell donation 
process, and are required to complete a health questionnaire and to provide a saliva or 
blood sample for HLA typing.  
 
Identi(ication	  and	  HLA	  typing	   Donor	  evaluation	   Donation	  procedure	   Follow	  up	  (if	  performed)	  	  




Potential donors will then be contacted, often many years later, when they have been 
identified as a possible match for a specific patient. At this point further information is 
provided to the donor, a detailed health questionnaire is completed, and, if the donor is 
considered fit and willing to proceed, a blood sample is arranged for verification typing.  
Once finally selected by a transplant centre, the unrelated donor then undergoes a 
formal evaluation in an affiliated collection centre of the donor registry by an 
experienced physician using defined medical suitability and eligibility criteria.   
 
Donors who are deemed to be suitable undergo donation in the registry collection 
centre, and are subsequently followed up by the collection centre or registry.  Any 
requests from the transplant centre for subsequent donations are formally reviewed by 
the registry.  
 
At each stage of this process the donor is protected by anonymity, and procedures are 
in place to prevent coercion of the volunteer unrelated donor. 
 
Figure 1.4 The unrelated donor care pathway
 
 
1.3.3 STUDIES EXAMINING RD CARE PATHWAYS  
Although very few studies have specifically focused on procedures for RD care, three 
groups have drawn attention to differences between care pathways for related and 
unrelated donors. In particular these have concentrated on determining the degree of 
uniformity of care in the related donor context.  
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The first study investigating the pathway for management of RDs was conducted by the 
European Group for Blood and Marrow Transplantation (EBMT) Nurses Group/Late 
Effects working party (Clare et al, 2010). The study population consisted of 63 nurses, 
delegates at the 2005 EBMT annual meeting, who completed questionnaires regarding 
the counselling, consent and follow-up of RDs at their centres. Their results showed 
significant variation in several areas. They demonstrated variation in donor counselling 
procedures, with only 32% of centres stating that RDs were consented by a 
professional who was not involved in the care of their recipient, and also highlighted 
that the donor’s HLA results would be first disclosed to their recipient in 11% of centres. 
In 48% of centres donors were provided with national or international written 
information regarding the donation procedure, while in the remaining centres only 
locally produced information was used. This information was relayed by a variety of 
methods, including written and face-to face communication in 36%, and verbal 
information alone in 27% centres. The authors identified a donor follow-up programme 
in 60% of responding centres, however the study did not examine the extent of this 
follow-up.   
This study was useful in outlining the variation in procedures between centres, but had 
several limitations. Firstly, the survey population were self-selected, and were not a 
population who were necessarily best placed to answer questions about related donor 
care at their centre. Secondly, there was regional bias with 34% of respondents 
working in UK centres.  Thirdly, although the scope of the survey was broad, and 
encompassed several stages of the RD care pathway, these areas were not studied in 
depth.  
In 2007, a larger study of RD care examining US centre practice was conducted by the 
Donor Health and Safety Working Committee of the Center for International Blood and 
Marrow Transplant Research (CIBMTR) (O'Donnell et al, 2010). The authors invited all 
222 directors of US transplant programs to participate in a survey which largely 
focused on determining whether practices protected donors from the potential for 
conflict of interest. They received 98 evaluable responses and reported that in >70% 
centres, the same physician caring for the donor had either simultaneous responsibility 




for, or might be involved in the care of, the recipient, and that 5% of centres had no 
written criteria for related donors. This study drew attention to a major issue in the 
donor care pathway- the routine practice in many centres for donor and recipient care 
to overlap. As a direct result of this study, changes to FACT-JACIE standards were 
made, described in section 1.8. 
A third study examining the pathway of related donor care was published by an Italian 
group (Coluccia et al, 2012). The authors retrospectively analysed the notes of 500 
related donors undergoing PBSC collection in Italy between 2005 and 2009. They 
showed that the donor eligibility criteria, collections and follow-up were managed 
differently in each of the nine centres studied.  They found that in 4/9 centres donors 
and recipients were managed by the same physician, and that only 26% of donors 
underwent thorough screening according to Italian Bone Marrow Donor Registry 
standards. They also described unsuitable pre-apheresis peripheral blood parameters 
in 39% of the apheresis procedures. This study added to the evidence for routine 
overlap of donor and recipient care and also raised the issue that related donors do not 
undergo the stringent screening procedures of UDs to ensure suitability.  
1.4 THE SAFETY AND WELLBEING OF HPC DONORS  
1.4.1 COMMON SIDE EFFECTS OF DONATION  
Almost all BM and PBSC donors will report some side effects associated with donation. 
These side effects have been extremely well characterised in prospective studies of 
healthy unrelated donors.   
1.4.1.1 Bone marrow 
Post-procedure collection site pain is the most commonly reported event in BM donors, 
and is experienced by over 80% of donors (Favre et al, 2003; Bredeson et al, 2004; 
Pulsipher et al, 2010). Fatigue is the second most common symptom in most studies 
and is reported by 50-80% donors. Approximately one third report throat pain related to 
anaesthesia and less commonly other post-anaethesia symptoms such as headache 




(Miller et al, 2008).  Although over 50% of BM donors will have mild on-going side 
effects at one week post-donation, these subside quite rapidly, with >80% reporting full 
recovery at one month. A small percentage of donors (<1%) develop long-standing 
pain following bone marrow donation (Pulsipher et al, 2013; Nishimori et al, 2002).  
1.4.1.2 PBSC donation 
The common short-term side effects of GCSF can be divided into those caused by 
GCSF and those due to the apheresis procedure.  
The side effects of GCSF mobilisation are well documented in patients, unrelated and 
related stem cell donors. Bone pain is experienced by >90% of donors, which typically 
starts 24-48 hours following administration of GCSF and peaks on day five (the day of 
the first apheresis procedure). Over 50% of donors report this pain as mild and 
interventions other than simple analgesia are very rarely required (Miller et al, 2008; 
Hölig et al, 2009).  40-70% of donors experience fatigue at some point during 
mobilisation and collection, and myalgia and insomnia are both reported in 
approximately half of healthy donors. Less common symptoms include nausea and 
anorexia, which are reported by approximately a quarter of donors. In prospective 
studies using Common Terminology Criteria for Adverse Events (CTCAE) the majority 
of symptoms are reported as mild (grade 1) (Pulsipher et al, 2010; Hölig, 2013).  
The most common side effects of the apheresis procedure are symptomatic 
hypocalcaemia, hypovolaemia and bruising, or nerve injury related to venepuncture 
(Pulsipher et al, 2009). Following completion of the harvest procedure, the side effects 
experienced by PBSC donors tend to resolve quickly with only 10% of donors 
complaining of on-going symptoms at 1 week post-donation.  While the largest studies 
have been performed in unrelated donors, symptoms in related donors appear to be 
comparable (Rinaldi et al, 2012). 
 




1.4.1.3 Comparison of the PBSC and BM donation experience 
In studies comparing experience of the two donation routes, the main difference is 
timing, with PBSC donors experiencing peak discomfort on day 5 (the day of the first 
harvest) compared to 1-2 days after collection for BM donors. PBSC donors reported a 
median time to recovery of 1 week compared to a median time to recovery of 3 weeks 
for BM donors. Overall, the latter report more days of restricted activity due to 
pain/fatigue (Pulsipher et al, 2013; Favre et al, 2003; Bredeson et al, 2004; Siddiq et al, 
2009). 
1.4.2 SERIOUS ADVERSE REACTIONS  
Serious adverse reactions are defined as an unintended response, that is fatal, life 
threatening, disabling, incapacitating or which results in, or prolongs, hospitalisation or 
morbidity (FACT-JACIE, 2012). Due to the absence of mandatory adverse event 
reporting in related donors, the majority of evidence regarding rates of SARs is derived 
from studies in unrelated donors. 
1.4.2.1 SARs in BM donors 
The serious risks of bone marrow donation include bone and soft tissue trauma at the 
site of aspiration, risks of anaesthesia, and hypovolaemia or anaemia following large 
volume aspiration. Recent reviews by the NMDP examining the incidence of SARs in 
normal adult donors suggest that these occur in 1-2% cases (Miller et al, 2008; 
Pulsipher et al, 2014).  
1.4.2.2 SARs in PBSC donors 
Large prospective and retrospective studies estimate that SARs occur in 0.5-0.6% 
unrelated PBSC donors (Miller et al, 2008; Pulsipher et al, 2014; Halter et al, 2009). 
These include splenic rupture, cardiovascular complications, thrombotic events, 
anaphylaxis and events relating to CVC placement. GCSF may also unmask or 




exacerbate autoimmune conditions (Parkkali et al, 1996; Nasilowska-Adamska et al, 
2010). 
1.4.2.3 Fatal adverse events 
Fatalities in one bone marrow and four PBSC donors within 30 days of donation were 
described in a retrospective EBMT study of 36,317 family donations between 1993 and 
2005 (Halter et al, 2009). Causes included a pulmonary embolus, a subarachnoid 
haemorrhage in a donor on aspirin, and two deaths from cardiac arrests without further 
information. Additional fatalities reported have included a sickle crisis in a PBSC donor, 
and others due to respiratory or cardiac arrests (Horowitz & Confer, 2005). The above 
deaths exclusively occurred in related donors, and to date, one UD death has been 
reported to the WMDA, caused by a haemothorax secondary to traumatic subclavian 
line insertion. 
1.4.3 LONG TERM CONSEQUENCES OF DONATION 
Following theoretical concerns about short-term growth factor therapy leading to 
leukaemia in donors, several large studies have been performed comparing the 
incidence of malignancies in donors who have received GCSF with either bone marrow 
donors or age/sex matched populations.  These studies have reported a reassuring 
lack of evidence for an increased incidence of haematological, malignant or other 
diseases (Pulsipher et al, 2014; Shaw et al, 2015; la Rubia et al, 2008; Hölig et al, 
2009).  
1.4.4 QUANTIFYING THE RISK OF DONATION IN RDS 
Far fewer publications have investigated adverse events in related donors, than those 
examining unrelated donors, and those that have done so have used diverse criteria 
and have largely reported retrospectively. Existing data suggest that related donors 
have an increased risk of adverse events compared to unrelated donors; particularly 




striking is the fact that fatal adverse events have almost exclusively occurred in the 
related donor setting.  
Defining risk factors associated with adverse events in related donors is especially 
difficult, and the retrospective nature of most investigations has complicated 
assessment of the causal relationship between reported events and the donation 
procedure. 
1.5 THE PSYCHOLOGICAL ASPECTS OF DONATING TO A 
RELATIVE  
While few studies have specifically evaluated the physical adverse events associated 
with donation in the related donor context, even fewer have concentrated on 
psychological outcomes.  
Studies in unrelated donors generally report positive psychological reactions, with 
donors reporting satisfaction and a greater sense of self-worth as a result of donation, 
although donors who experienced more side effects derived less psychological benefit 
(Butterworth et al, 1993). 
While donation can also be a positive experience for related HPC donors, a significant 
proportion report some psychological difficulty with the donation process, particularly if 
their recipient dies or develops GvHD (Switzer et al, 1998; van Walraven et al, 2010a; 
Wolcott et al, 1986). One study in BM donors reported significantly higher scores on 
the Beck Depression Inventory (a self-reported measure of depression) in donors 
whose sibling died, compared to those whose siblings remained alive (Chang et al, 
1998). Others have described guilt, a feeling of responsibility and on-going distress or 
anxiety regarding the recipient’s health (Pillay et al, 2012). These negative 
psychological impacts of HPC donation may manifest years after donation (Switzer et 
al, 1998). 




Investigations have universally shown very low ambivalence to donation, reporting that 
donors described donation as a ‘natural choice’ or one that required very little 
consideration (Christopher, 2000; Pillay et al, 2012). Despite this, there are 
suggestions that relatives nonetheless experience anxiety about the donation 
procedure, as well as about the outcome for the recipient. One study demonstrated a 
significant reduction in high anxiety levels immediately following donation (Fortanier et 
al, 2002). 
The nature of the relationship with the transplant recipient appears to be an important 
factor in RD experience, with a better relationship resulting in fewer negative 
psychological sequelae (Labott & Pfammatter, 2014). Likewise, a more positive 
experience has been reported in the presence of good emotional support from family, 














Table 1.3 Studies examining the psychological consequences of donation. 
Study 
population 








reactions to stem 
cell donation 
Donors reported very little ambivalence about 
donating. A better relationship with the 
recipient resulted in fewer negative emotional 








The effects of 
bereavement on 
adult sibling bone 
marrow donors’ 
psychological well-
being and reactions 
to donation. 
High self-esteem and happiness in adult 
related donors pre-donation. Reduction in the 
feeling of having helped during the first year 
post-donation. Donors whose recipient had 
died ultimately reported higher self-esteem, 
happiness and satisfaction which authors 
suggested was due to continuing concern for 
medical issues of their sibling in those who 








anxiety and pain in 
sibling donors 
donation BM or 
PBSC 
Levels of anxiety before the collection 
procedure were fairly high in both groups of 
donors. Levels of anxiety fell immediately 
following donation suggesting the major 
anxiety was around the procedure itself. In 
both groups of donors, the great majority of 
donors felt, after having completed the 
collection procedure, that it had been an ‘easy’ 









marrow to a relative 
Deep personal satisfaction that they were able 
to donate, and little or no reluctance. Stressful 
aspects related to unanticipated pain and 













High self-esteem and high life satisfaction 
among BM donors whose recipient survived 
but 10-20% experienced some psychological 
difficulty. Reported a link between the donor’s 
psychological status and the recipient’s health, 
suggesting that negative changes in recipient 









impact of PBSC 
donation before, 
during and after 
donation, and to 
gain insight into 
donors’ 
experiences of the 




Low ambivalence pre-donation, 68% reported 
that the decision required little consideration. 
Pre-donation donors described joy at being a 
match, but anxiety about the donation and 
outcome. During the donation process, donors 
reported satisfaction at being able to help but 
anxiety regarding the outcome. Post-donation 
donors felt glad they had donated but 
described guilt, responsibility, decreased 
mood and ongoing distress and anxiety about 
the recipient’s health. 55% stated that they 
















more distress than 
UDs 
Related donors report significantly more acute 







Analyse how family 
PBSC donors cope 
when confronted 
with this particular 
risk context quality 
of life (pain and 
anxiety) before, 
during and after 
donation 
Donors felt responsible for the recipients’ state 
of health, more so among female than male 
donors. Donors tended to underestimate the 
risks which the authors reported was due to 
pressure exerted by the family and the 
physicians at the time when the choice of 








aged 9-28  
Psychological 
experiences of 
sibling stem cell 
donors 
Donors reported feeling concerned about 
donation and a need for more information 
about the process, outcomes and 
complications. They also reported guilt about 









parents with a dual 
role of donating and 
caring for their 
children 
All parents felt inadequately informed about the 
effects for themselves as a donor, and  felt 

















Sibling donors whose recipients had an 
unsuccessful outcome reported greater 
negative impacts and feelings of guilt, 
compared with those whose recipients had a 
successful outcome. Both groups reported that 
informed consent involved “no choice” and that 
psychological aspects of the procedure 
outweighed physical aspects.  
(MacLeo














in donor and non-
donor siblings 
Sibling  perceptions 
of BM transplant 
process 
Self-report measures indicated significantly 
more anxiety and lower self-esteem for non-
donors than donors. Teacher-rated scales 
showed significantly more adaptive skills for 
donors and significantly more school problems 
for non-donors. A third of siblings in each 
group reported moderate levels of post- 
traumatic stress reaction  . Donors reported lack 
of choice regarding the decision to donate. 
(Packma









issues and coping 
in patients, and 
donor and non 
donor siblings 
The authors reported increased behavioural 











of paediatric sibling 
donors and their 
parents 
Sibling donors reported increased self-esteem 
post donation and increased closeness to their 
sibling, however some expressed anger about 
donation and concerns regarding the long-term 











1.6. RISKS TO THE TRANSPLANT RECIPIENT  
HPC products carry the same risk of transmission as blood products, but include the 
additional risk of cellular pathogen transfer. Recipient acquisition of infections from 
HPC products including bacteria, viruses, fungal disease and parasites to recipients of 
allogeneic stem cells is well documented. Table 1.4 describes infections reported in 
blood, organ and HPC transplantation and those that are believed to represent a risk 
but where transmission is not yet documented. 
Table 1.4 Infections with the potential for transmission via haematopoietic 
cell transplantation  
Reported in HPC 
transplantation 
Reported in blood transfusion or 
solid organ transplantation but 










Hepatitis C (Shuhart et al, 1996) 
HTLV1/2( Miyoshi et al, 1995; 
Ljungman et al, 1994) 
Parvovirus (Heegaard & Laub 
Petersen, 2000) 
HHV6 (Strenger et al, 2014) 
Malaria( Dharmasena & Gordon-
Smith, 1986; Lefrère et al, 1996; 
O'Donnell et al, 1998) 
Toxoplasmosis 
Crypotosporidiosis (Collier et al, 
1984) 
Brucellosis (Naparstek et al, 





fever(Petropoulou et al, 2010) 
Blood 




Swine flu (Griffiths, 2010) 
Strongyloides( Roseman et al, 
2013; Abanyie et al, 2015) 
Schistosomiasis (Ahmed et al, 
2007)  
 
Blood and solid organ 
West nile virus (Winston et al, 
2014; Stanley et al, 2009) 
Rabies (Kusne & Smilack, 2005) 
Dengue fever (Saigal et al, 2013; 
VWM Chuang, 2008)  











Malignant cells can be transferred during HPC donation and may lead to disease in the 
recipient, either though engraftment of HPCs causing haematological cancer, or via 
transfer of solid organ malignant cells causing metastases in the recipient. Case 
reports of donor-transmitted malignancies following HPC transplantation are currently 
limited to haematological cancers. However, reports of solid organ cancer transmission 
and development of donor-derived malignancies in recipients of organ transplants have 
occurred (shown in Table 1.5).  
Table 1.5 Malignancies transmitted by haematopoietic cell transplantation  
Reported in HPC 
transplantation 
Reported in solid organ 





AML(Niederwieser et al, 1990)  
CML(Baron et al, 2003) 
T cell lymphoma (Berg et al, 
2001) 
Follicular lymphoma (Hart et al, 
2007) 
Chronic lymphocytic leukaemia 
(Flandrin-Gresta et al, 2010; 
Ferrand et al, 2012)  
 
Glioblastoma multiforme 
(Frank et al, 1998) 
Choriocarcinoma (Braun-
Parvez et al, 2010) 
Melanoma (MacKie et al, 
2003; Kim et al, 2009) 
Pancreatic carcinoma 
(Gerstenkorn & Thomusch, 
2003) 
Lung cancer (Lipshutz et al, 
2003) 
Sarcoma (Garrido & Matesanz, 
2008) 
Prostate cancer (Loh et al, 
1997) 
Hepatocellular carcinoma (Ison 
et al, 2009) 
 
Small cell lung 
cancer (Nair et al, 
2007) 
Ovarian cancer 
(Lipshutz et al, 
2009) 
Bladder cancer 




As shown in Table 1.6, all inherited diseases that originate from HPCs can potentially 
be transmitted during HPC transplantation , as can passive transfer of autoimmune 
disease.  
 




Table 1.6 Autoimmune diseases transmitted by HPC transplantation 
Disease  
Myasthenia gravis (Smith et al, 1983) 
Atopy/allergy (Storek et al, 2011; Bellou et al, 1997) 
Thyrotoxicosis (Thomson et al, 1995) 
Immune thrombocytopenia (Minchinton et al, 1982) 
Psoriasis (Daikeler et al, 1999; Li et al, 2015) 
Sarcoid 
Antiphospholipid syndrome (Ritchie et al, 2005; Massoud et al, 2014) 
Type 1 Diabetes mellitus (Mellouli et al, 2009; Lampeter et al, 1998) 
Coeliac disease (Bargetzi,1997) 
Systemic lupus erythmatosus (Autoantibodies without disease) 
 
1.7 THE HEALTH AND WELL-BEING OF PAEDIATRIC DONORS  
1.7.1 ETHICAL CONSIDERATIONS OF DONATION IN CHILDREN  
Donation of HPCs carries a degree of risk, and is of no direct medical benefit to the 
donor. The accepted justification for permitting minor siblings to donate is that the 
donor will benefit from the greater likelihood of survival and reduced suffering of their 
sibling. This justification is supported by results of some studies, describing 
psychosocial benefits experienced by paediatric sibling donors, including increased 
self-esteem, pride, and worth of life and independence (Wiener et al, 2008; Packman et 
al, 2010; MacLeod et al,; van Walraven et al, 2013).  However, in some of these 
studies (as with adult donors), the donation experience was linked to recipient 
transplant outcome and some donors of unsuccessful transplants report negative 
experiences (van Walraven et al, 2013).  
Children have been permitted to serve as stem cell donors for >30 years, and expert 
ethical bodies have repeatedly concluded that it is appropriate to continue to allow 
them to do so (American Academy of Pediatrics, 2010; Bitan et al, 2015). Based on 
ensuring benefit and limiting harm, donation is only considered justifiable provided 
there is a strong positive link (or an anticipated strong positive link in very young 




children) and a reasonable chance of a successful transplant outcome (Pentz et al, 
2008). 
1.7.2 THE SAFETY OF DONATION IN CHILDREN 
While PBSC has overtaken BM as the requested cell source in unrelated donor 
transplantation and adult sibling donor allografts, BM collection remains the most 
common procedure for paediatric donors (Passweg et al, 2014). This is partly due to 
the fact that their intended recipient will usually also be a child, and many centres 
continue to prefer BM in this patient population. Secondly, due to historical concerns 
about the leukaemogenic potential of growth factors, and licensing restrictions in some 
countries, as well as technical challenges of the apheresis procedure in young children, 
PBSC products are less commonly collected from paediatric donors (Passweg et al, 
2014).  
1.7.3 BM HARVESTING IN CHILDREN 
BM harvesting has been performed in children for >30 years and appears to have an 
excellent safety profile, with the risk of life-threatening events of less than 0.5% 
(Buckner et al, 1984). The EBMT paediatric diseases working party (Styczynski et al, 
2012) conducted a study in 313 BM donors reporting a very low incidence of adverse 
events. The greatest risk in very small donors is causing anaemia requiring allogeneic 
transfusion, which is widely regarded as an inappropriate intervention in this 
population. Providing that the maximum aspirated volume does not exceed 20mls/kg 
donor weight, allogeneic blood products are very rarely required (Styczynski et al, 
2012).  
There are no regulations regarding a minimum donor age or weight in paediatric 
donors, and centre practice has not been widely studied.  If BM harvests are 
undertaken in very young donors (e.g. <6 months old) donating to an older sibling, it is 
likely that allogeneic transfusion would be required to obtain an adequate yield for 
engraftment.  




1.7.4 PBSC HARVESTING IN CHILDREN 
A retrospective analysis conducted by The Paediatric Blood and Marrow Transplant 
Consortium examined the safety and efficacy of PBSC donation by 201 paediatric 
sibling donors, aged 8 months to 17 years (Pulsipher et al, 2004). This study 
demonstrated few side effects during mobilisation, with <15% donors experiencing 
growth factor induced pain, which in no cases exceeded CTCAE grade 2.  However, 
92% of donors <20kgs required priming of the apheresis circuit with allogeneic blood, 
and although 80% of 13-16 year olds were collected using peripheral access, this was 
only possible in a third of 7-12 year olds. Further analyses corroborate the finding that 
children report fewer side effects during GCSF mobilisation than adults. The Spanish 
cooperative group studied 61 paediatric donors and found significantly fewer side 
effects in paediatric donors compared to an adult cohort (41% vs. 71%) (la Rubia et al, 
2001). A further study (Kawano et al, 1999) found that while children <10 years 
experienced less discomfort than those 10-19 years, the older age group did not 
experience more symptoms than one would expect in an adult cohort. The PBSC 
Transplantation Study group of Japan described side effects in 57 donors between the 
age of 9 months and 24 years. Again, the reported side effect profile compared 
favourably to studies using adult cohorts; bone pain was described in only 17.5% and 
headache in 5.3% donors during GCSF therapy (Watanabe et al, 2002).  
Although there are insufficient data to estimate a precise risk of SARs in paediatric 
donors undergoing PBSC harvesting, the above studies are reassuring and serious 
events do not appear to occur more frequently than in adult PBSC donors. The 
aforementioned EBMT paediatric diseases working party study (Styczynski et al, 2012) 
included 140 PBSC donors, and reported the only serious adverse event in a donor 
who developed a pneumothorax following insertion of a central venous catheter. 
There are a lack of long-term follow-up data in normal paediatric donors, and thus the 
long-term safety of GCSF in this donor population cannot be confirmed, however, 
experience with GCSF therapy in paediatric patients and adult donors are encouraging.  




In particular, no malignancies in patients with cyclic or idiopathic neutropenia have 
been reported to the severe chronic neutropenia international registry.  
1.7.5 THE EFFICACY OF PBSC DONATION IN CHILDREN 
A number of studies have included donors <18 years in assessments of PBSC yield 
following GCSF and concluded favourable efficacy in younger donors. In 2002 a 
Japanese group published a study examining factors associated with successful 
mobilisation with GCSF in PBSC donor and found a negative correlation between stem 
cell yield and age (Shimizu et al, 2002). These findings were echoed in a more recent 
Italian multi-centre study (Bertani et al, 2014), which investigated donor variables 
correlating with HPC mobilisation in 360 donors aged 13+ treated with GCSF. Again, 
younger age was associated with better mobilisation following GCSF. The report from 
the Paediatric Blood and Marrow Transplant Consortium detailing PBSC donations in 
201 paediatric siblings (Pulsipher et al, 2004) recorded good yields in all age groups. In 
2006, a study (Ings et al, 2006) examining the factors associated with successful 
mobilisation in 400 donors aged 12+ receiving lenograstim was published, reporting 
that poor mobilisation occurred exclusively in donors aged 54 years or older.  
1.8 LEGISLATION AND GUIDANCE IN RD STEM CELL DONATION  
1.8.1 NATIONAL UK LEGISLATION 
The Human Tissue Act 2004 sets out a legal framework for the storage and use of 
tissue from the living, and for the removal, storage and use of tissue and organs from 
the dead, and covers England, Wales and Northern Ireland. In Scotland there is 
separate legislation -The Human Tissue (Scotland) Act 2006. The fundamental 
principle of this legislation is informed consent.  
Following introduction of the Act, the Human Tissue Authority (HTA) was established to 
provide regulation for activities concerning the Act. The HTA produces nine codes of 




practice designed to provide professionals with practical guidance on the human tissue 
legislation. Code of Practice 6 (HTA, 2014) covers donation of allogeneic bone marrow 
and PBSC for transplantation, and includes principles relating to consent and 
communication for donation.  
Under the Human Tissue Act, donation of bone marrow and PBSC both by adults with 
capacity and children competent to give consent may be approved locally. The HT Act 
England and Wales, defines children as less than 18 years of age, however donation of 
bone marrow and PBSC by children competent to give consent can be approved 
locally. The competence of potential donors <18 years should be determined locally 
and children competent to give consent are considered ‘Gillick-competent’ and may 
consent.  In the Gillick case, the court held that a child was considered competent to 
give valid consent to a proposed intervention if they had sufficient intelligence and 
understanding to enable them to fully understand what was involved. Under the 
provisions of the HT (Scotland) Act, children are defined as being less than 16 years of 
age, therefore those over 16 may consent to donation in the same way as older adults.  
Consent for the first and each repeat donation must be obtained before harvesting 
bone marrow or PBSC from a donor for transplantation and the HTA requires that 
informed consent must cover the following:   
1) Details about the donation procedure, the long- and short-term risks and that a 
further collection of stem cells or lymphocytes might be requested   
2) The chances of the transplant being successful and any possible side effects or 
complications for both donor and recipient   
3) The right to withdraw consent at any time and the implications for both donor 
and recipient of the withdrawal of consent   
4) The fact that donation is an entirely voluntary act and that the donor (and where 
applicable the person consenting on their behalf) must be free of any kind of 
coercion or pressure   
5) The fact that it is an offence to seek or receive payment or reward for providing 
tissue, including bone marrow or PBSC for transplantation   




1.8.2 CONSENT OF MINORS 
Donations of bone marrow from children who are not competent to give consent, or 
from adults lacking capacity, must be approved by the HTA.  HTA regulations require 
that all cases of minors who are not competent to consent are reviewed by an 
independent assessor, who interviews the donor and submits a report to the HTA. The 
assessor must be satisfied that the best interests of the potential donor have been 
properly considered and that the HTA’s codes of practice have been appropriately 
implemented.  In particular, the assessor’s responsibilities are to:  
• Conduct  separate interviews with the donor, the person giving consent, and the 
recipient   
• Ensure, where appropriate, that the child has received all necessary information 
in a way they are most able to understand 
• Ensure that consent is obtained with no duress, coercion and no evidence of an 
offer of reward 
Legally, parents can consent on behalf of their child, however, it is recognised that a 
conflict of interest exists for parents of a child donating to their sibling. If the child 
objects, the independent assessor will explore the reasons behind this and, in 
exceptional circumstances, the decision may be referred to a court.   
1.8.3 INTERNATIONAL GUIDANCE  
1.8.3.1 World Health Organisation  
The World Health Organisation first produced guiding principles on human cell, tissue 
and organ transplantation in 1991. Covering the whole field of transplantation these are 
intended to provide an ethical framework for the acquisition and transplantation of 
human cells, tissues and organs for therapeutic purposes.  The principles relevant to 
HPC donation include:  




• Live donors should be informed of the probable risks, benefits and 
consequences of donation and consent should be free from undue influence or 
coercion.  
• Selection criteria for donors should be scrupulously applied and monitored. 
• Payment other than reimbursement of expenses is prohibited. 
• Psychosocial evaluation is needed to guard against coercion of the donor or the 
commercialism.  
• The national health authority should ensure that the evaluation is carried out by 
an appropriately qualified, independent party. 
• Specific measures should be in place to protect minors or those lacking 
competence and, wherever possible, assent should be obtained before 
donation.  
• Follow-up should be well organised. The long-term outcomes of cell, tissue and 
organ donation and transplantation should be assessed for the living donor as 
well as the recipient in order to document benefit and harm.  
1.8.3.2 FACT-JACIE Standards  
In 1996, the Foundation for the Accreditation of Cellular Therapy (FACT), was 
established by the International Society for Cellular Therapy (ISCT) and the American 
Society for Blood and Marrow Transplantation (ASBMT) to provide standards and 
accreditation in HPC transplantation in North America. Two years later, JACIE was 
founded by European Group for Blood and Marrow Transplantation (EBMT) and ISCT, 
to meet the same objectives in Europe. The two organisations collaborate and jointly 
produce FACT-JACIE Standards for the provision of quality medical and laboratory 
practice in HPC transplantation. The Standards consist of evidence-based 
requirements developed by consensus within committees consisting of clinicians, 
scientists and quality experts including international leaders in cell therapy, cord blood 
banking and HPC donor registries. Prior to publication the Standards undergo public 
and legal consultation.  




Transplant and cell processing programmes apply for FACT or JACIE accreditation, 
which is required for reimbursement of transplant costs in the UK, but is voluntary in 
many other European countries.  
JACIE adopted the first edition of FACT Standards in 1999, and subsequently the joint 
2nd Edition Standards were produced in 2002. Since the first edition, recommendations 
and requirements regarding the evaluation of allogeneic HPC donors have been 
included, and have become more extensive over time, as awareness around related 
donor health and well-being has increased.  A summary of the Standards pertaining to 
related donor care and the notable changes between editions are summarised in Table 
1.6. The Standards define that the term ‘shall’ indicates that the standard is to be 
complied with at all times while the term ‘should’ refers to activity that is recommended 
or advised, but for which there may be effective alternatives. Several of the studies 
described in this thesis refer to FACT-JACIE Standards. At the time these studies were 
undertaken, 5th Edition Standards were in use, and are referred to as the ‘current’ 











Table 1.7 Summary of FACT-JACIE Standards pertaining to the care of 
related donors and changes through the last three editions 
3rd Edition Oct 2006 4th Edition Oct 2008 5th Edition March 2012 
Training 
Physicians should be 
knowledgeable in BM harvest 
and apheresis procedures 
Physicians shall be trained and competent in BM harvest and 
apheresis procedures 
  Specific training and 
competency annually in  
donor informed consent 
Policies and procedures 
There shall be written criteria for allogeneic donor selection, evaluation, and management 
The Collection Facility shall establish and maintain policies and procedures shall address: 
Donor and recipient confidentiality.   
Donor consent.   
Donor treatment.   
Donor screening.   
Management of donors, including pediatric donors if applicable 
There shall be a policy covering the creation, regular review, and retention of donor records. 
Donor Evaluation 
  Allogeneic donor suitability 
should be evaluated by a 
physician who is not the 
physician of the recipient. 
The donor shall be evaluated for potential risks of the collection procedure. The risks of 
donation shall be documented, including: 
Possible need for central venous access. 
Mobilisation therapy for collection of HPC, Apheresis. 
Anesthesia for collection of HPC, Marrow. 
 
 Donors shall be evaluated for risk factors for disease 
transmission by medical history, physical examination, 
examination of relevant medical records, and laboratory 
testing.   
The medical history for allogeneic donors shall include at least the following:   
Vaccination history. Travel history.   Blood transfusion history. 
Questions to identify persons at high risk for transmission of communicable disease  
Questions to identify persons at risk of transmitting inherited conditions. 
Questions to identify persons at risk of transmitting a hematological or immunological disease. 
Questions to identify a past history of malignant disease. 
Within thirty (30) days prior to collection, all HPC donors shall be tested for  
Human immunodeficiency virus, type 1. Human immunodeficiency virus, type 2. Hepatitis B 
virus.  Hepatitis C virus. Treponema pallidum (syphilis) 
Any abnormal findings shall be reported to the prospective donor 
The use of an ineligible allogeneic donor shall require documentation of the rationale for 
his/her selection and suitability by the transplant physician, urgent medical need 












  Sufficient information 
regarding the donation 
process shall be provided to 
the potential allogeneic donor 
prior to HLA typing. 
The donor shall have an opportunity to ask questions. 
The donor shall have the 
right to refuse to donate.   
 
The donor shall have the right to refuse to donate and be 
informed of the potential consequences to recipient of such 
refusal.   
 
Informed consent from the donor shall be obtained and documented by a licensed physician 
or other health care provider familiar with the collection procedure.   
 
  Informed consent from 
allogeneic donors should be 
performed by licensed 
physicians or other 
healthcare providers other 
than the potential recipients’ 
primary physicians.   
 
The collection procedure shall be explained in terms the donor can understand, and shall 
include the following information at a minimum: 
The risks and benefits of the procedure. 
Tests and procedures performed to protect the health of the donor and the recipient. 
The rights of the donor to review the results of such tests. 
Alternative collection methods. 
Minors 
  Written criteria shall include 
criteria for the selection of 
minor allogeneic donors.   
There shall be a process to address age specific issues including informed consent, donor 
size, and venous access. 
Specific consent is required for the use of growth factors, if utilised, in a minor, allogeneic 
donor. 
For minor donors assent should also be obtained in an age appropriate manner 
In the case of a minor donor, informed consent shall be obtained from the donor’s parents or 
legal guardian in accordance with applicable laws 
  There should be a donor 
advocate available to 
represent minor allogeneic 
donors and allogeneic donors 




 There shall be a policy for follow-up of donors that includes 
routine management and the management of donation-
associated adverse events.   
 




1.8.3.3 WMDA recommendations for family donor care management  
In 2010, the Ethics Working Group and the Clinical Working Group of the WMDA 
formed a subcommittee, which established consensus recommendations for family 
donor care (van Walraven et al, 2010b). 
These included that:  
• Counselling, including written information covering all aspects of BM/PBSC 
donation should be available for each family member before HLA testing. This 
should cover the option for the donor to choose not to donate. 
• TCs should establish procedures to ensure that donors are appropriately 
counselled regarding their right to refuse typing or donation. 
• The practitioner (for example, independent advocate, physician) counselling the 
donor should have a documented donor advocacy role and should not be 
involved in the recipient’s care. 
• Systems should be in place to evaluate clinical risk to the donor against defined 
criteria and to document decisions made. 
• Systems should be in place both for adverse event reporting and for long-term 
follow-up of related as well as unrelated donors.  
1.8.3.4 WBMT recommendations for standardised reporting of donor outcomes 
In 2013, consensus recommendations were published (Halter et al, 2013) regarding the  
standardised assessment of donor outcome, recommending identical follow-up for 
related and unrelated donors.   
These guidelines include that: 
• All consenting donors who start the donation procedure for allogeneic HSC or 
other therapeutic cells from peripheral blood or BM shall be registered and 
followed for 10 years after the last donation procedure. 




• A minimum data set including survival status, development of haematological or 
non-haematological malignancy or autoimmune disease should be collected.  
1.8.4 REGULATION OF UNRELATED DONOR CARE 
The World Marrow Donor Association (WMDA) was founded in 1994 with the purpose 
of establishing a global network facilitating the provision of quality hematopoietic stem 
cell products and preserving the health and safety of the volunteer unrelated donors 
providing such products. WMDA provides accreditation for donor registries, which are 
required to conform to WMDA Standards, covering all aspects of unrelated donor care 
from donor recruitment, consent, medical assessment, collection, and donor follow-up.   
The WMDA donor suitability working committee produces criteria for acceptance of 
unrelated donors, these take a conservative approach to preserving donor health, 
recommending deferral of any donors with issues that may represent a risk to their 
health during donation.  
WMDA member organisations are also obligated to report to a central Serious Events 
and Adverse Effects Registry, using standardised criteria. All events are reviewed by a 
committee with specific expertise in donor health, and any concerning incidents are 
then disseminated through registry networks to physicians involved in unrelated donor 
assessment, and addressed through changes to the WMDA medical suitability criteria. 
Although the WMDA collaborates with other organisations within the transplant field, 
there are no clear channels through which such information is communicated to the 
physicians who evaluate related HPC donors.  
1.8.5 REGULATION OF SOLID ORGAN DONATION FROM RELATED DONORS  
Regulations regarding the donation of solid organs from related donors are far more 
comprehensive than those in HPC transplantation. This occurs in part because of a 
clear need to prevent organ trafficking, which is not an issue in HPC transplantation, 




and also a difference (or perceived difference) in donor risk since HPCs are by 
definition self-renewable.  
While HPC donation from competent adults does not require approval, all living solid 
organ donations from living donors must be approved by the HTA, with a report 
submitted by an Independent Assessor (as is the case for minors or donors lacking 
capacity in the context of HPC donation).   
A second regulatory framework for solid organ donation also exists, the EU Organ 
Donor Directive, which sets minimum standards that must be met by all member states 
aiming to reduce variation in donor care standards between EU countries.  The HTA is 
also the competent authority for implementation of this framework, which is entrenched 
into UK law through the Quality and Safety of Organs intended for Transplantation 
Regulations 2012. These regulations encompass both procurement and transplantation 
activities. In contrast to HPC donation, these regulations specifically require central 
reporting of serious adverse events or reactions (which are reported to NHSBT acting 
on behalf of the HTA) and requires arrangements for donor follow-up.  
Since 2000, UK Guidelines for Living Donor Kidney Transplantation have been  
produced by a joint working party of  the British Transplantation Society and the Renal 
Association. These comprehensive evidence-based guidelines include the ethical and 
medico-legal aspects of donor selection, donor evaluation, medical deferral criteria, and 
the management of complications.  This includes clear recommendations for: 
• Separate teams managing the donor and recipient 
• Psychological evaluation and support must be available if required 
• Long term follow-up for all donors 
In addition there are several international sources of consensus guidelines on 
managing related organ donors. These include comprehensive international guidelines 
by The Ethics Committee of the Transplantation Society (TTS) with consensus 
statements on the care of live renal donors (The Consensus Statement of the 




Amsterdam Forum on the Care of the Live Kidney Donor, 2004)  and on live Lung, 
Liver, Pancreas, and Intestine Donors (Pruett et al, 2006).  
1.9 CONCLUSION 
Over the last 30 years HPC transplantation has developed as a treatment modality 
offering the chance of long-term cure to an increasing number of patients with 
haematological disease. Although other donor options are now available, fully matched 
siblings offer the best results and recent advances have also resulted in increasing 
numbers of mismatched transplants using other relatives.  Compared to both the 
unrelated HPC donor and related solid organ donor field there is a relative lack of 
regulation to protect the health and interests of related HPC donors. Several recent 
studies have drawn attention to the increased occurrence of serious health events 
among related HPC donors, but the lack of a process for centralised SAR reporting 
makes it difficult to determine the precise incidence of such events. In addition, with 
retrospective analyses and small donor cohorts forming the majority of available 
evidence, it is difficult to establish a causative relationship between specific medical 
issues or donor characteristics and adverse events.    
Furthermore, concerns have been raised that current procedures may not sufficiently 
protect RDs from a potential conflict of interest, and it is also clear that we currently 
know very little about the pathway of RD care in transplant centres. This thesis will 
explore current pathways of RD care focusing on procedures at each stage of the 
donor care pathway and will endeavour to look for solutions to concerns that have been 
raised thus far.  
 
 




CHAPTER	  2.	  MATERIALS	  AND	  METHODS	  
2.1 INTRODUCTION 
This chapter describes the methodology behind the five studies that are detailed in 
subsequent chapters of this thesis. These include a retrospective study examining the 
impact of JACIE accreditation on RD care, a study of RD care provision in UK 
transplant centres, a study of RD care provision in the USA and Europe, a study of 
related donor experience in a single UK centre and a prospective study exploring 
provision of RD care in a UD registry setting.  
2.2 A RETROSPECTIVE STUDY OF THE IMPACT OF JACIE 
ACCREDITATION ON RELATED DONOR CARE 
2.2.1 IDENTIFICATION OF THE STUDY POPULATION 
All sequential evaluations of adult potential RDs occurring between 1st January 2004 
and 31st December 2013 at the Royal Marsden Hospital were retrospectively analysed. 
This included the evaluations that resulted in donor deferral, as well as those resulting 
in allogeneic donation.  
The details of all recipients of related donor allogeneic HPC transplants during the 
study period were obtained from the hospital’s ProMISe database.  Using the patient 
electronic records, the details of all related donors who had proceeded to HPC 
donation were acquired.  I then retrieved the details of all patients who had undergone 
HLA typing from January 2003 to December 2013 from the Anthony Nolan SOLAR 
database. I reviewed the results of the 879 relatives of all 485 patients who had 
undergone HLA typing, to identify patients who had a fully matched donor but who did 
not proceed to transplant with this donor. I was thus able to identify any relatives who 




had been evaluated and deferred.  Details of any subsequent therapeutic T cell 
collections were not collected.  
2.2.2 DATA COLLECTION 
The data regarding the medical evaluation of the study cohort were collected from the 
hospital’s electronic patient records.  All records from the study period included a 
detailed summary of the evaluation and description of the consenting process from the 
assessing physician. All blood results, donor medical observations, investigations and 
consent forms were available electronically and were reviewed.  Data regarding the 
apheresis procedure(s) or bone marrow procedure were also reviewed using electronic 
medical records.  
During the study period The Royal Marsden quality team prospectively collected 
information regarding donors who were contacted and offered follow-up. This team 
provided information regarding donors who were offered follow-up, and, where donors 
had participated, data from the follow-up questionnaires were collected from the 
electronic medical records.  
The presence of adverse events was determined by reviewing donor medical records 
for any events occurring from the start of mobilisation until 30 days post-donation. Any 
adverse events requiring admission to hospital, modification of the mobilisation 
regimen or the apheresis procedure were classed as severe. Data regarding well-
recognised side effects of donation such as bone pain and citrate toxicity, that required 
only standard interventions, were not recorded.  
The electronic medical records of the recipients of these donors were examined and 
data regarding HPC dose infused, and engraftment data and recipient demographics 
were collected.  
2.2.3 ASSESSMENT OF DONOR SUITABILITY STATUS IN ADULT DONORS 




Using the details of the donor demographics, results of investigations, and the medical 
summary recorded by the evaluating physician, I was able to retrospectively assess 
whether all adult donors in this study would have been accepted as unrelated donors. 
This assessment was performed using the Anthony Nolan medical suitability criteria, 
available at http://med-guidelines.org.uk, accessed on 12th November 2013.  
2.2.4 ASSESSMENT OF THE IMPACT OF JACIE STANDARDS ON DONOR 
MANAGEMENT 
During the time-period studied, changes to FACT-JACIE Standards regarding the care 
of related donors were introduced at two time points.  In April 2011, the 4th FACT-
JACIE Standards (FACT-JACIE, 2011) introduced a requirement for  “a policy for 
follow-up of allogeneic donors that includes routine management and the management 
of donation-associated adverse events”. In March 2012, the 5th edition of the Standards 
came into effect and introduced the stipulation that allogeneic donors should be 
assessed by a “licensed health care professional who is not the primary transplant 
physician overseeing care of the recipient”.  The impact of each change was assessed 
by comparing donor care before and after the introduction of the relevant standard.  
2.2.5 STEM CELL COLLECTION PROCEDURES 
Apheresis donors were mobilised with lenograstim (glycosylated GCSF; Chugai 
Pharma, London UK) with a dose of 10 μg/kg/day administered subcutaneously ± 10% 
for 4 consecutive days. Where less than 90% of the CD34+ target yield was achieved 
with the first procedure on day 5, a further dose of GCSF was administered and a 
subsequent collection performed on day 6.  
The standard procedure for bone marrow harvests entailed aspiration from bilateral 
posterior iliac crests under general anaesthetic. Multiple-side-hole needles were used, 
with the exception of small paediatric donors in whom these were considered 




unsuitable.  All harvests were performed by Consultant-level Haematologists who had 
undertaken specific credentialing, and had extensive experience in this procedure. 
2.2.6 STATISTICAL ANALYSES 
The relationship between era of transplant (pre-and post introduction of 4th JACIE 
Standards) and the existence of donor follow-up, and between era (pre and post-
introduction of 5th JACIE Standards) and independent donor consent were examined 
using the chi-squared test.  
To analyse factors associated with adverse events, continuous donor characteristics 
were categorised and relationships between donor characteristics and the occurrence 
of severe adverse events, or achievement of requested harvest yield were examined 
using chi-squared, or Fisher’s exact test where appropriate.  
The relationship between continuous donor variables and CD34+ yield as a continuous 
outcome was determined using linear regression analysis. The relationship between 
categorical donor variables and CD34+ yield as a continuous outcome was examined 
using the Mann-Whitney-U test.  Only first HPC donations were considered in 
evaluations of HPC yield achieved.  
2.3 A STUDY OF RELATED DONOR CARE IN THE UK AND 
TRANSPLANT PHYSICIAN OPINIONS 
2.3.1 DEVELOPMENT OF THE SURVEY 
A 47-question survey was developed to address the study objectives (see Appendix 1), 
using multiple-choice questions where possible to increase likelihood of response.  
Questions aiming to determine compliance with regulatory standards were phrased 
using language identical to the regulation concerned. The draft survey was piloted by 
five healthcare workers in the field of HPC transplantation to ensure comprehensibility 




and to identify ambiguities.  The final survey was then reviewed by the BSBMT clinical 
trials committee who approved the study.  
2.3.2 DATA COLLECTION 
The study population consisted of programme directors of all 28 UK transplant centres 
performing adult allogeneic HPC transplants and one apheresis centre managing adult 
related donors. Since it was anticipated that the centre director might not always be 
fully cognisant with their centre’s donor care policies, the invitation letter requested that 
the survey be forwarded to the physician responsible for donor care in their centre.  
In order to maximise the response rate, the survey was administered by email via the 
BSBMT. The study population were sent an invitation requesting completion of the 
internet-based questionnaire via a secure hyperlink (surveymonkey.com). Following the 
initial email invitation in April 2014, non-responders received three further email 
reminders, and the study closed on 31st July 2014. Where more than one response 
was received from a centre, the most complete was used for analysis. The survey 
allowed participants to skip questions they were unwilling/unable to answer. 
Data regarding centre transplant volumes (number of allografts per year) were obtained 
from the BSBMT, this data refers to transplant volumes in 2012.  
2.3.3 STATISTICAL ANALYSES  
Due to the small number of transplant centres in the UK, this study was not powered to 
generate statistically significant differences between transplant centres, and analyses 
were therefore largely descriptive. Centre volume (defined as the total number of 
allografts performed per year) was categorised (<10, 11-20, 31-50, 51-70, and >70) 
and relationships between centre volume and response rate or adherence to standards 
were examined using the chi-squared test.   




2.4 A STUDY OF RELATED DONOR CARE IN THE US AND 
EUROPE 
2.4.1 DEVELOPMENT OF THE SURVEY 
This study was designed to examine RD care in two distinct geographical regions: the 
US and Europe. A single survey was developed to study both regions, but with differing 
primary objectives. In the US, where an earlier survey of donor care had been 
previously undertaken, the primary objective was to determine whether improvements 
had occurred following international donor care initiatives. In EBMT transplant centres, 
the primary objective was to determine whether appreciable differences in care were 
present between JACIE accredited and non-accredited centres.   
In order to allow comparison between eras, the 38-item survey (see Appendix 1) I 
developed for this study contained some questions with wording identical to the earlier 
US survey, as well as new questions to address areas of care that had not been 
previously examined in either region.  
The survey included questions examining all aspects of RD care, but with a particular 
focus on those areas which have been addressed by consensus guidelines, or where 
regulatory bodies have made recommendations or stipulations.  
The areas of care studied included: 
• The information supplied to RDs prior to HLA typing 
• The presence and method of RD health assessment prior to HLA typing 
• Assessment of RD willingness prior to HLA typing 
• The person to whom donor HLA results are first disclosed 
• The existence of a written RD care policy 
• The presence of written eligibility criteria for acceptance of RDs 
• The existence of a process for credentialing physicians performing BM harvests 




• The involvement of the RDs consenting physician in the care of the recipient.  
• The presence and duration of a RD follow-up programme 
The draft survey questions and all procedures were reviewed by the CIBMTR Donor 
Health and Safety Working Committee, including statistical review. The survey was 
then tested by 10 transplant physicians from the US and Europe, to identify ambiguities 
and to ensure that the terminology used was appropriate for both regions. The study 
was approved by the NMDP Institutional Review Board and by the Donor Outcomes 
Committee of the EBMT.  
2.4.2 STUDY POPULATION 
The study population consisted of programme directors of EBMT and CIBMTR 
allogeneic transplant member centres, who were contacted via email using CIBMTR 
and EBMT mailing lists for programme directors. CIBMTR centres that were recorded 
as purely paediatric centres were excluded, but this information was not available for 
EBMT centres.  All centres were contacted simultaneously with an initial invitation sent 
in August 2014 via the CIBMTR requesting completion of the internet-based 
questionnaire via a secure hyperlink (surveymonkey.com), or, to forward the survey to 
the appropriate donor care physician in the centre. Entry into a draw for a free Tandem 
meeting registration was offered as an incentive to increase the response rate.  Non-
responders received a further three email reminders prior to closure of recruitment on 
31st November 2014.   
The invitation to this study specified that the study referred to the care of adult related 
stem cell donors only, and the survey terminated if respondents answered ‘no’ to the 
first question “Does your centre perform allogeneic HPC transplants from adult (>18 
years old) related donors?”. 




Where >1 response was received from a centre, the most complete was used for 
analysis. The survey allowed participants to skip questions they were unwilling or 
unable to answer.  
2.4.2 STATISTICAL ANALYSES 
For analysis of response rates, EBMT centres were categorised by centre volume, 
defined as the number of first allografts performed per year (<10, 11-25, 26-50, 51-75, 
>75) using data collected from the most recent EBMT activity survey (Passweg et al, 
2013). Centres were also grouped according to their geographical location (Eastern 
Europe, Northern Europe, Southern Europe, Western Europe, Non-European nations).  
For analysis of response rates US centres were grouped by size in the analysis, 
defined as the number of allografts per year, as reported to CIBMTR (2011-2012). 
Centres were also grouped according to their geographic location by US regions 
including: New England (ME, NH, VT, MA, RI, CT), Mid-Atlantic (NY, NJ, PA), South 
Atlantic (DE, MD, DC, VA, WV, NC, SC, GA, FL), East North Central (OH, IN, IL, MI, 
WI), East South Central (KY, TN, AL, MS), West North Central (MN, IA, MO, ND, SD, 
NE, KS), West South Central (AR, LA, OK, TX), Mountain (MT, ID, WY, CO, NM, AZ, 
UT, NV); and Pacific (WA, OR, CA, AK, HI). Relationships between these categorical 
centre variables and survey response rates were analysed using Chi-squared or 
Fisher’s exact test where appropriate.   
For the purpose of analysing adherence to the international recommendations listed 
above, EBMT centres were grouped into two centre volume categories (above and 
below the median 23 allografts per year) and were categorised by the presence or 
absence of JACIE accreditation. US transplant centres were grouped into two centre 
volume categories (above and below the median 25 related donor allografts per year). 
 




2.5 A PROSPECTIVE STUDY EXPLORING THE FEASIBILTY OF 
UD REGISTRY INVOLVEMENT IN RD CARE 
2.5.1 OVERVIEW 
This study explores the potential role(s) of an UD registry in related HPC donor care. In 
conjunction with the Anthony Nolan donor provision and follow-up teams, and 
physicians from three large transplant centres, I devised three models of RD care and 
explored the feasibility of each, before setting up a prospective pilot study of the most 
feasible.  
2.5.2 DEVELOPMENT OF POTENTIAL DONOR CARE PATHWAYS FOR PILOT 
STUDY 
I used the thoughts expressed at an EBMT annual meeting 2013 session debating the 
potential role for UD registries in the management of related donors at (outlined in 
detail in Chapter 6) as a basis for determining where input from an UD donor registry 
would be more helpful in RD care. I considered each of these advantages and 
disadvantages in the context of the UK healthcare system and transplant centre set-
ups.   
I next contacted donor physicians from three European registries where the registry 
has successfully assumed responsibility for some aspects of RD care in recent years. I 
obtained details of these models from the teams responsible, and analysed the 
advantages and disadvantages of implementing these models in the UK.  
I used this data to formulate three potential related donor pathways with options 
ranging from the registry conducting the whole care pathway to the registry providing 
one aspect of donor care. Briefly, these included the following:  
Model 1) A pathway where the registry provided all aspects of care following 
identification of a suitable related donor  




Model 2) A pathway with donor evaluation performed in the transplant centre by an 
independent external physician and donor follow-up performed by the registry with 
other aspects of care unchanged   
Model 3) A pathway with donor follow-up performed by the registry, and all other 
aspects of care managed by current procedures within the transplant centre 
These models are discussed in detail in Chapter 6.  
I worked with staff within the Operations, Quality and Finance teams of the Anthony 
Nolan to define each step of each pathway and determine the changes in procedures 
required by the registry. I obtained internal approval for pilot studies for each proposed 
model. Standard operating procedures and donor information and consent forms 
provided at each stage of the pathway for unrelated Anthony Nolan donors were 
reviewed and altered where necessary to be fit for purpose in RDs.  
I next discussed these pathways with three large UK transplant centres and modified 
the models to best accommodate transplant centre needs. For Model 1, I also 
discussed the processes involved in this pathway with the clinical Haematology team at 
the largest affiliated collection centre, The London Clinic.  
2.5.3 COST ANALYSIS 
As part of assessment of the feasibility of these three pathways of donor care I had 
devised, I conducted a cost analysis to determine whether a) funds would be required 
for a pilot study and b) whether these models would require additional resourcing for 
related donor care if implemented on a national scale in the future.  
In order to conduct a cost analysis I examined each proposed model of donor care that 
I intended to pilot, from the point of request for donor work up to donor follow-up to 




determine where proposed changes in procedures from current transplant centre 
based care would influence the cost care provision.  
I interviewed the managers of Anthony Nolan Donor Provision, Medical and Donor 
Follow-up teams and obtained estimates for the number of hours work required per 
donor. Costs for each team member per hour were then obtained from the Anthony 
Nolan human resources department allowing calculation of registry manpower costs for 
each donor. I obtained the costs for the aspects of the donor care performed by the 
affiliated collection centre from the pricing agreement between Anthony Nolan and the 
largest affiliated collection centre. This included the donor medical procedure, donor 
investigations, and charges for the harvest procedure. I calculated the likelihood of a 
one-day or two-day PBSC collection in related donors using data I obtained from the 
study outlined in Chapter 3, and thus calculated an overall apheresis cost per donor. 
The travel, accommodation and employment reimbursement costs that are provided by 
the registry for unrelated donors were not included in this model, as these are not 
usually covered in the related donor context.  
In order to provide transplant centres with a comparison, I also calculated typical costs 
for provision of related donor care within the transplant centre setting. I obtained these 
costs by interviewing team members within a large transplant centre, The Royal 
Marsden - one of the centres invited to participate in this study. I obtained estimates for 
the number of hours work per donor provided by the nursing, medical, data 
management and apheresis teams. I obtained costs per hour for each staff member 
from The Royal Marsden clinical trials team.  
2.5.4 SET UP OF PILOT STUDIES 
After defining work flows and cost calculations for these three models of donor care, I 
contacted three large UK transplant centres, The Royal Marsden, King’s College 
Hospital, and Nottingham University Hospital. These were selected for two reasons. 
Firstly, as large transplant centres, these use the highest number of RDs. Secondly, 




these centres all use the Anthony Nolan Graft Identification and Advisory service and 
strong links exist between Anthony Nolan and these organisations.   
Following discussions with transplant centres confirming initial interest, proposals (see 
Appendix 1) were sent to The Royal Marsden and King’s College Hospital outlining 
Model 1 ‘Provision of Related Donor care in a UD registry setting from the point of 
donor identification’ and Model 2 ‘Evaluation of Related Donors within a transplant 
centre by an external physician’. A proposal regarding the Model 3 ‘follow-up of related 
donors by Anthony Nolan’ was sent to Nottingham University Hospital (see Appendix 
1). 
As detailed in Chapter 6, the proposed pilot studies for Model 1 and Model 2 were not 
finally approved by either centre for logistical and financial reasons. Following 
acceptance of the pilot study for Model 3 by the Anthony Nolan Institutional Review 
Board and by Nottingham University Hospital, recruitment to the study commenced on 
1/10/14 for a thirteen-month period to 1/11/15.   
2.5.5 ASSESSMENT OF FEASIBILITY  
In order to determine the future potential of this care model I wanted to evaluate the 
pathway from 3 perspectives; those of the related donors who undertook follow-up at 
Anthony Nolan, the transplant team at Nottingham University Hospital, and the Anthony 
Nolan donor follow-up team. Since the follow-up of these donors is on-going to 10 
years post-donation, it was not possible to complete an evaluation of the whole follow-
up process, for discussion in this thesis, but an initial evaluation to ‘troubleshoot’ 
problems was conducted.  
Related donors were given the opportunity to feed back on the donation process and 
the initial contact from the Anthony Nolan donor follow-up team during completion of 
the Day 7 medical questionnaire. This questionnaire contained identical questions to 




the version sent to all Anthony Nolan unrelated donors, allowing some descriptive 
comparisons between the two groups.  
At the mid-point and end-point of study recruitment, I conducted an interview with the 
Anthony Nolan donor follow-up manager responsible for the related donors on the pilot 
study, to determine any problems with the process and consider modifications that 
would be necessary if this follow-up model was to be offered nationally.  Initial 
acceptability of the pathway to the transplant centre was evaluated by email.  
2.6 A STUDY EXAMINING THE EXPERIENCE OF RELATED 
DONORS  
2.6.2 THE DONOR CARE PATHWAY 
The process for donor care in the centre studied, The Royal Marsden, is summarised in 
Figures 2.1 and 2.2. Donors are initially identified by their relatives who pass the details 
of potential donors to a transplant clinical nurse specialist who acts as donor 
coordinator throughout the process. Donors are contacted by telephone and the details 
of the donation procedure are discussed. Willingness to donate is determined and a 
health assessment is conducted, either by email, phone or in person. Written 
information about donation is also supplied at this point.  
Blood for HLA typing is drawn at the hospital or via the GP depending on the donor’s 
location. The donor is informed of the HLA results by telephone or email and donors 
are again asked to confirm willingness to proceed and consent to inform the recipient of 
their matching status is taken.  
 
 




Figure 2.1 Process for identification of matched related donors at The Royal Marsden 
 
Donors visit The Royal Marsden for evaluation and consent, which is conducted by a 
transplant physician who is not responsible for the care of the recipient. Donors are 
assessed using modified Anthony Nolan suitability criteria for unrelated donors. Donors 
are offered a choice of donation route.  
GCSF administration is arranged at the hospital, or via the GP for the first injection, 
following which donors may administer their own subsequent doses if desired. Donors 
attend The Royal Marsden for donation. A follow-up phone call is made by the donor 
coordinator or an apheresis nurse within 7 days of donation to ensure the donor is 
recovering as expected. Donors then receive annual follow-up questionnaires for 10 
years post-donation, according to the WBMT recommended minimum data set (Halter 
et al, 2013). A summary of the recommendations that this pathway meets is provided in 
Table 2.1 
Figure 2.2 Process for the donation and follow-up of related donors at The Royal Marsden
 
Initial	  donor	  contact	  to	  determine	  willingness	  to	  proceed	  
Health	  assessment	  (over	  phone	  or	  in	  person)	  and	  written	  information	  provided	  
HLA-­‐typing	  performed	  (in	  person	  or	  via	  post)	  
Donor	  informed	  regarding	  HLA	  results	  and	  willingness	  to	  proceed	  is	  determined	  
Donor	  evaluation	  and	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GCSF	  administered	  by	  GP,	  donor	  or	  hospital	   Donation	  at	  hospital	  	  
Follow-­‐up	  phone	  call	  within	  one	  week	   Annual	  questionnaire	  to	  10	  years	  









2.6.3 SURVEY DEVELOPMENT AND ADMINISTRATION 
A 20-item questionnaire was created to evaluate the emotional support and information 
provided at each stage of the donation process, and the physical and psychological 
effects of donation. Questions were also asked to allow identification of any logistical 
difficulties experienced by donors, and their thoughts on ways to improve the pathway 
were sought.  
 
Recommendation  Source of recommendation 
Information is provided prior to HLA typing FACT-JACIE 
Willingness is determined prior to HLA typing WMDA subgroup 
recommendations 





Donor evaluation is conducted by a physician not 




Donors are offered a choice of donation routes WMDA subgroup 
recommendations 
The risks and benefits of the procedure are 
discussed 
FACT-JACIE 
Policies for related donor care include donor 
evaluation, BM and PBSC harvesting from donors 
FACT-JACIE 
Written eligibility criteria are used to assess related 
donors 
FACT-JACIE 
Donors are followed up to 10 years post-donation FACT-JACIE 
WBMT 
WHO guiding principles 




The following domains were addressed: 
1) Care before the donor medical evaluation  (6 items)  
2) The donor evaluation and donation procedure (9 items) 
3) Post donation care (5 items) 
The study questionnaire and letter of invitation was reviewed by the Royal Marsden 
Audit committee, HPC Transplant Consultants and Clinical Nurse Specialists.  
The study population consisted of all adult (>16 year old) related donors who had 
undergone stem cell donation under the adult RD pathway at The Royal Marsden 
between 1st January 2009 and 31st December 2014. The survey was administered by 
post, using the last recorded address in the donor medical records. Donors received a 
letter outlining the study aims and inviting them to participate along with a printed copy 
of the survey questionnaire and a return envelope. The invitation also contained a link 
to an internet-based version of the same questionnaire via a secure hyperlink 
(smartsurvey.com) with a unique identifier to allow donors the choice of response 
methods. Following the initial invitation on 14th April 2014, non-responders received 1 
further reminder, sent in an identical manner six weeks after the first invitation. The 
study closed to recruitment on 1st August 2015.  
Details regarding donor demographics, donation dates and participation in follow-up 
were obtained from the hospital electronic patient records.  
2.6.4 STATISTICAL ANALYSES 
Continuous donor characteristics were categorised for the purpose of analysis. Age 
above or below the median 50 years at the time of donation, era of transplant (pre and 
post 2012) and the relationship between these variables and donor sex to responses 
rates and to selected questions about donor experience were examined using chi-
squared. Elsewhere descriptive analyses were applied.   




CHAPTER	  3.	  A	  RETROSPECTIVE	  	  STUDY	  EXAMINING	  THE	  
IMPACT	  OF	  JACIE	  ACCREDITATION	  ON	  RD	  CARE	  
A paper based on the findings of this study was published in the journal Bone Marrow 
Transplantation in November 2014, entitled “The impact of improved JACIE standards 
on the care of related BM and PBSC donors”   (Appendix 2) 
3.1 INTRODUCTION  
In the introduction to this thesis I described some of the studies conducted by large 
unrelated donor registries, which have demonstrated a reassuringly low incidence of 
short-term adverse events (Pulsipher et al, 2009; 2014) and a lack of evidence for long-
term effects of donation in this population (Shaw et al, 2015).  
There are far fewer data on which to base estimates of adverse events in related 
donors, however, studies to date suggest that these donors are at greater risk than 
UDs during BM and PBSC donation (Halter et al, 2009; Wiersum-Osselton et al, 2013; 
Kodera et al, 2013). In addition, surveys performed in Europe and the United States 
have outlined concerns regarding the potential for a conflict of interest when a single 
physician is simultaneously responsible for a related donor and their intended recipient. 
Differences between the care received by UD and RDs was also noted, including the 
absence of organised follow-up in the RD setting (Clare et al, 2010; O'Donnell et al, 
2010).  
As a result of such studies, changes have been made to FACT-JACIE Standards 
aiming to promote the interests of related donors. In April 2011, the 4th Standards 
(FACT-JACIE, 2011) introduced a requirement for  “a policy for follow-up of allogeneic 
donors that includes routine management and the management of donation-associated 
adverse events”. This was followed by a further recommendation in the 5th edition 
(March 2012) (FACT-JACIE, 2012) that allogeneic donors should be assessed by a 




“licensed health care professional who is not the primary transplant physician 
overseeing care of the recipient”   
Other organisations with an interest in donor health and safety have offered consensus 
recommendations in this field. The most comprehensive of these were produced by the 
Ethics Working Group and the Clinical Working Group of the WMDA (van Walraven et 
al, 2010b) and focus on donor counselling prior to HLA typing, consenting procedures 
(including the importance of independent consent, and offering donors a choice of 
donation route), and donor follow-up.  In 2013, a Worldwide Network for Blood and 
Marrow Transplantation (WBMT) consensus statement was published outlining the 
importance of standardised global follow-up for both RD and UD, with a recommended 
minimum data set to be collected at a minimum of 1, 5 and 10 years post-donation 
(Halter et al, 2013).  
To date, the impact of these efforts to improve related donor safety and to standardise 
care, has not been evaluated.  
Due to a lack of national or international medical suitability for related donors, 
screening procedures for RDs are likely to be less thorough than those undertaken for 
UDs internationally. One study (Coluccia et al, 2012) showed that just 26% of 500 RDs 
donating in Italy were screened in accordance with national UD protocols, and a large 
prospective study in Japan (Kodera et al, 2013) showed a 5 times greater risk of SAEs 
in RDs who did not meet national UD criteria.  
Most experts feel that RDs who undergo fully informed consent should be permitted to 
proceed with conditions for which an UD would be deferred, providing that the 
increased risk is felt to be minimal; but defining which conditions should be accepted is 
very difficult.  The question of an upper age limit for RDs in the absence of medical 
issues is particularly challenging. Most transplant centres accept donors above the UD 
upper limit of 55-60, but WMDA Standards for evaluation of UDs (Lown et al, 2014) 
were developed for donors under the age of 55-60, and the optimal approach to older 




donors is unclear, i.e. whether additional screening procedures are warranted 
(Niederwieser et al, 2004).  
A second concern when considering the use of older haematopoietic progenitor cell 
(HPC) donors is the quality of stem cells harvested. Older age (>55) correlated with 
lower CD34+ yields in some studies (Lysák et al, 2010; Richa et al, 2009; Vasu et al, 
2008) but despite this, adequate engraftment occurred, and medically fit older donors 
usually harvest adequate CD34+ cells to allow transplantation to proceed (de Lavallade 
et al, 2009; Richa et al, 2009; Vasu et al, 2008). 
To address these questions, I carried out a single centre retrospective study of related 
donors who underwent donation before and after introduction of these JACIE 
Standards. The primary objectives of the study were: 
1) To determine whether donors’ follow-up became more prevalent following the 
introduction of 4th FACT-JACIE Standards in April 2011 requiring “a policy for 
follow-up of donors that includes routine management and the management of 
donation-associated adverse events” 
2) To determine whether consenting procedure changed following introduction of 
the 5th FACT-JACIE Standards in March 2012 recommending that allogeneic 
donors should be assessed by a “licensed health care professional who is not 
the primary transplant physician overseeing care of the recipient”. 
Secondary objectives included: 
1) To evaluate whether serious adverse events were more likely to occur in donors 
who would not have been accepted as unrelated donors.  
2) To evaluate whether age alone was associated with an increased likelihood of 
serious adverse events in otherwise healthy donors.  
3) To assess whether donors >60 years old were less likely to achieve an optimal 
harvest.  




3.2 METHODS AND MATERIALS 
This was a retrospective study of all adult and paediatric allogeneic donors donating 
from January 2004 to December 2013 at the Royal Marsden Hospital. Donor health 
history, details of the harvest and yield, and adverse event and follow-up data were 
collected from the donor electronic medical records. The full material and methods can 
be found in Chapter 2.  
3.3 RESULTS 
3.3.1 DONOR AND PATIENT CHARACTERISTICS 
221 related donor transplants occurred during the study period. Five of these were 
excluded from the analyses, four because frozen HPCs were used which had been 
collected prior to the study period, and one because sibling cord blood was used. The 
data regarding the remaining 216 donations from 207 related donors were collected 
and analysed (9 siblings donated twice during the study period).  204 donors were fully 
matched siblings, one was a fully matched mother, one a fully matched cousin, and 
one was a haplo-identical son.  
 
Table 3.1 describes the donor characteristics. The median RD age at donation was 
43.5 years (range 22 months-74 years). 181 PBSC harvests were performed, of which 
two were classed as mobilisation failures and were followed by an emergency bone 
marrow harvest. 37 BM harvests were performed. 30 (14.5%) donors were paediatric 












Table 3.1. Characteristics of the 207 related donors and 216 donations 
studied 
 
*two BM harvests were performed as ‘rescue’ procedures following poor PBSC 
mobilisation  
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65 (31) 
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25  (12) 






























































Table 3.2. Characteristics of the transplant recipients  
Recipient 
characteristics 
N = 207 









89   (42%) 
 
3.3.2 THE EFFECT OF CHANGES TO FACT-JACIE STANDARDS ON 
DONOR CARE 
I was able to show significant improvements following changes to FACT-JACIE 
Standards. Prior to the introduction of a specific recommendation to separate donor 
and recipient consent in 2012, the same physician consented both the donor and their 
recipient in 34/173 (20%) cases, compared to 0/43 cases occurring after this event 
(p=0.003).  Despite this, on review of the patient records, I found that although the 
consenting procedure had been separated, in 26% of these 43 cases, the physician 
consenting the donor had nevertheless been responsible for the care of their intended 
recipient within the last month.  
I examined donor follow-up before and after the introduction of a specific FACT-JACIE 
requirement for donor follow-up in April 2011. I again found significant improvements, 
with follow-up beyond 1 week post-donation having been attempted in 37% of donors 
before this time point, compared 58% of donors after this point (p=0.007).   
Although insufficient details were available retrospectively to determine compliance 
with all the consensus recommendations published by WMDA (WMDA, 2013), I was 
able to analyse the reports of the consent discussions, and found that discussions had 
become more extensive over time, specifically regarding discussion of both potential 
routes of donation for adult donors. After guidelines recommending that donors be 




offered a choice of donation route were published in 2010, 80% adult donors were 
offered this choice, compared to 33% prior to 2010 (p<0.001). 
3.3.3 RETROSPECTIVE EVALUATION OF ADULT RDS USING ANTHONY 
NOLAN DONOR SUITABILITY CRITERIA 
On retrospective review of all adult RDs using national (Anthony Nolan) medical 
suitability criteria (available at http://med-guidelines.org.uk, accessed 12th November 
2013), I found that 53 of 177 adults (30%) would have been deferred as unrelated 
donors. The reasons for deferral are outlined in Table 3.3. Age over 60 years was the 
most common reason (29 donors, 55% deferrals) and of these donors, 19 would have 
been deferred for age alone, while the other 10 had a second deferrable condition 
(most commonly uncontrolled hypertension). 
Table 3.3. Deferral conditions for 53 deferrable donors on retrospective 
assessment using Anthony Nolan medical suitability criteria  
Reason would have been deferred Number of donors 
Age>60 29* 
Uncontrolled Hypertension 16 
Diabetes on treatment 5 
BMI >40 2 
Other ** 12 
*19 of these donors were also deferrable for a second reason other than age 
**Sickle trait undergoing PBSC donation; Gout three weeks pre-PBSC donation; endometrial 
cancer; gene repair defect msh2; previous intravenous drug user; central nervous system 
symptoms following head injury; multinodular goitre awaiting surgery; severe chronic back pain 
and paraesthesia; SVT pre-ablation; ischaemic heart disease  
3.3.4 SERIOUS ADVERSE EVENTS 
The serious adverse events reported in this donor cohort are described in Table 3.4. All 
SAE occurred in donors undergoing their first donation. Five adults (2.7%) and one 
paediatric donor (3.2%) developed SAEs. A 67-year-old male donor developed severe 
gout two weeks post donation, which did not respond to treatment. He then developed 




hypotensive episodes, which resulted in admission to hospital three weeks post-
donation.  A 62-year-old female with no previous cardiac history developed chest 
discomfort towards the end of her first apheresis procedure. Her ECG showed new T 
wave inversion, but her chest discomfort settled and cardiac enzymes were negative. 
The apheresis procedure was prematurely terminated, but the yield was nevertheless 
satisfactory (8.5x106 CD34+ cells/kg recipient weight). She was referred to her GP for 
follow-up cardiac investigations, the results of which were not available.  
In the third case, a 62-year-old male donor developed severe chest pain during 
mobilisation. On day 3 of mobilisation, he attended for review and was admitted for 
pain control and observation. Although the pain was not felt to be cardiac in nature, due 
to the severity of his symptoms the dose of GCSF was halved for subsequent doses. 
He went on to collect a satisfactory harvest (5.7x106 CD34 cells/kg recipient weight).  
The fourth SAE occurred in a 60-year-old male, who developed chest pain during 
mobilisation, which was relatively mild and was not reported to the transplant centre. 
He then described the same pain on arrival for apheresis and was found to have new 
ischaemic ECG changes in the anterior leads and a borderline troponin rise. He 
underwent PBSC harvest and was given aspirin and a statin but collected a CD34+ 
dose of 1.56x106/kg recipient weight on the first day. He was not given further GCSF 
and the following day his ECG had normalised and he underwent a second apheresis 
procedure. He subsequently underwent extensive cardiac investigations, which were 
unremarkable.    
The fifth SAE occurred in a 55-year-old man with no previous medical history who 
complained of pain in his right foot on arrival for apheresis. Examination was consistent 
with gout. He was harvested but symptoms continued to deteriorate over the next two 
days, such that he was unable to mobilise and could not return home by plane. His 
symptoms settled over a period of several months.   




One paediatric donor aged 22 months, received an allogeneic red cell transfusion 
following bone marrow harvest due to a post procedure haemoglobin 62g/L. This was 
the sole severe adverse event amongst paediatric donors. 
Table 3.4. Procedure related serious adverse events in five adult donors 
 
I analysed the donor characteristics associated with SAEs in these adults and found 
that 10.3% donors who were >60 years developed SAEs compared to just 1.3% of 
those aged 60 or less (p=0.020).  I also found that adults who would have been 
deferred due to donor health risks, had they been assessed according to Anthony 
Nolan donor suitability criteria, were more likely to develop SAEs. 8% of these 
deferrable adults developed SAE compared to 0.7% of donors who would not have 



















67 M 2012 PBSC Yes Age, 
hypertensio
n 
Gout + hypotensive 
collapse 3 weeks post-
donation 
62 F 2011 PBSC Yes Age Ischemic ECG changes 
during donation 
62 M 2008 PBSC Yes Age Chest pain requiring 
modification of GCSF 
dose during mobilisation 
60 M 2005 PBSC Yes Age Chest pain with ischemic 
ECG changes during 
apheresis 
55 M 2009 PBSC No NA Severe gout during 
donation  





Table 3.5 Factors influencing the incidence of severe adverse events 
 
3.3.5 THE IMPACT OF DONOR CHARACTERISTICS ON HPC YIELD AND 
ENGRAFTMENT 
3.3.5.1 PBSC donations 
A median yield 4.83x106 CD34+/kg recipient weight (range 0.15-54) was harvested 
from PBSC donors.  Engraftment occurred at a median 14 days in these recipients. 
There were no cases of primary graft failure, however 3 patients died of infection within 
28 days of transplant without engrafting.  
As shown in Figure 3.1, a significant reduction in CD34+ yield was associated with 
increasing donor age. Of note, this resulted in an effect on engraftment, recipients with 
a donor >60 years were more likely to take longer than the median 14 days to engraft 
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Figure 3.1 the relationship between donor age and CD34+ yield achieved at PBSC harvest.  
 
Table 3.6 The relationship between donor or recipient characteristics and 
recipient engraftment  
Characteristic  Number of recipients taking 
>14 days to engraft 
p 





































Although first PBSC harvests from male and female donors were equally likely to 
achieve the requested cell dose (>4x106/kg), harvest from male donors had a 
significantly higher yield than those from female donors (median 5.72 versus 4.66; 
p=0.02).  





3.3.5.2 Bone marrow donations  
Bone marrow donors harvested a median 2.66x106/kg CD34+ cells, and engraftment 
was seen at a median 20 days post-transplant in recipients of BM.  Harvests from 
paediatric donors who were donating to an older sibling were significantly less likely to 
achieve the target CD34+ cell dose of 4x106/kg recipient weight (18% versus 53%; 
p=0.031). I noted similar findings examining HPC yield as a continuous variable; a 
median of 4.16x106 CD34+/kg was seen in paediatric donors to a younger sibling 
compared to 2.6216x106 CD34+/kg from paediatric donors donating to an older sibling 
(p=0.037). 










3.3.6 DONOR FOLLOW-UP  
 
85 donors (41%) were offered follow-up beyond one week post-donation, achieving in 
total 95 donor follow-up years. Follow-up was undertaken using medical questionnaires 
to collect the minimum data set recommended by WBMT (Halter et al, 2013) in 54 
donors, and were returned by 30 donors (56%) with a  significant difference seen in 
response rate, depending on recipient health status. Only 31% of donors whose 
recipient had died returned their follow-up questionnaires, compared to 66% of donors 
whose recipient was alive at time of follow-up (p=0.020).  
27 donors had been offered clinic appointments at 3-9 months post donation, which 23  
(85%) attended.  GPs had been asked to provide follow-up for a further 4 donors.  




There was no record of an attempt to contact the remaining 124 RDs beyond one week 
post-donation, of whom 11 were living overseas and had no permanent address 
recorded by the hospital. I was, however, able to collect follow-up medical data from 19 
of the donors, who had either failed to return medical questionnaires or had not been 
offered follow-up, from reports from medical evaluation prior to subsequent lymphocyte 
donations, which occurred 2-60 months following their initial donation.   
In total, as detailed in Table 3.7, six donors described new medical issues at follow-up, 
none of which were felt to be donation related.  












M 66 Yes Age PBSC Required further 
hypertensive meds 
M 45 Yes Hypertension PBSC Macular degeneration 
F 57 Yes Multinodular 
goitre 
PBSC Neutropenia and 
rheumatoid arthritis 
M 50 Yes Gout 3 weeks 
pre-donation 
PBSC Gout 5 months post-
donation 
F 74 Yes Age PBSC Hypertension 
diagnosed 6 months 
post donation 
F 21 No NA PBSC On-going tiredness 2 
years post donation 
 
 
3.3.7 MATCHED DONORS WHO DID NOT PROCEED TO DONATION 
Over the period studied, 28 patients had at least one fully HLA matched sibling 
identified, but did not proceed to transplant with this donor. In 11 patients this occurred 
because the patient developed progressive disease or became subsequently 
unsuitable for allograft, due to clinical deterioration. Nine patients were considered for 
matched sibling allograft but finally determined to be more suitable for alternative 




treatment strategies. In one case a matched sibling donor was identified after having 
samples sent for HLA typing to the UK from the potential donor’s home abroad, but 
subsequently declined to donate due to the personal financial burden of travelling from 
abroad.     
Figure 3.4 The reasons for failing to proceed with sibling transplants in 28 patinets with matched 
sibling donors 
 
A further seven HLA-matched siblings were scheduled for donation but subsequently 
failed at the point of donor medical assessment. Of note, these cases all occurred in 
the latter part of the study period, between 2011-2013.   The reasons for deferral are 
described in Table 3.8. Six donors were failed for medical reasons and one for failure to 
commit to abstaining from high-risk sexual practices. Interestingly, 5/6 of these siblings 
failed medical evaluation due to abnormal haematological indices.  In three of these 
cases, two with eosinophilia and one with polycythemia, it was felt that the donor could 
potentially have been used if further investigations could be undertaken to exclude a 
primary haematological diagnosis.  However, these donors all lived overseas, and were 
unable to remain in the UK for sufficient time to allow such investigations to be 
completed. In each of these cases the decision was made to use a previously identified 
well matched UD instead.  
 
Patient	  unsuitable	  
Patient	  alternative	  treatment	  Sibling	  failed	  medical	  assessment	  




Table 3.8  Details of 6 related donors who were failed at the time of donor 
medical  
Reason for failing donor 
medical  
Patient outcome 
Anaemia+ eosinophilia UD HSCT  
Polycythaemia with 
microcytosis 
Foreign self-employed donor decision not to 
await investigation UD HSCT 
Eosinophilia + weight loss UD HSCT 
BMI 43+ polycythaemia Transplant delayed. Cord HSCT  
High risk behaviour UD HSCT 
High platelets. JAK2 positive 
on further testing 
UD HSCT 
Uncontrolled Hypertension Matched younger sibling used  
 
3.4 CONCLUSIONS 
Following the introduction of requirements for donor follow-up in 2011 and separation of 
donor and recipient consent in 2012, my results show significant improvements in 
these areas.  However, although donors were not consented by the physician 
consenting their intended recipient after 2012, I found that the donor’s physician had 
been responsible for the recipient’s care in a quarter of cases within the last month. 
This finding suggests that some potential for conflict of interest remains.  
To completely avoid a potential conflict of interest, the recipient and donor should 
ideally be cared for by separate teams. Although historically transplant physicians have 
provided donor care in the majority of centres, there is no reason that they should be 
uniquely able to do so. Stem cell donor evaluation should be performed by a clinician 
with the skills to identify occult medical conditions that may present a risk to the donor 
or recipient, however, a general physician or non-transplant haematologist should be 
equally well placed to conduct such an assessment. The important thing is that this 
donor assessor should undergo specific training in donor health, and should evaluate 
the donor independently.  




In this study, I found a similar incidence of SAEs to those reported previously 
(Wiersum-Osselton et al, 2013) but importantly, I was able to identify predictive factors 
here.   I found that donors who did not meet Anthony Nolan medical suitability criteria 
for reasons of donor risk, were more likely to experience SAEs. This was also true of 
donors aged over 60 years.   
The problem with this finding lies in the fact that deferral of all donors who did not meet 
the Anthony Nolan deferral criteria would have resulted in deferral of 28.6% of these 
adult donors, thereby depriving their recipients of the optimally matched donor. If age 
were not included as a deferral criterion, this high deferral rate would have fallen to 
18.4% of adults. Whilst it would be overly conservative to consider deferring all donors 
over the age of 60 on the basis of these results, my results suggest that consideration 
should be given to enhance screening procedures undergone by donors in this age 
group.   In both this study and other reports, cardiovascular complications constitute 
the majority of SAEs and additional cardiac assessment may therefore be warranted.  
Perhaps understandably, donors whose recipient had died were less likely to respond 
to follow-up questionnaires. This raises the question of whether donors may find it 
more acceptable to be followed up by an organisation separate to the centre where 
their relative was treated, or whether they are simply less willing to engage in follow-up 
due to negative connotations about the donation episode.  
This study had some notable limitations. Firstly, since the data were collected 
retrospectively, it is possible that additional adverse events other than those detailed 
occurred, but were not recorded in the donor record or were not reported by the donor 
to the transplant centre.  Secondly, the donor health information was collected from the 
report by the assessing physician, and since a number of different physicians were 
responsible for donor evaluation over this period, it is possible that some donors had 
medical conditions that were missed in these reports.  
In conclusion, this study importantly demonstrates that FACT-JACIE, as a regulatory 
body, can drive change in the field of related donor care. The identification of donor 




characteristics associated with increased likelihood of adverse events adds to current 
evidence in this area and should act as a basis for development of additional screening 
strategies in these donors, and for fully informing donors of additional risks posed.   
Ultimately, risk stratification and screening of older donors and those who do not meet 
UD medical suitability criteria should serve to reduce rates of SAEs in related donors.  
  




CHAPTER 4. A STUDY OF RELATED DONOR 
CARE IN THE UK, AND TRANSPLANT PHYSICIAN 
OPINIONS 
A paper based on the findings of this study was submitted to the British Journal of 
Haematology entitled “Variations in practice in UK transplant centres: results of a 
related donor care survey”. 
4.1. INTRODUCTION 
In the previous chapter I retrospectively assessed the changes resulting from the 
introduction of two FACT-JACIE standards directly addressing donor care, in a single 
UK transplant centre. I was able to show that practice had improved following as a 
result of regulatory standards, but that a potential for conflict of interest remained.  I 
also showed that this centre had been unable to fully comply with the requirement for 
donor follow-up.  
There are no published studies exploring the management of RDs UK wide.  A survey 
of RD care (Clare et al, 2010), conducted at the EBMT Annual Meeting in 2007, was 
completed by 22 UK nurses, comprising 34% of total survey respondents. The results 
of UK centres in this study were reported in aggregate with those of other nations, and 
showed variation in a) the way that donors were informed regarding the donation 
procedures, b) consenting procedure and c) follow-up policies. A weakness of this 
study was that the survey was completed by nurses who were not necessarily well 
versed in their centre’s procedures for managing related donors.  
Experts who have reported on the few studies performed to date examining related 
donor care have suggested two potential avenues towards improvement in this field. 
The first relates to standardisation of care within transplant centres through introduction 
of consensus guidelines for donor care procedures, along with specific medical criteria 
against which to evaluate donors. Some parties have suggested that these could be 
best implemented using existing regulatory frameworks to ensure compliance. The 




second option that has been proposed is that related donor management (or parts of 
the care pathway) could be performed by a separate organisation to the transplant 
centre, thus removing the problem of conflicted priorities for a transplant clinician 
assessing the donor while being involved in the care of their intended recipient. This 
idea was explored in detail in a debate session during the EBMT annual meeting 2013, 
where the perceived advantages and disadvantages of UD registry involvement in the 
care of RDs were discussed. Overall, the transplant physicians and donor care experts 
present at that debate expressed enthusiasm for exploring alternative models of related 
donor care. However, these experts were a group of self-selected clinicians who likely 
attended this session due to a pre-existing interest in donor welfare and these opinions 
cannot be generalised to the transplant community as a whole. 
Before starting to consider the optimal approach to donor care in the UK, a vital first 
step was to comprehensively define current UK care pathways, and to engage the 
physicians who are currently providing this care in discussion regarding alternative 
models of donor care.  I hypothesised that logistical and financial difficulties within 
transplant centres may result in incomplete compliance with some mandatory FACT-
JACIE Standards, and that the lack of defined criteria for RD care may lead to variation 
between centres regarding donor evaluation procedures and regarding the medical 
conditions with which RDs are accepted. To explore these hypotheses I undertook a 
UK-wide survey of related donor care.  
The primary objectives of this study were: 
• To determine compliance with recommendations including: 
a) mandatory FACT-JACIE Standards  
b) consensus recommendations on donor care   
i) WBMT recommendations for standardised donor outcome reporting    
ii)WMDA subgroup recommendations for family donor care management  
• To detect variations in RD evaluation procedures.  
 




The secondary objectives were:  
• To define how donor care in the UK is carried out for the whole pathway from 
initial contact with the donor through to follow-up procedures.  
• To investigate the views of UK physicians involved in RD care regarding current 
care pathways and attitudes to potential development of national guidance and 
alternative care pathways.    
4.2. METHODS AND MATERIALS 
A 47-item survey was sent to transplant directors of all UK transplant centres 
performing allogeneic stem cell transplants in adults. The survey was administered via 
a secure hyperlink (surveymonkey.com) from April to July 2014, with invitations sent 
via the BSBMT.  A full description of the materials and methods employed can be 
found in chapter 2. 
4.3. RESULTS 
4.3.1 RESPONSE RATE 
26 responses were received from 29 invited transplant centres. Duplicate responses 
were received from three centres, and one centre was excluded after answering ‘no’ to 
the first question “Does your centre assess/manage adult related donors?” This left a 
total of 22 responses for analysis; a response rate of 76%.  No statistically significant 
difference was seen in response rate by centre size, however all eight of the highest 
volume transplant centres (those performing >60 allografts per year) responded. The 
median number of allografts performed was 49 per year (range 4-92) and overall the 








Figure 4.1 The effect of centre volume on the response rate  
 
 
Of note, 19 of the 22 centres (86%) were JACIE accredited, and a further one centre 
had undergone first time inspection but not yet received accreditation.  
 
4.3.2 COMPLIANCE WITH FACT-JACIE STANDARDS  
I found very good compliance with the recommendations and requirements of FACT-
JACIE Standards in UK centres. 21 of the 22 respondents (96%) surveyed stated that 
their centre had a written policy for RD care.  Accreditation status influenced the 
likelihood of centres having a defined policy for RD care. Of the two centres that were 
not JACIE accredited nor had undergone first time inspection, 1 centre (50%) did not 
have a policy for RD care, while all 19 centres with accreditation or on the pathway to 
accreditation had an RD care policy (p=0.005). 
19 respondents (86%) stated that defined medical suitability are used for evaluation of 
related donors in their centre. Of these 15 respondents stated the origins of their 
suitability criteria. Four centres used the Scottish NHSBT related donor criteria, four 
used criteria based on UK UD criteria, and one centre on US (NMDP) criteria, and 
three centres based their criteria on UK blood transfusion service criteria. The 
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neither of which produce guidelines for determining donor medical fitness to proceed. 
Two accredited centres and one non-accredited centre lacked defined medical 
suitability criteria for adult related donors.   
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Table 4.1.  UK transplant centre compliance with regulatory standards and 



















All respondents confirmed that their centres comply with the requirement to provide 
RDs with information about donation prior to HLA typing. In 3 (14%) centres information 
about donation was communicated verbally at this point, while the other 19 (86%) 
Guideline or standard N (%) 
Existence of a written policy for RD 
care  
21 (95%) 
Medical suitability criteria exist 19 (86%) 
Information supplied to donors prior 
to HLA typing 
Verbal only 
Local written information 
National written information 
 
 
3  (14%) 
14 (64%) 
5  (23%) 
RD heath assessment prior to HLA 
typing 
By written health questionnaire 
Health questionnaire over phone 










Willingness to donate is verified pre-
HLA typing 
21 (96%) 
Donor consent and evaluation is 
undertaken by  
The same transplant physician 
managing the recipient 
A different transplant physician 
A physician from a different team 









Donor follow-up is performed 
To one week 
To one month 
To 1 year 
To 5 years 







There is a process for credentialing 











provided written information. In 5 (26%) centres this written information was nationally 
produced, with four centres supplying donors with the information booklet produced by 
Lymphoma and Leukaemia Research ‘donating stem cells’ (Bloodwise, 2012) and one 
centre supplying approved written information produced by SNBTS (Douglas, 2014). 
The other 14 centres produced their own local written information for donors.  
Respondents stated that RDs are consented by transplant physicians in 50% centres, 
by a physician from a separate team in 41% centres and by a physician from another 
organisation in 9% centres.  Only one respondent indicated that their centre was 
unable to meet the JACIE recommendation to separate donor and recipient care, by 
stating that the same physician would be simultaneously responsible for the care of the 
recipient.  
18 of the 20 centres that perform BM harvests on RDs comply with FACT-JACIE 
Standards in having a process for specific training of physicians performing BM 
harvests. 
The responses regarding donor follow-up procedures were varied. 21 (96%) centres 
performed short-term donor follow-up at either one week or four weeks post donation, 
however only 5 (23%) centres performed follow-up to 5 years and only 3 (14%) centres 
continued to 10 years.  As shown in Figure 4.3, donor follow-up was undertaken by a 
variety of methods, the most common being telephone calls. Of note, only three 
centres used written donor follow-up questionnaires, all of which were centres where 
one of the transplant physicians is concurrently employed by a UK UD registry. 23% of 
centres report data to EBMT using donor outcome forms, a further 36% were familiar 
with these forms but these were not used in their centre, and the remaining 36% of 
respondents were not familiar with this option for reporting donor data.  
 
 




Figure 4.3 Practice patterns of related donor follow-up: a) The time-points at which follow-up is 






4.3.3 ADHERENCE TO CONSENSUS RECOMMENDATIONS 
When I examined aspects of care that have not been addressed in FACT-JACIE 
Standards, but where published consensus criteria have aimed to harmonise practice, I 
found consistency in some areas. This included that 21 (96%) centres stated 
compliance with the consensus recommendation to verify donor willingness to donate 
before performing HLA typing, and 18 (82%) centres adhered to the recommendation 
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that donors should be informed of their HLA matching status before the recipient, (van 
Walraven et al, 2010b) while one centre informed the recipient first, and two stated ‘no 
consistent practice’.   
Regarding other recommendations, compliance was more varied. Perhaps most 
notably, 36% of respondents stated that their centre did not perform any assessment of 
donor health prior to HLA-typing of a potential donor. In centres where a health 
assessment was completed, this took the form of a formal questionnaire completed 
either over the phone or in person in 9 centres (43%) while in 4 (19%) this consisted of 
a verbal discussion with open-ended questions. 
4.3.4 ASSESSING THE MEDICAL SUITABILITY OF RELATED DONORS 
As shown in Table 4.2, I found considerable diversity regarding whether transplant 
centres would accept donors with specified health parameters that are known to 
influence either donor or recipient risk. Regarding donor risk, 12 (57%) stated that their 
centre had a limit for donor blood pressure, and 9 (43%) for donor BMI. Regarding 
recipient risk, 12 (57%) had a policy regarding previous allogeneic blood transfusion 
and 14 (67%) had a policy regarding previous tattoos. Age, which could be considered 
as both a donor and recipient risk factor, had an upper limit for acceptance in 9 (43%) 
centres.  
While routine full blood counts and basic biochemistry tests were performed by all 
centres, other investigations performed as standard by UD registries were not 
universally undertaken. ECGs are performed in all donors by 67%, Chest Xrays by 
33% of centres, and 43% of centres perform urinalysis in all donors.   
 
 




Table 4.2 Medical assessment of related donors in UK transplant centres 
Policies regarding donor care N (%) 














Related donors are accepted with the following 
conditions: 
Diabetes mellitus on insulin 
Asthma on tablet medication 
Previous IHD 






Full blood count 
Renal and electrolytes 
Bone profile 
Thyroid function 
Liver function tests 
LDH 
ESR 
Serum Protein Electrophoresis 











Table 4.3  The investigations performed as part of the related donor 
evaluation in UK transplant centres 







CXR 7 14 0 
ECG 14 7 0 
Abdominal US 0 19 2 
Haemoglobinopathy 
screen 
2 18 1 
Urinalysis 10 9 2 
ECHO 0 20 1 
Bone marrow 
aspiration 
0 15 6 




I found similar discrepancies between the answers regarding whether RDs would be 
permitted to proceed with specific medical conditions, with many centres  allowing 
relatives who would be refused as UDs to proceed with donation.  Most notably, 52% of 
centres stated that they would accept RDs with a history of IHD and 62% would accept 
donors taking insulin for diabetes mellitus.  
4.3.5 POLICIES REGARDING THE DONATION PROCEDURE 
All centres surveyed had apheresis facilities on site, but 3 centres did not have facilities 
for BM harvesting. RD BM harvests are performed by transplant physicians in 96% of 
centres, and in 73% of centres these physicians have simultaneous responsibility for 
the transplant recipient. Collection of autologous blood unit(s) prior to BM harvest was 
undertaken by only two centres (9%) which in one centre collected units are routinely 
returned. 63% of centres routinely give oral iron to BM donors. Donors are routinely 
kept overnight following BM harvest in 84% of centres, and in 43% of centres the donor 
will be cared for on the same ward as their recipient.  
Transplant physicians were responsible for the apheresis procedure in 16 centres 
(73%). 89% of centres use Granocyte® (lenograstim) or Neupogen® (filgrastim) to 
mobilise RDs. Two centres (9%) use a biosimilar GCSF, and, notably, 5 respondents 
(23%) stated that their centre had used off-label plerixafor to mobilise RDs. 50% of 
centres allow donors to give the first dose of GCSF and 59% allow donors to give 
subsequent doses. In the remaining centres GCSF is administered either by the 
transplant centre or by the donor’s GP. In 96% of centres donors are asked to contact 
the transplant team if they develop any issues during mobilisation, while in the 
remaining centre, donors contact the apheresis team.   
Regarding policies for donation limits for RDs, I found that only 5 centres (23%) have a 
policy for subsequent donations, while 59% have a limit for the number of apheresis 
procedures a donor may undergo at their initial donation and 14 (67%) have specified 
limits for the volume of BM collected at harvest. Where details of these policies were 
stated, limits were consistent with national UD policies in nearly all cases. 




4.3.6 VIEWS OF UK PHYSICIANS RESPONSIBLE FOR RD CARE 
As shown in Figure 4.4A, 57% of physicians described UK RD care as satisfactory. 
The most commonly stated reasons for considering care to be unsatisfactory were lack 
of standardised guidelines (72%) and inadequate donor follow-up (65%).  67% of 
respondents felt that national RD suitability criteria would improve donor health and 
81% responded that guidelines for the whole donation process would improve care. As 
shown in Figure 4.4C, mixed opinions were reported regarding the optimal model for 
RD care in the UK, but notably, only 27% of respondents thought that RD care should 
be performed by a separate organisation to the recipient’s transplant centre.  
 
 
Figure 4.4. The views of responding physicians in UK transplant centres regarding current 
practice in related donor care: A) Overall opinion; B) Reasons for finding care unsatisfactory; 















4.4 CONCLUSIONS  
The results of this study provide a unique in-depth analysis of RD care which, with a 
response rate of >75%, is representative of current UK practice.  I was able to show 
near universal consistency in practice in areas where clear FACT-JACIE Standards 
exist. This included the presence of policies for RD care, provision of information to 
potential RDs prior to HLA typing, and measures to prevent the same physician being 
simultaneously responsible for an RD and their intended recipient.   I showed that 
international consensus recommendations in RD care have not been so widely adopted 
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in the UK, particularly regarding assessment of donor health prior to HLA typing and 
regarding length of donor follow-up.  
I found distinct differences between transplant centres in both the suitability criteria and 
the investigations employed during evaluation of potential RDs, and crucially, I was 
able to show that this leads to RDs who would be accepted by some centres being 
deferred by others.  
The major limitation of this study was that despite a very satisfactory response rate, the 
low number of respondents limits the possibility to explore the relationship between 
practice and centre characteristics, and for this reason, the analysis I performed is 
purely descriptive. Secondly, although I was able to demonstrate diverse practice in the 
medical conditions with which relatives would be permitted to proceed, I was unable to 
investigate this in depth. For example, accepting a donor with a history of ischaemic 
heart disease who has undergone a curative intervention and who undertakes informed 
consent regarding this specific risk, is very different to accepting a donor who has had 
a recent myocardial infarct, or a donor with whom an increased donation-associated 
risk has not been discussed.  Thirdly, although I requested that transplant directors 
forward the survey to the person in their centre responsible for donor care, there was 
no guarantee that this person was familiar with every aspect of their centre’s 
procedures.  
Discrepancies between centres in their approach to acceptance of RDs is not 
surprising given the lack of specific RD suitability criteria. While clear medical criteria 
have been published for UDs, it is not possible to directly apply these to RDs. Although 
some experts would argue that it is not right to allow RDs to undergo more risk than a 
UD, many others feel that the risk/benefit ratio is different for an RD who often has a 
potential psychological benefit to gain from a successful transplant outcome. There is a 
general agreement that it is not right to expose any donor to a known substantial health 
risk, but there are grey areas, where the risks are theoretical or inadequately defined. 
In the UD setting these grey areas rightly lead to deferral, but in the RD setting 




flexibility may be appropriate. For example, using a protocol exception system to gain 
specific consent regarding potential increased risk in such cases.   
The most notable areas in which consensus guidelines are not adhered to are 
assessment of RD health prior to HLA typing, and RD follow-up.  Although donors are 
counselled before HLA typing in all centres, and willingness to proceed is verified in all 
but one centre, 36% of centres do not undertake a health assessment at this time. 
Assessment of potential RD health prior to HLA typing is necessary, both to prevent 
delays to the transplant recipient by reducing deferrals at the point of donor medical, 
and by reducing potential distress or guilt to the RD by being cancelled after they are 
known to be HLA-matched.  Likewise, there is a strong rationale for long-term donor 
follow-up, which was only performed in 3 centres, which is particularly important given 
my finding that >20% of centres have used off-label plerixafor in RD mobilisation. I 
suspect that logistical issues are responsible for the failure to develop follow-up 
systems in UK transplant centres, however, these can potentially be conducted with 
minimal resource implications if standardised questionnaires are used to collect a 
minimum data set. This finding raises the question of whether this particular aspect of 
care could be provided by another organisation e.g. a UD donor registry.  Finally, I was 
able to show enthusiasm for development of national guidelines for RD care and 










CHAPTER	  5:	  AN	  INTERNATIONAL	  PERSPECTIVE	  ON	  
RELATED	  DONOR	  CARE	  
Two papers based on the findings of this study were published in the journal Biology of 
Blood and Marrow Transplantation in December 2015, entitled “EBMT transplant 
centres with FACT-JACIE accreditation have significantly better compliance with 
related donor care standards” and “Significant improvements in the practice patterns of 
adult related donor care in US transplant centres” (see Appendix 2) 
5.1 INTRODUCTION 
In the previous chapter of this thesis I described current UK related donor care practice 
and demonstrated variation in both how care is delivered, and regarding the medical 
conditions with which relatives are permitted to proceed as donors. In order to consider 
how further initiatives in this field might result in greater uniformity, it was necessary to 
establish care patterns in other nations economically comparable to the UK.  
Three studies described in the introduction have directly addressed this topic. Their 












Table 5.1 Investigations examining the pathway of related donor care  
 US Italy Europe 
Year of 
study 
2007 2005-2009 2005 
Study 
design 
Prospective survey Retrospective review 






9 centres, with 352 
RD notes analysed 
63 Nurses attending 





>70% centres the 
same physician 
consenting the 
donor had either 
simultaneous 
responsibility for, 
or might be 
involved in the 




consent. 91% were 
offered information 
about both BM and 
PBSC procedures 
75% indicated RDs 
were consented by a 
physician who was 





Not studied Not studied 11% centres donor HLA 
results were first 




>70% centres the 
physician 
providing donor 




or might be 
involved in the 
care of, the 
recipient  
Only 26% donors 
underwent thorough 
screening according 






Not studied 8/9 provided follow-
up to one month 
post-donation. 5/9 
provided follow-up 
beyond 1 year. 
60% respondents 
stated their centre 
provided follow-up but 
this was limited follow-
up in 10% and duration 




5% centres lacked 
written policies for 
management of 
RDs 




Information for related 
donors was from local 
sources in >50% and 
was relayed by 
transplant team in 84% 
cases 
 




As a result of these studies, guidelines and regulations aimed at improving the safety 
and wellbeing of related donors were published, but the impact of these efforts had not 
been evaluated. This chapter details two studies, conducted in parallel, to explore in 
detail pathways of related donor care internationally, and to assess the influence of 
regulatory change.  
 
5.1.1 OBJECTIVES OF THE STUDY OF RD CARE IN US TRANSPLANT 
CENTRES 
The study published by O’Donnell et al in 2010 focused on the potential conflict of 
interest that exists when a single healthcare professional is responsible for the care of 
both a related donor and their recipient. This publication had practice- changing 
consequences and directly led to changes in FACT-JACIE standards.  
By examining current practice in the USA, I would be provided with an opportunity to 
directly assess the effect of these changes on healthcare provision of RD care by 
asking transplant directors identical questions to the earlier study and comparing 
responses between eras. I therefore proposed a repeat study, but with a broader 
scope, to examine the whole donor care pathway. The proposal was accepted by the 
donor health and safety working committee of the CIBMTR.  
The objectives of this study were: 
• To determine whether a greater proportion of centres now ensure separation of 
related donor care compared to reports from the 2007 survey conducted by 
O’Donnell et al.  
• To evaluate compliance with regulatory standards and international consensus 
recommendations.  
• To explore practice patterns in areas of care that are hypothesised to differ from 
unrelated donor paradigms.    
 
 




5.1.2 OBJECTIVES OF THE STUDY OF RELATED DONOR CARE IN EBMT 
MEMBER TRANSPLANT CENTRES 
As described in Chapter 3, I found key differences in provision of care following the 
introduction of FACT-JACIE requirements in specific areas. These findings led me to 
the hypothesis that adult RD care in Europe is more likely to conform to FACT-JACIE 
Standards and international guidelines in centres with JACIE accreditation, compared 
to those that have not gone through the accreditation process. To test this hypothesis I 
decided to undertake a study of RD care in EBMT centres addressing all the areas of 
care that has been studied in the 2005 survey by the EBMT Nurses Group/Late Effects 
working party. In addition I aimed to examine other aspects of care where clear 
standards exist in the UD setting, but which have not yet been considered by regulatory 
bodies in RD care. 
The objectives of this survey in EBMT member transplant centres were: 
• To compare provision of related donor care between JACIE accredited and non-
accredited transplant centres.  
• To evaluate compliance with regulatory standards and international consensus 
recommendations.  
• To explore practice patterns in areas of care where clear UD standards exist, 
but which are not yet embedded in regulatory guidance for RDs. 
• To determine, where possible, changes in care since the 2005 survey (Clare et 
al, 2010).  
 
5.2 METHODS AND MATERIALS 
A 38-item survey developed to examine related donor care practice (see Appendix 1) 
was administered as an internet-based questionnaire. I worked with the authors of the 
earlier US study (O'Donnell et al, 2010) to ensure identical language was used to the 




earlier survey. Invitations were sent by email to transplant directors of all CIBMTR and 
EBMT member centres. UK centres were excluded, these having been evaluated in the 
study described in Chapter 4. The full materials and methods are described in Chapter 
2.  
5.3 RESULTS OF THE STUDY IN US TRANSPLANT CENTRES 
5.3.1 RESPONSE RATE 
Excluding 3 duplicates, 73 responses from 139 eligible centres in the US were 
received, a response rate of 53%. All respondents answered ‘yes’ to the question ‘does 
your centre assess/manage adult related donors?’. 
Centre transplant volume (defined as the number of allografts per year) significantly 
impacted the likelihood of a response, with similar patterns observed to those reported 
in the 2007 survey (shown in Figure 5.1); 67% of non-responding centres performed 
less than 30 allografts per year, compared to 22% of responding centres (p<0.0001). 
Since non-responding centres tended to have small transplant volumes, centres who 
responded to the survey had performed >80% of total allogeneic HCTs and 79% of 
total related donor HPC transplants reported to NMDP (2011-2012).   
Figure 5.1 Survey response rate by centre volume (number of allogeneic hematopoietic cell 
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Figure 5.2 Distribution of responding and non-responding transplant centres by geographic 
region: NE indicates, New England; Mid-Atl, Mid-Atlantic; S-Atl, South Atlantic; ENC, East North 
Central; ESC, East South Central; West North Central; WSC, West South Central; Mtn, 
Mountain and Pac, Pacific. (Anthias et al, 2015a) 
 
 
FACT accredited centres were more likely to respond; 70/109 (64%) accredited versus 
3/30 (10%) non-accredited centres responded (P<0.001). 70 (96%)  responding 
centres were FACT accredited, one further centre had undergone first time inspection, 
and the remaining centres were working towards accreditation. A response rate of 59% 
was seen in NMDP-affiliated centres but no responses were received from non-NMDP 
centres. As shown in Figure 5.2, the response rate did not vary significantly between 
US regions, with a similar pattern to the earlier survey. 
 
 













5.3.1.3 Comparison of US centre responses with 2007 survey 
I compared responses regarding provision of donor care between my study and the 
earlier study conducted in 2007 (O'Donnell et al, 2010). All 73 respondents to the 2014 
survey indicated that their centre had a written donor care policy, which had been 
lacking in 5% of centres in the earlier study. 
I found that transplant physicians remained responsible for donor clearance in 77% of 
centres, a very similar figure to the earlier survey (shown in Figure 5.3). However, there 
had been a major improvement in separation of donor and recipient care between the 
two eras (shown in Figure 5.4), with 62% of respondents now indicating that their 
centre ensures separation of recipient and donor care, an increase from 23% in the 
previous survey. In just 7% of centres the physician responsible for donor clearance 
  Responding centres (N = 73) 
Median related donor allografts per 
year  (range) 
25 (1-167) 
Related donor allografts per year, n 
(%) 
 
<10 12  (16) 
11-40 45  (62) 
41-70 9    (12) 
71 or more 7    (10) 
  
Median total allografts per year 
(range) 
63  (1-397) 
Total allografts per year, n (%)  
<30 16 (22) 
31-50 15 (21) 
51-99 25 (34) 
100-299 14 (19) 
300 or more 3  (4) 
  
NMDP-affiliated transplantation centre 
n (%) 
73 (100) 
FACT accredited centre, n (%) 70 (96) 




routinely currently has responsibility for the transplant recipient (reduced from 32% 
centres in 2007), and in 30% of centres the physician responsible for donor clearance 
may be involved in the care of the transplant recipient (a reduction from 42% centres in 
2007); p<0.0001. 
Figure 5.3 Professional background of the provider responsible for donor clearance in US 
transplant centres (Anthias et al, 2015a)
 
 
Figure 5.4 Involvement of the physician providing donor clearance in the care of the recipient in 
US transplant centres (Anthias et al, 2015a) 
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The five respondents who stated that the physician providing donor clearance in their 
centre would always be simultaneously responsible for the recipient were asked 
additional questions about the use of a donor advocate and provision of donor care at 
other points.  
In four (80%) of these centres, both donor consent and donor medical management 
were also performed by the physician with simultaneous responsibility for the recipient, 
while one respondent stated that this physician may have responsibility for the 
recipient.  
Four (80%) of these centres stated that related donors would always have a specific 
donor advocate, distinct from the transplant recipient’s primary treating physician, to 
fully inform and protect the interests of the donor.  
 
Figure 5.5 Involvement of the physician providing donor consent and donor medical 
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5.3.2 COMPLIANCE WITH REGULATORY STANDARDS AND CONSENSUS 
RECOMMENDATIONS IN ASPECTS OF RD CARE NOT ADDRESSED IN THE 
2007 SURVEY 
5.3.2.1 Care of potential donors prior to HLA typing 
I observed considerable variation in the management of RDs during the early stages of 
donor care (shown in Table 5.2). In almost half of centres RDs were informed about the 
donation process through a verbal discussion, without receiving written information. 
Despite specific information for RDs being freely available from the NMDP, this was 
used by only 7% of centres, with a further 45% producing local written information for 
donors. Verification that the donor was theoretically willing to undertake donation was 
not determined in 25% of centres before drawing blood for HLA typing. Furthermore, in 
30% of centres an assessment of donor health was not undertaken prior to determining 
RD matching status, and only a small proportion of centres (17%) conduct a formal 
health history questionnaire at this point.   
Disclosure of donor HLA typing results was not performed in accordance with 
recommendations in the majority of centres, with 25% centres informing the potential 
recipient about their donor’s HLA matching status before the donor themselves. In 17% 
of centres these results were disclosed to a referring physician, 19% of respondents 
stated that their centre had no consistent practice, and only 39% indicated that the 









Table 5.3 Responses regarding the care of related donors prior to HLA 
typing in US transplant centres 
  
 
5.3.2.2 Donor care policies and harvesting procedures  
As demonstrated in Table 5.3, the policies required for compliance with current (5th 
edition) FACT-JACIE Standards were almost universally in existence in responding 
centres. In addition to a written RD care policy in all centres, 67 respondents (92%) 




Number of centres 
Source of  
recommendation 
Healthcare provider making initial 
contact prior to HLA typing: 
Transplant physician 
Other Physician 














Information supplied to donors pre- 
HLA typing: 
Verbal only 
Local written information 










RD heath assessment pre-HLA typing 
By written health questionnaire 
Health questionnaire over phone 
Verbal discussion open ended questions 







Family donor care 
management  
Willingness to donate is verified pre-HLA 
typing 
55 (75%) Family donor care 
management 
Individual to whom donor HLA results 














Family donor care 
management 




based on NMDP suitability criteria for unrelated donors in 59% of centres and on 
WMDA criteria in 4%.  
84% of respondents from centres where BM harvests are performed on related donors 
stated compliance with FACT-JACIE standards by having a process for credentialing 
the physicians performing these procedures.   






5.3.2.3 Donor follow-up 
Despite explicit FACT-JACIE requirements for a follow-up policy for RDs and 
international consensus recommendations, I found that long-term donor follow-up in US 
centres is non-existent. As shown in Figure 5.6, >90% of centres provided short-term 
follow-up at one week post-donation. This was usually conducted by telephone, 
although 18% of centres arrange a donor follow-up clinic appointment at this stage. In 
the majority of centres, no further follow-up occurred, and in only 14% of centres did 
the duration of follow-up extend beyond a week, with no US centres surveyed providing 
follow-up of RDs beyond one year post-donation.  
 
 Number of 
centres 
Existence of a written policy for RD care  73 (100%) 
Written eligibility criteria exist for 
acceptance of RDs 
67 (92%) 
A health history questionnaire forms part 
of the donor assessment 
65 (89%) 
There is a process for credentialing 
physicians performing BM harvests 
61 (84%) 




Figure 5.6 Related donor follow-up: The duration of donor follow-up offered and the method by 
which follow-up is provided in US transplant centres (Anthias et al, 2015a).   
 
5.3.2.4 Comparison of care with unrelated donor care standards 
I examined other aspects of care where clear policies exist for UDs, but which have not 
been addressed in current RD recommendations. Policies regarding specific limits for 
donation were present in some centres but were not universal. Only 45% participants 
stated that their centre had a limit for the maximum number of apheresis procedures 
per donation, which where specified were in line with UD practice in 59% of cases.  Of 
note, 29% of centres had used off-label plerixafor for RD mobilisation outside a clinical 
trial context.   
 
BM harvest policies were more prevalent, with 68% of centres reporting a limit for 
aspirated BM harvest volume, most commonly 20mls/kg, and in only one case did the 
specified limit exceed NMDP guidelines for UD marrow harvests with a centre allowing 
up to 2500mls to be collected from donors weighing >50kg. Autologous blood was 
collected from donors and returned in 50% of centres, and collected but not returned in 
a further 14%.  As per standard US UD practice, 64% BM harvests donors were 
discharged on the day of donation.  
 
26 centres (37%) had a policy regarding subsequent donations from RDs. Interestingly, 





















with one centre not allowing any subsequent donations.  
Table 5.5 Comparison of related donor care in US transplant centres with 
unrelated donor care practice 
 
 




Existence of a policy for maximum number 
of apheresis procedures during initial 
donation 
Yes, 2 procedures 
Yes, 3 procedures 












Maximum of 2 
procedures 
Who gives the 1st GCSF dose to donors 
Transplant centre 








Medical responsibility for apheresis  
Transplant physician 




Never a physician 
involved in recipient 
care 









Registries must have a 
policy 






As per NMDP 










Routinely 1 further 
stem cell donation and 
1 T cell donation with 
further donations 
potentially allowed at 
MD discretion (WMDA) 
BM harvests are performed by: 
The transplant team caring for the recipient 






BM harvests are never 
be performed by 
professionals involved 
in recipient care 
A policy defines the maximum volume aspirated 
at bone marrow harvest apheresis procedures a 
donor may undergo for their initial donation 
 
44 (60%) 
Maximum 20mls/kg in 
most registries 











Plerixafor is not used 




5.3.2.5 The effect of centre volume on related donor care 
I compared transplant centres performing fewer than the median 25 RD HPC 
transplants per year to higher volume centres (Table 5.6) and found that RD marrow 
harvests were more likely to be performed by the same transplant physicians caring for 
the recipient in lower volume centres (70% versus 38%; P=0.009). Low volume centres 
were also less likely to have a policy defining the limit for BM volume aspirated at 
harvest, which was present in 57% lower volume versus 79% higher volume centres 















Table 5.6 The impact of transplant centre volume on related donor care in 
US transplant centres 






≥ 25 RD 
transplants 
per year 
RD heath assessment pre-HLA 
typing 
28 (75.7%) 23 (63.9%) 0.27 
Willingness to donate is verified pre-
HLA typing 
28 (75.7%) 27 (7 7.1%) 0.88 
Donor HLA results are disclosed 
first to the donor  
17 (45.9%) 11 (31.4%) 0.21 
Written eligibility criteria exist for 
acceptance of RDs 
33 (89.2%) 34 (97.1%) 0.19 
Is plerixafor ever used for 
mobilisation of RDs 
Yes 
No 














There is a policy defining the limit 
for the number of apheresis 
procedures RDs may undergo for 
their initial donation 
16 (47.1%) 17 (50%) 0.60 
There is a policy regarding 
subsequent donations from related 
donors 
13 (36.1%) 13 (38.2%) 0.85 
Physician responsible for donor 
clearance has simultaneous 
responsibility for the recipient 
2 (5.4%) 3 (8.6%) 0.38 
Donor follow-up extends beyond 1 
week 
6 (16.2%) 8 (22.2%) 0.79 
RD marrow harvests are performed 
by the recipient’s transplant team 
25 (70%) 12 (37.5%) 0.009 
There is a process for credentialing 
physicians performing BM harvests 
32 (91.4%) 29 (96.7%) 0.81 
There is a policy defining the limit 
for the BM volume aspirated at 
harvest  
20 (57%) 23 (76.7%) 0.077 
 
 





5.4 CONCLUSIONS FROM THE STUDY OF US TRANSPLANT 
CENTRES 
This study provided an opportunity to directly assess the impact of a change in 
regulatory standards on practice patterns in related donor care. I was able to show a 
significant improvement regarding the potential for conflict of interest with only 7% of 
centres now routinely allowing a physician to be responsible for medical clearance of 
an RD while having simultaneous responsibility for their recipient, compared to 32% in 
2007.  I also made important observations regarding aspects of RD care, which have 
never been previously evaluated in the US.   
The centres responding to this survey perform approximately 80% adult RD 
transplants, and these results therefore provide an accurate overview of the care the 
majority of RDs currently receive. Since there was a very low response rate in the small 
number of centres performing <30 allografts annually, as well as centres lacking FACT 
accreditation or NMDP affiliation, the results cannot be generalised across these 
centres. 
Overall, I found practice in US centres to be largely compliant with the majority of FACT 
requirements, including the existence of a policy for RD care, written donor eligibility 
criteria and a credentialing process for physicians performing BM harvests.  However, 
this was not the case for RD follow-up, which is universally absent in US transplant 
centres, despite a FACT requirement and international (WBMT and WMDA) 
recommendations advocating 10 year follow-up for all donors. 
Regarding aspects of care in which there are no regulatory requirements, but where 
World Marrow Donor Association Standards for UDs could be used as a comparison, 
practice was markedly inconsistent. Of particular concern were the observations 
around lack of assessment and counselling prior to HLA typing. Counselling at this 




stage is essential, both to identify health issues that would preclude donation, and 
reluctance about donation and hence, allow early deferral of unwilling or unfit donors. 
5.5 RESULTS OF THE STUDY IN EBMT MEMBER TRANSPLANT 
CENTRES 
5.5.1 RESPONSE RATE 
Excluding 2 duplicates, and four cases that prematurely terminated when respondents 
answered ‘no’ to the first question: “Does your centre perform allogeneic HPC 
transplants from adult (>18 years old) related donors?” responses were received from 
118 of a total of 304 invited centres, a response rate of 39%. Data were not available 
from EBMT to identify centres that performed only paediatric transplant and would 
therefore have been ineligible for this study.   
A significantly higher response rate was observed in JACIE-accredited compared to 
non-accredited centres (52% versus 33%; p=0.001) and overall 59 (50%) responding 
centres had JACIE accreditation.  As shown in Figure 5.7, the centres (those 
performing <10 allografts per year), had the lowest response rate, but no other 
consistent pattern in response rate by centre size was observed.  The median number 
of first allografts per year in responding centres was 23 (range 1-172).  As shown in 
Figure 5.8, no significant difference in response rate was observed between 








Figure 5.7 Distribution of transplant centre volumes at responding and non-responding EBMT 
centres (Anthias et al., 2015b) 
 
Figure 5.8 Distribution of responding and non-responding transplant centres by geographic 
region: Eastern Europe; Northern Europe; Southern Europe; Western Europe and Non-








5.5.2 PROCEDURE FOR ASSESSMENT AND COUNSELLING DURING HLA 
TYPING 
The first stages of RD care were delivered by the transplant team in the majority of 
cases with transplant physicians or specialist nurses making initial contact with donors 
in two thirds of centres.  There was a trend towards accredited centres being more 
likely to provide written information to donors at this point, which was supplied by 55% 
of accredited and 40% of non-accredited centres. (p=0.073). Almost all of the written 
information given to donors was produced locally, with only 4 centres using national 
sources, which in 3 cases were specified as publications produced by the national UD 
registry.  
I found poor compliance, in both accredited and non-accredited centres, with 
recommendations on family donor care management (van Walraven et al, 2010) 
regarding assessment of donor health prior to HLA typing. No assessment of health 
was made in 43% of centres, and, in centres where this was undertaken it was most 
likely take the form of a verbal discussion with open-ended questions, with only 21% of 
centres using a health questionnaire.    
 
Accredited centres were significantly less likely to first disclose the donor’s HLA results 
to an individual other than the donor themselves (61% versus 86%; P=0.007). In fact, 
non-accredited centres were more likely to disclose donor HLA results to the recipient 












Table 5.7 Responses regarding the care of donors at the point of HLA 











Healthcare provider making 
































Information supplied to 
donors pre HLA typing 
Verbal only 
Local written information 



















RD heath assessment pre-
HLA typing 
By written health questionnaire 
Health questionnaire over 
phone 
Verbal discussion open ended 
questions 
No assessment 
Not a JACIE 
requirement. 
Recommende




















Willingness to donate is verified 
pre-HLA typing  
Not a JACIE 
requirement. 
Recommende








Individual to whom donor 


































Figure 5.9 The individual to whom donor HLA result are first disclosed in accredited and non-
accredited EBMT transplant centres (Anthias et al., 2015b) 
 
5.5.3 HEALTHCARE PROVIDERS INVOLVED IN EVALUATION OF RELATED 
DONORS 
The medical clearance of RDs was undertaken by transplant physicians in 45% of 
accredited and 69% of non-accredited centres (P=0.036). Overall, in 24% of centres 
this physician was routinely responsible for the transplant recipient, and a further third 
of respondents indicated that the physician providing donor clearance would be 
affiliated with the transplant programme and may be involved in the recipient’s care. 
The practice of overlapping donor and recipient care occurred more frequently in non-










Donor	   Recipient	   Referring	  physician	   No	  consistent	  practice	  
Accredited	  Non-­‐accredited	  




Figure 5.10 Professional background of the provider responsible for donor clearance in EBMT 
transplant centres (Anthias et al., 2015b) 
 
Figure 5.11 Involvement of the physician providing donor clearance in the care of the recipient 
in EBMT transplant centres (Anthias et al., 2015b)
 
The 24 respondents who stated that the physician providing donor clearance in their 














































additional questions regarding the potential for conflict of interest.  As shown in Figures 
5.12 and 5.13, in 23 (96%) of these centres the physician(s) taking consent and 
providing medical management for the donor would also be routinely responsible for 
the recipient or might be involved in recipient care.  In only a quarter of these centres 
would donors always have a specific donor advocate to protect their interests. 
Figure 5.12 Comparison of the role of the physician consenting related donors in accredited and 




























involved in the 




program but not 
involved in 
recipient’s care
Not involved in 
the transplant 









Figure 5.13 Comparison of the role of the physician medically managing related donors in 
accredited and non accredited EBMT centres	  
	  
I explored other areas, not previously studied, where there may be a potential for 
conflict of interests. I found that BM harvests were performed by the same transplant 
physicians caring for the recipient in 82% of centres. In 80% of centres donors were 
asked to contact the transplant team if they developed complications during the 
mobilisation period, and transplant physicians were responsible for the apheresis 
procedure in 42% of centres. In these areas no significant difference between 
accredited and non-accredited centres was observed. 
5.5.4 DONATION POLICIES AND PROCEDURES IN RELATED DONOR CARE 
As shown in Table 5.8, accredited centres were far more likely to conform to FACT-
JACIE requirements regarding donor care policies. This included that accredited 
centres were significantly more likely to have a policy for RD care (98% versus 83%; 
P=0.004), to use defined eligibility criteria to assess RDs (93% versus 78%; P=0.02), 
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and to have a process for credentialing physicians performing BM harvests (86% 
versus 63%; P=0.008).	  
A trend was also observed towards accredited centres being more likely to have a 
policy defining a limit to the number of apheresis procedures a donor could undergo 
during their initial donation (72% versus 55%; p=0.057). However, no impact was 
observed on the likelihood of a policy defining BM harvest limits, which existed in 66% 
of centres or a policy regarding subsequent donations, which was reported by 44% of 
centres.  
Somewhat surprisingly, a third of centres had used off-label plerixafor as a mobilising 
agent in related donors, with a significantly higher proportion of non-accredited centres 













Table 5.8 Reponses regarding donor care policies in accredited and non-
accredited EBMT transplant centres 
 
5.5.5 DONOR FOLLOW-UP 
As demonstrated in Figure 5.14, 89% of centres described a donor follow-up 
programme, which extended beyond a year post-donation in over two thirds of centres, 
and up to 10 years in 20% of centres. Although accreditation was not associated with 
the presence of donor follow-up programme, centres with FACT-JACIE accreditation 






Written eligibility criteria exist for acceptance of 
RDs 
 53 (93%) 45 (78%) 0.02 
Source of eligibility criteria:  
Locally written  
Based on NMDP criteria  










A health history questionnaire forms part of the 
assessment at donor medical 
52 (91%) 41 (72%) 
 
0.008 
There is a policy defining the limit for the 
number of apheresis procedures RDs may 
undergo for their initial donation 
39 (72%) 31 (55%) 0.057 
Plerixafor has been used for mobilisation 
of RDs  
Yes 
No  















BM harvests are performed by:  
Transplant physicians caring for the recipient 










There is a process for credentialing physicians 
performing BM harvests 
48 (86%) 29 (63%) 0.008 
There is a policy defining the limit for the BM 
volume aspirated at harvest 
37 (66%) 30 (65%) 0.984 
Long term (10 year) follow-up is performed 20 (34%) 8 (14%) 0.05 




follow-up (34% versus 14%; p=0.05).  The majority of follow-up programmes included 
outpatient clinic appointments, with only a minority using donor questionnaires.  
Figure 5.14 Duration and methods of related donor follow-up in EBMT-member transplant 
centres 
 
5.5.6 THE IMPACT OF TRANSPLANT CENTRE VOLUME  
Centres performing fewer than the median of 23 allogeneic HPC transplants each year 
were less likely to be accredited than higher volume centres. In univariate analysis the 
practice of a single physician having simultaneous responsibility for RD clearance and 
care of their recipient was significantly more likely to occur in lower volume centres, 
and these centres were also more likely to disclose the donor’s HLA results to the 
recipient first. However, when these factors were included in multivariate analysis, only 









1	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  years	   10	  years	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JACIE accreditation 37% 67% 0.002 
Existence of a written SOP for RD care 90% 92% 0.63 
Written eligibility criteria exist for acceptance of 
RDs 
84% 86% 0.836 
Willingness to donate is verified pre-HLA typing 77% 70% 0.376 
Donor health is assessed pre-HLA typing 61% 54% 0.476 
Donor’s HLA results are first disclosed to the 
recipient 
29% 12% 0.045 
Recipient’s physician routinely has simultaneously 
responsibility for their RD 
32% 14% 0.030 
There is a policy defining the number of RD 
apheresis procedures (per donation) 
60% 69% 0.327 
There is a policy defining the limit for the BM 
volume aspirated at harvest 
60% 72% 0.147 
There is a process for credentialing physicians 
performing BM harvests 
75% 76% 0.824 
Donor follow-up beyond one year  48/67 42/51 0.175 
 
5.5.7 COMPARISON WITH THE RELATED DONOR CARE SURVEY 
CONDUCTED IN 2005  
Although the study population and question formats differed, I was able to make 
comparisons between my results and those of the earlier EBMT survey (Clare et al, 
2010) in two areas (shown in Table 5.10).  I observed improvement regarding donor 
follow-up, with 89% of responding centres now providing a follow-up programme, 
compared to 60% in 2005. However, the percentage of centres ensuring that donors 
are first to be informed of their HLA results was lower than the earlier survey, a result 
which must be interpreted with the caveat that the options offered as responses 
differed between the two surveys. Finally, in the earlier survey, only 32% of 
respondents stated that RDs were consented by a professional not involved in recipient 




care. Although not a direct comparison, I showed here that in 75% of centres the 
physician providing medical clearance of the RD was not routinely responsible for the 
care of the recipient.  
Table 5.10 Comparison of responses to surveys  of EBMT member centres 
in 2005 and 2014  
 2005 2014 
Donor HLA result 






5.6 CONCLUSIONS FROM THE STUDY OF EBMT TRANSPLANT 
CENTRES 
This study offers unique observations into the pathway of RD care in EBMT transplant 
centres. Responses were obtained from centres with diverse geographical 
representation and a wide range of HPC transplant volumes, which I believe gives an 
accurate portrayal of the current approach to RD care across Europe.  Although the 
survey response rate was relatively low at 39%, it is likely that many of the non-
responding centres were ineligible due to being purely paediatric centres, but I did not 
have data available to identify and exclude these centres.   
I found that centres with FACT-JACIE accreditation showed better compliance with 
internationally recognised donor care paradigms, but also observed important 
deficiencies in all centres regardless of their accreditation status. Perhaps 
unsurprisingly, compliance with FACT-JACIE Standards was generally highest where 
the standards are a) very specific and b) a requirement rather than a recommendation. 
For example, 98% accredited centres had a written policy for donor care, 93% had 




defined medical criteria for RDs, and 86% a process for training BM harvest physicians, 
all of which are clearly required by 5th edition standards.  
However, only 38% of accredited centres ensure the donor is informed about their HLA 
results first, which is a JACIE requirement, but is not precisely defined in the applicable 
standard, which states: “The allogeneic donor shall give informed consent and 
authorization in advance to release the donor’s health information to the transplant 
physician and/or the recipient as appropriate”. But is then further explained in the 
accreditation manual with the statement:  “The purpose of this standard is to protect 
donor confidentiality…the recipient does not have the right to review all the HLA typing 
of siblings or other potential donors who are not considered for transplant”.  In a similar 
manner, in >10% of centres, healthcare providers of recipient and donor care routinely 
overlap in all aspects of donor management and consent, putting the donor in danger 
of real or perceived coercion, despite a FACT-JACIE recommendation against this 
practice.  
5.8 CHAPTER CONCLUSIONS 
The results of the two studies detailed in this chapter, in conjunction with the study of 
UK transplant centres described in Chapter 4, allowed me to compare care between 
the UK, other EBMT centres and the USA. Although the UK transplant physicians 
completed a longer survey with some differences between questions, I had included 
sufficient identical questions to allow comparison across the donor care pathway, as 
summarised in Table 5.11.  
Good compliance across all geographical regions was seen with respect to several 
FACT-JACIE requirements, including the existence of a specific policy for RD care, and 
the use of defined eligibility criteria. The practice of a single physician being 
responsible for both donor and recipient care has become much less prevalent since 
the introduction of a specific standard in this area and is now routine practice in only a 
small minority of UK and US centres, but was seen in 1/3 of non-accredited EBMT 
centres. In a similar manner, a process for credentialing physicians performing BM 




harvests (which was less consistently seen in non-accredited EBMT centres only). 
These findings demonstrate the impact of quality management in driving change. 
One of the most striking differences between regions was the complete absence of 
long-term donor follow-up in the USA, compared to 41% of EBMT centres and 23% of 
UK centres providing follow-up to at least 5 years.  This may be attributable to the 
development of a system for centralised reporting for related donor outcome data by 
the EBMT donor outcome group, in addition to national regulations mandating follow-up 
in some countries. The lack of US long-term follow-up may be connected to the funding 
streams for US RDs, where provisions are not currently made for RD follow-up by 
insurance companies. In addition, the FACT-JACIE standard is slightly vague in that it 
requires a ‘policy for follow-up of donors that includes routine management and the 
management of donation-associated adverse events’ but does not specify the duration 
of follow-up required.  
This last point also applies to the second notable difference between regions; that while 
>80% UK centres ensure the donors HLA results are first disclosed to themselves, this 
happens in <40% of US centres and <30% EBMT centres. The FACT-JACIE standard 
aimed at protecting confidentiality is not particularly clear, and in both of these areas, 
further refinement of the relevant standard may improve compliance.  
Regarding aspects of care that have not been addressed by FACT-JACIE Standards, 
care standards differed considerably from WMDA requirements for unrelated donors. 
This included that roughly 1/3 of centres in all regions do not assess donor health prior 
to HLA typing. In these centres a donor’s medical issues will thus only be identified at 
the formal donor medical assessment, which usually occurs shortly before donation 
(often within 30 days to avoid the need for repeat virology testing). This practice may 
lead to donors purposefully or inadvertently failing to disclose medical issues during 
their medical assessment (and in doing so, putting themselves – and potentially the 
recipient - at risk when donating) or being cancelled at the point of donor medical 
clearance, which can incur a critical delay to the recipient’s transplant. Secondly, over a 
quarter of centres in each region have used off-label plerixafor to mobilise RDs outside 




the clinical trial setting. It was beyond the scope of this study to examine how plerixafor 
had been used. For example, administration as a one-off ‘rescue’ in a donor who has 
failed mobilisation, but has a contraindication to BM harvest and gives specific consent 
for off-label use, is a different situation to pre-emptive use to ‘boost’ stem cell yield in a 
donor who has not specifically consented. However, clinical trials including long-term 
follow-up for both patients and donors is essential before new mobilisation agents can 
be adopted into routine practice.  
Centres in the UK were significantly more likely to supply donors with written 
information prior to HLA typing, possibly due to the production of specific RD 
information by UK donor registries and charities (Bloodwise, 2012; Anthony Nolan, 
2014), which are distributed to transplant centres. UK centres were also more likely to 
ensure willingness to proceed before performing HLA typing.  In the US and non-UK 
EBMT centres, autologous units are collected in >50% centres prior to RD marrow 
harvests. This rarely occurs in UK centres, nor is it routine practice for donor registries. 
Several studies have questioned the benefit of this process, since donors in whom 
<20mls/kg is collected should not develop significant anaemia. Definitive guidance in 
this area would be useful.  
A limitation of these studies was that despite requesting that the survey be forwarded 
to the most appropriate specialist for completion, I cannot be certain that this person 
was familiar with all areas of donor care in their centre. However, the surveys were 









Table 5.11 Comparison of responses between key areas of RD care in 
EBMT, US, and UK centres.  
 EBMT 
centres 
US UK P 
FACT-JACIE accreditation 59 (50%) 70 (96%) 19 (86%) <0.0001 
Healthcare provider making initial 
contact prior to HLA-typing 
Transplant physician 
Other Physician 




























Information supplied to donors pre 
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Verbal only 
Local written information 

















RD heath assessment pre-HLA 
typing 
By written health questionnaire 
Health questionnaire over phone 
























Willingness to donate is verified pre-
HLA typing  
86 (74%) 55 (75%) 21 (95%) 0.09 
Individual to whom donor HLA 


























Background of the provider with 
































Role of the physician clearing the 
donor in the recipient’s care 
Affiliated with transplant program with 
simultaneous responsibility for the 
recipient 
Affiliated with the transplant program 
and may be involved in the care of the 
recipient 
Affiliated with the transplant program 
but not involved in recipient’s care  
Not involved in the transplant program 
















































Existence of a written SOP for RD 
care  
107 (91%) 73 (100%) 21 (96%) 0.24 
Written eligibility criteria exist for 
acceptance of RDs 
98 (86%) 67 (91%) 19 (86%) 0.23 
Source of eligibility criteria  
Locally written  
Based on NMDP criteria  
Based on WMDA criteria 
Based on UK UD criteria 
 
















A health history questionnaire forms 
part of the donor assessment 
93 (80%) 65 (89%) 18 (82%) 0.19 
There is a policy defining the limit for 
the number of apheresis procedures 
RDs may undergo for their initial 
donation 
70 (60%) 33 (45%) 13 (60%) 0.0007 




















Plerixafor has been used for 
mobilisation of RDs  
Yes 
No  



















BM harvests are performed by:  
Transplant physicians caring for the 
recipient 

















There is a process for credentialing 
physicians performing BM harvests 
77 (67%) 61 (84%) 18 (90%) 0.01 
There is a policy defining the limit for 
the BM volume aspirated at harvest 
67 (66%) 44 (60%) 14 (67%) 0.73 
There is a policy regarding 
subsequent donations from related 
donors 
45 (40%) 26 (37%) 8 (36%) 0.72 
Practice regarding autologous unit 
collection 
Unit(s) collected and returned 
Unit(s) collected but not routinely 
returned 
No autologous collection 
 
 






































CHAPTER	  6.	  A	  PROSPECTIVE	  STUDY	  EXPLORING	  THE	  
FEASIBILTY	  OF	  UD	  REGISTRY	  INVOLVEMENT	  IN	  RD	  CARE	  	  
	  
A paper based on this subject was published as a Special Report in the journal Bone 
Marrow Transplantation in January 2015, entitled “Related hematopoietic cell donor 
care: is there a role for unrelated donor registries?”  (see Appendix 2) 	  
6.1 INTRODUCTION 
In the introduction to Chapter 4, I briefly described a session at the EBMT Annual 
Meeting 2013, where the question of whether UD registries should play a role in the 
care of RDs was debated.  This session was attended by a broad range of transplant 
centre physicians and specialist nurses, as well as donor registry representatives. 
Enthusiasm was unanimously expressed regarding exploration of alternative donor 
care pathways and many parties felt that UD registries were well placed to provide 
aspects of RD care. However, a number of hurdles to UD registry input were also 











Table 6.1 The perceived advantages and disadvantages of UD registry 
involvement in RD care, as discussed at a debate session at the EBMT 
Annual Meeting 2013.  
 Advantages Disadvantages 
Registry functions Many existing registry 
procedures could be adapted 
Several key registry functions 
e.g. donor search are not 
required 
RD health and safety RDs would be assessed by 
physicians with extensive 
experience in donor health 
RD health could be assessed 
using standard tools.  
It is not appropriate for UD 
suitability criteria to be used for 
RDs in every situation 
Donor 
consent/counselling 
The issue of conflict of interest 
would be removed since donors 
would not be managed by 
professionals involved in the 
care of their intended recipient.  
The risk benefit ratio in RD 
situation is different and requires 
a different discussion to UDs 
Registries do not currently have 
experience in the psychological 
issues of related donation  
BM harvests Would avoid harvests being 
conducted by the recipients 
transplant team 
Harvests likely to be performed 
by the most experienced 
operators 
Logistical difficulties if the 
harvest alone performed by 
registry and workup done 
elsewhere 
Potentially more expensive? 
Harvest would have to be 
transported to transplant centre 
Follow-up Allows centralised follow-up 
Same process can be 
undertaken for UD and RD 
regarding collection of minimum 
data set 
UD registries do not necessarily 
have appropriate team for 
follow-up of any psychological 
issues raised (however 
transplant centres may not have 
this) 
Financial issues The costs of donor care would 
become more explicit which may 
mean that insurance companies 
or governments would make 
specific funds available for 
donor care.  
Likely to be more expensive for 
transplant centres to pay a 
registry for care.  
Additional costs to courier cells  
	  	  




The study discussed in this chapter explores some of the perceived barriers to UD 
registry involvement in RD care. The primary objective was to establish the feasibility, 
both logistically and financially, of an UD registry undertaking RD care nationally, either 
by managing the entire donor care pathway or aspects thereof.  
6.2 METHODS AND MATERIALS 
6.2.1 DEVISING MODELS OF CARE 
I contacted donor physicians from European registries and obtained details of 
successful models of RD care provided by UD registries. I assessed the pros and cons 
of implementing each of these in the UK, and then devised three potential models of 
UK RD care where the UD registry would undertake part of the care pathway.  In 
conjunction with transplant centres and UK UD donor collection centres, I conducted an 
in-depth analysis of the logistics and costs of these three pathways with the intention of 
setting up a one-year pilot study for each of the three models.  
6.2.2 SET-UP OF PILOT STUDIES 
After defining work flows and costs for these two models of donor care, three large UK 
transplant centres were contacted: The Royal Marsden, King’s College Hospital, and 
Nottingham University Hospital. These were selected for two reasons. Firstly, as large 
transplant centres, they use the highest number of RDs. Secondly, these centres all 
use the Anthony Nolan Graft Identification and Advisory service and strong links exist 
between Anthony Nolan and these organisations. 
Following preliminary discussions with the transplant centres confirming initial interest, 
proposals were sent to The Royal Marsden and King’s College Hospital regarding 
Model 1 ‘Provision of Related Donor care in a UD registry setting from the point of 
donor identification’ and Model 2 ‘Evaluation of Related Donors within a transplant 
centre by an external physician’ (proposals are included in Appendix 1) and a proposal 




regarding Model 3 ‘Registry provision of donor follow-up’ was sent to Nottingham 
University Hospital (see Appendix 1). 
A single pilot study of related donor follow-up by Anthony Nolan was finally undertaken 
from 1/10/14 for a 13-month period.  The detailed material and methods is found in 
Chapter 2. 
6.3 RESULTS 
6.3.1 SUCCESSFUL MODELS OF RD CARE BY UD REGISTRIES 
6.3.1.1 Evaluation of related donors prior to HLA typing in Denmark  
As per standard practice in most countries, related donors in Denmark were historically 
managed by the recipient’s transplant team and initial contact to arrange HLA typing 
was made by transplant physicians. After incidents where RDs were deferred at a late 
stage when medical issues were discovered at the time of donor medical or donors 
were unwilling to donate, a novel procedure was developed by the UD registry.  
Contact details for potential RDs are now passed directly to the UD registry, who make 
initial contact with RDs. Comprehensive information about donation is provided and 
potential RDs are instructed to contact an independent registry physician by telephone 
if they have any medical issues, wish to discuss donation, or do not wish to donate. If 
the physician decides the relative is unfit or unwilling to donate, HLA typing is not 
performed. A standard report is then produced stating ”Donor is not fit to donate based 
on information from donor” for every donor  who is not HLA-typed, thus preserving 
confidentiality. 
 




Figure 6.1 The pathway of RD management in Denmark, with the UD registry providing care 
prior to HLA typing (figure supplied by Dr Betina Sorenson, Danish Bone Marrow Donor 
Registry)  
 
6.3.1.2 Assessment of feasibility in the UK 
	  
Advantages  
Deferral of donors who are unfit to donate at the earliest point possible is beneficial to 
the patient, the donor and the transplant team, and as shown in Chapter 4, assessment 
of RDs prior to HLA typing in the UK is varied. 
Although donor confidentiality can be preserved within the transplant centre setting, a 
donor who is unwilling to proceed with donation may feel more comfortable discussing 
this with a team who are completely separate from their relative’s transplant centre.  
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Unlike Denmark, the HLA typing of RDs in the UK is only performed by the registry for 
selected transplant centres, with many instead processing HLA typing in their local 
histocompatibility and immunogenetic laboratories.  For this reason, it would be virtually 
impossible to implement this model in all UK transplant centres, without first 
centralising all HLA typing for patients and donors.   
6.3.1.3 Bone Marrow harvesting of related donors by the Europdonor Foundation 
and affiliated collection centres in the Netherlands  
As the number of HPC donors undergoing BM harvest has declined, some transplant 
centres in the Netherlands have become unable to comply with the minimum of one 
BM collection per year required by FACT-JACIE Standards. Some centres therefore 
requested the Europdonor Foundation and its affiliated collection centres to undertake 
BM harvests on their related donors.  
The logistics of the BM donation for these donors are organised by Europdonor 
Foundation and an affiliated collection centre undertakes the entire donor process.  
Donors are evaluated using national related donor suitability guidelines, WMDA 
Standards and suitability criteria, and NMDP medical assessment tools are utilised. 
Donor clearance is undertaken by the collection centre in a similar manner to unrelated 
donors with decisions regarding donor safety made by the harvest centre physician, 
while those regarding recipient safety are referred to the recipient’s transplant 
physician.  Harvesting occurs at the collection centre. 
Europdonor Foundation and the harvesting centres are jointly responsible for RD 
follow-up of the donors whose harvests they have undertaken. Data collection is 
performed according to WBMT recommendations (Halter et al, 2013).  
 




Figure 6.2 The pathways of care for RDs undergoing BM harvests in the Netherlands (Based on 
information supplied by Dr Anne-Marie van Walraven, Europdonor) 
	  
6.3.1.4 Assessment of feasibility in the UK 
Advantages of implementation in the UK 
Each UK transplant centre performs relatively few bone marrow harvests on adult RDs, 
and there is a recognised difficulty with transplant physicians maintaining expertise in 
this procedure (Remberger et al, 2015; Anthias et al, 2015). 
  




Disadvantages of implementation in the UK 
In the current UK healthcare system, invoicing transplant centres for related donor care 
would be problematic because management of RDs outside the transplant setting is 
likely to represent a more costly option which transplant centres may not be willing or 
able to support. If the registry were to perform the entire RD care pathway for BM 
donors, decisions would need to be made jointly with transplant centres regarding the 
deferral criteria against which RDs would be assessed, since implementation of WMDA 
or national UD criteria is likely to lead to a high deferral rate for RDs. 
It may be confusing for transplant centres to have two separate pathways for RDs 
depending on the route of donation. Furthermore, at times medical issues precluding a 
particular route of donation only come to light at the donor medical consult. Therefore, if 
a RD who intended to donate PBSC were found to only be suitable for BM donation, 
their care would then need to be transferred shortly before donation. Likewise, if a 
PBSC donor failed to mobilise, their care would then need to be urgently transferred to 
a separate (geographically distant) location if they were to undergo an urgent BM 
harvest. 
6.3.1.5 Standardized Donor follow-up of Swiss Blood Stem Cells (SBSC) for 
related and unrelated donors 
Prior to 2007, related donors were followed up by their recipient’s transplant centre, 
using funding provided by the recipient’s health insurance (providing the recipient 
remained alive).  
In July 2007, a change in law made donor follow-up mandatory for both unrelated and 
related HPC donors. The Swiss Blood Stem Cells (SBSC) and Swiss Blood Stem Cell 
Transplantation agreed to undertake related donor follow-up, with slight differences 
between related and unrelated donors.   
The procedure for donor follow-up is now as follows: one month post-donation, UDs 
and RDs attend a medical appointment at their collection centre. At 6 months, 1 year, 




and then every 2 years until 10 years post donation, UDs and RDs receive a health 
questionnaire from the SBSC. The data collected from these questionnaires is based 
on the minimum data set recommended by WBMT (Halter et al, 2013) and collected 
data is entered into the donor follow-up section of each patient’s record in the EBMT 
ProMISe database by SBSC. Prior to donation, donors sign informed consent for 
follow-up by SBSC and data transfer to EBMT.  
At the time of (first) RD or UD donation, an identical lump sum for the entire follow-up 
process is charged to the patient’s health insurance, and then transferred to a specific 
donor follow-up fund at SBSC. SBSC compensates all donor follow-up activities from 
SBSC and involved partners out of this fund. Contracts are made with partners 
(collection and transplant centres) based on the transplantation law and defining all 
aforementioned aspects. 
Figure 6.3 Pathway of donor follow-up for related donors by Swiss Blood Stem Cells (based on 
information supplied by Dr Grazia Nicholoso, SBSC).  
	  
6.3.1.6 Assessment of feasibility in the UK 	  
Advantages of implementation in the UK 
FACT-JACIE accreditation is mandatory in the UK, and since 2011, Standards have 
included a requirement for ‘a policy for follow-up of allogeneic donors that includes 




routine management and the management of donation-associated adverse events’ 
(FACT-JACIE, 2011). Management of follow-up by a registry would enable transplant 
centres to meet this requirement. The median total number of allogeneic HPC 
transplants in UK centres is 49 (BSBMT, unpublished data). For a transplant centre to 
set up a system for follow-up may be time consuming and is difficult to automate. In 
contrast, the Anthony Nolan donor registry follows up thousands of UDs, using 
automated systems that could be easily adapted for use in RDs. While assessment and 
donation of RDs is likely to be more expensive when performed outside the transplant 
centre, the costs of providing follow-up are minimal. 
 
Disadvantages of implementation in the UK 
Provision would need to be made for communication between the registry follow-up 
team and the transplant centre regarding donors who develop complications post-
donation or who do not wish to be considered for further donations.  
	  
6.3.2 DEVELOPMENT OF POTENTIAL MODELS FOR A PILOT STUDY 
Following the above analysis I worked with donor provision, donor follow-up and 
finance teams within Anthony Nolan, and with the largest affiliated collection centre, 
The London Clinic, to develop three potential models of related donor care.  
6.3.2.1 Model 1. Provision of Related Donor care in a UD registry setting from the 
point of donor identification 
6.3.2.1.1  Background 
I chose to evaluate whether an UD registry could successfully provide the entire donor 
pathway for two reasons. Firstly, UK UD registries intermittently receive requests from 
transplant centres to work up related donors, in cases where there are logistical 
barriers to work up occurring at the transplant centre, so determining a process was felt 
to be an important starting point. Secondly, if the growth in haplo-identical donor 




transplants continues, it may become difficult for UK transplant centres to absorb the 
additional work of donor care and registries may be asked to provide this service.  
 
6.3.2.1.2 Pathway logistics 
Potential matched related donors would be identified by the intended recipient’s	  
transplant centre. Related donors would be referred to the Anthony Nolan where 
evaluation and donation would occur at an affiliated collection centre, The London 
Clinic. For the purpose of the pilot study I would have an honorary appointment at The 
London Clinic and would perform donor evaluations. Donor assessment would be 
performed according to medical suitability/eligibility criteria previously agreed with 
transplant centres, derived from Anthony Nolan medical criteria for unrelated donors. In 
the event that a related donor did not meet these criteria, there would be a discussion 
with the transplant physicians at the referring hospital and a joint decision made about 
whether to accept the donor.	  	  
Following the donor medical evaluation, all investigations and the donation process 
would follow the same procedures used for unrelated donors.   
Post donation, related donor follow-up would be performed by the Anthony Nolan, at 
identical time-points to unrelated donor practices, using adapted standard 
questionnaires. To evaluate the pathway, donors would receive an additional internet-
based survey at 30 days post-donation.  
Service level agreements already in existence would be adapted to include related 
donors.  
	  	  	  
















6.3.2.1.3 Cost Analysis  
Table 6.2 Costs for related donor assessment at Anthony Nolan affiliated 
collection centre (PBSC) 
Procedure Hours per donor Cost per hour 
(£) 
Cost per donor 
(£) 
Harvest coordinator 20 20 400 
Medical officer 1.5 20 30 
Administration for 
donor visit 
2 15 30 
Donor Follow-up  

















PBSC donation at 
collection centre 
NA 1,985 1 day 
3,313 2 days 
2502* 
GCSF cost NA NA 362** 
GCSF 
Administration 
NA NA 350 
Transport of cells NA NA 50 
Total   £3,814 
Total excluding 
staff time 
  £3,264 	  
*Calculated based on data from the study described in in Chapter 3 (61% related donors 
requiring one procedure, 39% required two procedures)  














Table 6.3 Internal costs per RD donating in the transplant centre, for 
comparison 






Nurse transplant coordinator 
Initial administration 
Counselling and investigations 
Coordination of apheresis/GCSF 
Review on apheresis 
D7 Phone call 
Additional support by phone/email 

















Medical transplant coordinator 
Donor evaluation 
Admin/prescribing GCSF  
Review of results/donor clearance 
























Other laboratory tests 














Total   £1,394 
* Based on a band 7 nurse 
** Based on median 789mcg/donor for 4 days 
***Calculated based on data from the study described in in Chapter 3 (61% related    donors 













Table 6.4 Summary of comparative costs per related apheresis donor (£) 
Transplant centre Anthony Nolan & Collection centre 
Nurse coordinator 117 Donor provision 600 
SPR coordinator 70 Medical officer 30 






312 GCSF + 
administration 
362+ 350 
Apheresis  572 PBSC donation 2502 
Virology+bloods 280 Transport of cells 50 
Total 1394 Total 3814 	  
	  
6.3.2.1.4 Summary of comparison  
If all the calculated costs were passed on from the registry to the transplant centre, the 
transplant centre would pay approximately an additional £2,400 per related donor. If 
the registry were to pass on the direct costs to the transplant centre but absorb the 
costs of registry staff time the transplant centre would pay an additional £1,870 per 
related donor.  
6.3.2.1.5 Outcome 
I was able to secure funding from Anthony Nolan to offer this model as a pilot study to 
10 donors from each of two transplant centres. Following discussions with both King’s 
College Hospital and The Royal Marsden, neither finally accepted the proposal. In both 
cases this was due to a reluctance to undertake a new pathway for a limited number of 















The greatest concerns in related donor care to date have been regarding the potential 
conflict of interest that exists when a single physician is responsible for the care of a 
related donor and their intended recipient.  A second issue lies in the fact that related 
donors are permitted to proceed with medical conditions that would confer deferral in 
the unrelated donor context, and there are convincing suggestions that this puts them 
at a greater risk of complications during donation.  These two problems were 
addressed in my first model by providing the entire donor care pathway through a 
registry and their affiliated collection centre. The main issue with this approach, 
however, is likely to be financial constraints, with by far the biggest cost attributed to 
provision of the apheresis procedure by a registry-affiliated collection centre. I therefore 
wanted to explore a model where the donation procedure remained within the 
transplant centre but where evaluation and counselling are provided by an independent 
physician who is not part of the transplant team caring for the recipient. 
6.3.2.2.2 Pathway logistics 
In this model a suitably matched related donor would be identified by the transplant 
centre. A donor evaluation appointment would then be booked with a physician from an 
external organisation with expertise in donor care. For the purposes of the pilot study I 
would fulfil this role, with the idea that following a successful pilot this role could be 
fulfilled by a physician from a separate team within the same organisation or a 
transplant physician from another centre. The related donor would be evaluated using 
identical procedures to an unrelated donor with respect to screening investigations and 
assessed against previously agreed medical suitability/eligibility criteria, derived from 
AN medical criteria for unrelated donors. In the event that a related donor did not meet 
these criteria, there would be a discussion with the transplant physicians and a joint 
decision made about whether to accept the donor.  The donor would sign consent for 




donation during the evaluation, and would also be asked to consent to data transfer 
and future follow-up by the Anthony Nolan.  
The clearance paperwork would be completed by the independent physician evaluating 
the donor, following which donors would undergo donation according to the usual 
centre procedures. Donor follow-up would be performed through the Anthony Nolan 
with ten-year follow-up and data collection covering the minimum requirements 
recommended by WBMT.  Donors would be asked to complete an additional survey 















Figure 6.5 Proposed pathway of related donor care with evaluation in the transplant centre by 
an external physician 
	  
6.3.2.2.3 Cost analysis 
As calculated in Model 1, the costs of providing donor follow-up by the UD registry 
would purely be staff time with a total cost of £122 per donor. The registry therefore 
agreed to absorb these costs and offer related donor follow-up as a free service for the 
purpose of a pilot study.  For the purpose of the pilot study, no costs would be attached 
to the independent physician providing donor evaluation.  




6.3.2.2.4 Feasibility assessment 
Advantages 
This model provides a lower-cost method of testing the logistics of independent 
evaluation of RDs and centralised donor follow-up; two areas in which care is currently 
lacking.  	  
Disadvantages 
Following a successful pilot, it may be difficult to set up arrangements for a physician 
with appropriate experience to travel to a transplant centre to perform donor evaluation. 
However it may be possible to create reciprocal arrangements between two transplant 
centres where a physician from each provides donor care in the other centre. 
Alternatively the independent physician could be a non-transplant haematologist or 
non-haematology physician within the same organisation.  
6.3.2.2.5 Outcome 
During the process of attempting to set up this pilot study I encountered a number of 
issues for which I could not find optimal solutions. These included the following: 
1. If additional investigations were required following the donor medical, how 
would these be arranged and reviewed? 
2. How would the external physician provide donor clearance from off-site? 
3. How would a decision be reached if there were a difference of opinion between 
the external physician and the transplant consultants regarding acceptance of a 
donor with health risks for donation?  
4. Who would make a decision regarding proceeding with donation if the donor 
was unwell on the day of donation? 
It became clear that as an external physician I would have to work closely with an 
onsite coordinator (nurse or administrative) and that this person would need to send 
donor investigation results via secure email in some instances. This, however, was felt 
by the transplant coordinators to represent extra work that was not considered feasible.  




This pilot study was considered, but not finally accepted, by King’s College Hospital 
due to a recent decision to introduce a new internal system for donor care, similar to 
that proposed in this model, where donor assessment would be performed by a non-
transplant haematologist. The Royal Marsden initially accepted the proposal for this 
pilot study, however the pilot study was subsequently abandoned when I accepted a 
post within the transplant team at that hospital and was no longer able to fulfil the role 
of an independent physician.   
6.3.2.3 Model 3: follow-up of related donors by Anthony Nolan 
6.3.2.3.1.Background  
The purpose of this pilot study was to explore the logistics of related donor follow-up by 
Anthony Nolan and to determine acceptability to transplant teams, to related donors 
and to the Anthony Nolan. 
6.3.2.3.2 Pathway logistics 
Related donors would be seen and undergo assessment and donation as per current 
practice at the transplant centre. Prior to the donor medical evaluation, donors would 
be provided with a donor information sheet outlining the pilot study and follow-up 
process. At the donor medical evaluation, consent would be taken for data transfer and 
follow-up by Anthony Nolan providing the donor was willing.  
Following donation, the transplant coordinator from the transplant centre would contact 
the donor once at 2-3 days post-donation to ensure no immediate complications had 
occurred. A specific referral form for related donor follow-up would then be completed 
by the transplant coordinator and sent, with the consent form, to the donor follow-up 
team at Anthony Nolan. 
From this point onwards, related donors from participating transplant centres would 
receive identical follow-up to Anthony Nolan unrelated donors. This would include a 




health questionnaire at 7 days post-donation, a health questionnaire annually at years 
1-6 and then biannually until 10 years post-donation.  Follow-up questionnaires would 
capture the minimum information required as per WBMT guidelines and EBMT donor 
outcome forms.  This would include a question about whether the donor would be 
willing to donate again if required.  
Any medical issues identified during follow-up would be discussed within the medical 
team at Anthony Nolan. In the event of donors reporting any complications felt to be 
directly related to stem cell donation, the Anthony Nolan medical officers would report 
complications to the clinical team at the referring transplant centre with a joint 
discussion regarding any further action required.   
Related donors would not receive any other type of communication from Anthony 
Nolan, such as fundraising information.  
	  
6.3.2.3.3 Cost analysis 
As calculated in Model 1, the costs of providing donor follow-up by the UD registry 
would be purely staff time with a total cost of £122 per donor. The registry therefore 
agreed to absorb these costs and offer related donor follow-up as a free service for the 
purpose of a pilot study.  
Advantages 
This is by far the simplest model, and is likely to be easy to implement nationally 
following a successful pilot study. It allows centralised reporting of RD data, and 
provides assistance to transplant centres in an area of care that can be difficult to 
perform in a transplant centre setting (there is often no defined team responsible for 
this).  
	  





This pathway does not address conflict of interest or RDs not being assessed using 
standardised procedures.  	  
6.3.2.3.4 Outcome  
The proposal for a pilot study was accepted by Nottingham University Hospital for a 13-
month period.  
6.3.3 RESULTS OF PILOT STUDY OF RELATED DONOR FOLLOW-UP BY 
ANTHONY NOLAN 
6.3.3.1 Recruitment 
This study recruited from 1/09/14 to 1/10/15, during which 10 donors were enrolled. 
The characteristics of the participating donors are summarised in Table 6.5. 
Figure 6.6 Cumulative number of related donors recruited to donor follow-up study  
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Table 6.5 Characteristics of participating related donors 
Donor characteristic N 
Donor age: median (range) 
 
 60 (42-66) 

















5 	  	  
6.3.3.2 Responses to day 7 donor follow-up questionnaires 
All donors were contacted via email and invited to complete a health questionnaire at 7 
to 10 days post-donation administered via a secure Internet site  (surveymonkey.com 
to January 2016, smartsurvey.com thereafter). Eight donors (80%) responded. 
Unfortunately, the donor follow-up team were unable to locate the data relating to one 
of these responses at the time of analysis, and therefore 7 responses were available 
for analysis.  
All 7 donors (100%) reported full recovery at 7 days post donation. The median time to 
recovery was 5 days, and all donors reported being back to work or normal activities at 
7 days post-donation.  Four donors reported no symptoms at follow-up one described 
grade 1 stiffness and one reported grade 1 insomnia and muscle pain. No donor had 
started any new medications post-donation.  
All donors reported feeling physically normal but responses regarding emotional state 
were more varied. Three donors who responded to this question (60%) reported feeling 
normal, one felt much better than usual and one donor described feeling much worse 
than usual and commented “my bit is easy, but having to wait 3 weeks until knowing 
whether it is a success is debilitating for me”. 




6.3.3.4 Comparison to unrelated donors responses 
I performed an analysis of day 7 questionnaire responses on a cohort of 470 unrelated 
donors who donated at the Anthony Nolan between February and November 2015.  As 
expected these donors were generally much younger than the related donors, with a 
median age of 29, and 90% of donors had donated PBSC.  These donors took a 
median of 3 days to recover, and 93% reported full recovery at one week post-
donation. Only 9% reported feeling worse physically at this point, and 2% felt worse 
than usual from an emotional point of view (shown in Figure 6.7).  1.7% donors had 
started a new medication post-donation. 	  
Table 6.6 Characteristics of unrelated donors in comparison group 
Unrelated donor characteristics N	  
Median age (range) 29 (18-59) 






Median days to recovery (PBSC donors) 3 
 
Figure 6.7  Responses from UDs and RDs to day 7 follow-up questions regarding A) physical 
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6.3.3.5 Feedback during the pilot study 
During the follow-up process, one donor, aged 49, contacted the donor follow-up team 
to complain that he found the approach of emailing donors impersonal and that he did 
not think all donors in their 50s would be able to complete electronic questionnaires. 
When I contacted this donor to discuss his complaint, it became apparent that he was 
unhappy with the donation process at the transplant centre because he did not have a 
good relationship with his recipient and was surprised that the staff at the transplant 
centre were unable to guarantee that he would be informed about his matching status 
before his recipient. He was also unhappy that he had been asked to administer his 
own GCSF injections. His concerns were fed back to the transplant centre and the 
donor confirmed that he was happy to continue donor follow-up by Anthony Nolan.  
No concerns were voiced by the clinical contacts at the transplant centre, and the 
process for transfer of donor care was felt by both sides to have run smoothly. When I 
interviewed the donor follow-up team at Anthony Nolan following the pilot study, the 
sole concern was regarding how they would deal with donors who contacted them with 
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nationally, it would be helpful for one of the members of the donor follow-up team to 
undergo formal training in counselling.  
6.4 CONCLUSIONS 
In this chapter I explored in depth three potential alternative models of related donor 
care, where part(s) of the care pathway would be performed by an unrelated donor 
registry. I was able to assess the logistic and financial feasibility of these options, with 
findings that can guide future efforts to improve the related donor journey in the UK.  
During analysis of Model 1, I demonstrated that the costs of providing the whole donor 
care episode in a registry setting as opposed to a transplant centre would result in an 
increased cost of £2,400. Currently, this cost would need to be met by the transplant 
centre, which seems unlikely to be a palatable option in the current NHS climate.  It is 
important to bear in mind that there are likely hidden costs to donor care in transplant 
centres above those considered in my analysis, whereas the costs of donor provision 
by a registry were already well defined.  A second issue that arose during discussion 
with transplant centres was regarding the medical suitability criteria against which RDs 
would be assessed, with some concerns raised that deferral rates for RDs may be 
higher if they were assessed by medical staff who usually evaluate unrelated donors. 
This second issue could be solved if consensus related donor medical suitability criteria 
were created.   
Model 2 initially presented an attractive option because it overcame the cost issues 
encountered in Model 1, yet still ensured independent donor evaluation by an 
experienced physician and standardised donor follow-up. However, as I tried to set up 
the pilot study, it proved increasingly complex to define a robust pathway. It became 
clear that in addition to an external physician, a dedicated donor coordinator onsite 
would be necessary. The major problem, and the ultimate reason for failure to set up a 
pilot study was the concerns from transplant centres regarding identification of an 
appropriate external physician after the closure of the pilot study. Although this role 
could have been fulfilled either by a registry physician or a physician from a separate 




transplant centre, even large centres only facilitate approximately 30 adult RDs per 
year, and these donors will not be required at evenly spaced intervals throughout the 
year. For this reason it would be difficult to schedule a timetable for an external 
physician to attend on an ‘as required’ basis.  In summary, although this was 
theoretically a desirable model of donor care, it appears to be unfeasible in the current 
set-up of UK transplant centre practice.  
Model 3 resulted in a successful pilot study, which showed that donor follow-up by an 
unrelated donor registry represents a feasible way of ensuring standardised follow-up 
for related donors. Although only one transplant centre was enlisted in the pilot study, it 
would be relatively easy to offer this service to transplant centres nationally.  There 
were no issues encountered in providing follow-up in a separate organisation and 
transfer of donor care between the transplant centre and the registry was very 
straightforward. Although the study was not powered to statistically compare recovery 
between related and unrelated donors, the RDs in this pilot study did not appear to 
require more comprehensive early follow-up. If this initiative were expanded nationally, 
a detailed comparison of recovery between donor cohorts would be possible.  The 
main potential issue raised during this study was regarding management of RDs with 
psychological problems as a result of donation, which the registry follow-up team were 
not accustomed to dealing with. There is currently no provision for psychological 
support post-donation in transplant centres, but if this model is offered nationally some 
expertise in this area within the registry would be helpful. 
In conclusion, I encountered a number of challenges in setting up pilot studies for the 
more complex models of RD care, and the first two models described in this chapter do 
not appear feasible at this time. Provision of donor follow-up by the registry was far 
more successful and the Anthony Nolan is therefore currently considering offering RD 
follow-up services nationally.  
	  




CHAPTER	  7.	  A	  STUDY	  OF	  RELATED	  DONOR	  EXPERIENCE	  OF	  
THE	  DONATION	  PATHWAY	  	  
7.1 INTRODUCTION 
In Chapters 3, 4 and 5 of this thesis I demonstrated that practice patterns in related 
donor care have changed following the introduction of international guidelines in this 
area.  While I was able to show improvements in specific aspects of care, I also 
identified some areas, such as donor follow-up, where relatively few centres comply 
with current recommendations. The consensus guidelines (van Walraven et al, 2010b; 
Halter et al, 2013) and regulatory standards (FACT-JACIE, 2012; WMDA, 2013) 
against which I evaluated transplant centres were formulated by experts in the field of 
donor health and are based on ethical principles, safety data from large donor cohorts, 
and in some cases, UD care paradigms. Despite some physical differences between 
RDs and UDs (RDs being older, and more likely to have health issues) and a remaining 
need for data from RD-specific safety studies, we can nevertheless be confident that 
adherence to such guidelines will maximally protect the physical health of RDs.   
It is more difficult to be confident that adherence to current standards and 
recommendations will ensure that a transplant centre meets the psychological needs of 
RDs. There are major differences between RDs and UDs regarding the psychological 
investment in the transplant. Best practice in this area should be informed by the 
results of studies in RDs, yet there are little available data on which to base such 
recommendations.  
The studies performed to date that have explored the psychological impact of donation 
for RDs have shown differing results.  Although long-term psychological benefits (for 
example increased self-esteem), have been reported in some studies, other groups 
have demonstrated detrimental psychological effects post-donation, which 
unsurprisingly, appear to be linked to the recipient’s transplant outcome (Switzer et al, 




1998; van Walraven et al, 2010a; Wolcott et al, 1986). There are several difficulties 
with interpreting the results of these studies; some were conducted >30 years ago, and 
almost all studies were performed using very small donors cohorts (<30 donors). 
Furthermore, as described in Chapters 4 and 5 of this thesis, RD care is 
heterogeneous, and the psychological experience of donors will inevitably be partially 
determined by the support they receive and the information with which they are 
provided.  
Larger studies have been performed in related renal donors, and corroborate the 
finding that the donor’s quality of life is strongly dependent on the recipient’s outcome 
(Giessing et al, 2004). However, recipients of HPC transplants have a far greater risk of 
mortality than recipients of renal transplants, and a much higher probability of severe 
long-term morbidity, so the experience for donors of these two procedures is quite 
different.   
In order to consider future improvements in related donor care, it was first necessary to 
evaluate whether compliance with consensus recommendations results in an 
acceptable experience for the related donor, and to determine areas where donors 
perceive that improvements are needed.   
The primary objective of this study was to determine donor experience in the setting of 
a transplant centre where FACT-JACIE Standards and international RD 
recommendations have been adopted. This included answering the following 
questions: 
• Do donors feel fully informed? 
• Do donors feel that they are presented with a choice about donating? 
• Do donors experience stress about the procedure and if so why? 
• Do donors feel that they are offered adequate support at the time of donation 
and post-donation? 
• Are there any areas in which donors feel that care is lacking? 




The secondary objective was to investigate whether any donor demographic factors 
correlate with a worse experience, or with the need for more support.  
7. 2 METHODS AND MATERIALS 
A 20-item questionnaire was developed to address the study objectives. This survey 
was sent by post to all adult related donors who had donated at The Royal Marsden 
between 1st January 2009 and 31st December 2014, with a letter explaining the study 
objectives (see Appendix 1).  Donors were offered the option of completing the 
questionnaire via the internet (smartsurvey.com) or by post. Non-responders received 
one reminder six weeks later, using identical materials.  The full materials and methods 
can be found in Chapter 2.  
7.3 RESULTS 
7.3.1 RESPONSE RATES 
Responses were received from 53 of the 102 donors invited to participate, a response 
rate of 52%.  Two factors significantly influenced the likelihood of responding: donors 
older than the median of 50.5 years were more likely to respond than younger donors 
(65% versus 39%; p=0.01), as were donors who had previously responded to annual 
follow-up questionnaires (76% versus 35%; p<0.0001). Responding donors had a 
median age of 55 years and had donated a median of 10 months previously. In 62% of 









Table 7. 1 Comparison of donor characteristics between responders and 
non–responders  














Donor age at survey 




























































Table 7.2 Characteristics of responding donors.  
Characteristics of respondents  
 
N=53 
Median donor age at survey (range) 55 (18-78) 
Donor sex male/female 28/25  (47%/53%) 
Recipient sex male/female 34/19  (64%/36%) 











42  (79%) 









Median months to death  (range) 10 (2-47) 




7.3.2 DO DONORS FEEL FULLY INFORMED ABOUT THE DONATION 
PROCESS? 
Over 75% of donors were satisfied with the amount of information they received at 
each stage of the donation procedure.  87% felt that they received sufficient information 
to understand the donation procedure prior to HLA typing.  
91% of donors stated that they had received information about the donation procedure 
from more than one source, and 60% recalled receiving written information from the 
hospital. 28% had done their own additional research about donation on the internet.  



































Donors were asked to identify the most helpful source of information, however the 
majority cited more than one source, and a quarter specifically commented that it was 
important to be provided with multiple sources of information with statements such as 
“all [sources]; the written [information] because you can read it at leisure, then the 
nurse and doctor to ask questions later”  
21% of donors stated that they would have liked to be provided with more information; 
most commonly (13% of donors) more information about the side effects of donation, 
Questions about provision of information Number of 
donors 
Do you think you received enough information to 
understand the donation procedure before your 
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while 4% felt they would have liked more information about the complications for their 
relative and 4% commented that they would have liked to see the apheresis machine in 
use prior to donating.    
7.3.3 DO DONORS FEEL THAT THEY ARE PRESENTED WITH A CHOICE 
ABOUT DONATING? 
94% of donors reported feeling no pressure to donate. In addition to selecting ‘no’ in 
response to this question, 40% reiterated this point by writing additional unsolicited 
comments on the questionnaire such as “no, it was purely my choice, made by me 
alone”. Of the three (6%) donors who reported feeling pressurised, in two cases this 
pressure was from the intended recipient, while one donor reported feeling pressurised 
by the recipient’s medical team.   
I found very low ambivalence to donation with 45 donors (85%) describing the decision 
to donate as requiring ‘no consideration’ and only one donor stated that the decision 
required a lot of consideration.  
Regarding preparedness for donation, only one donor reported feeling ‘not very well 
prepared’ and no donors felt ‘completely unprepared’ for donation. Interestingly, male 
donors were more likely to state that the decision required some consideration, a 
statement made by 25% male compared to 4% female donors  (P=0.018). However, 
male donors were more likely to feel totally prepared for donation 93% male versus 
48% female donors (p=0.001).  I also found that donors who had donated in the earlier 
years of the study (2009-2011) were significantly less likely to have felt totally prepared 













Figure 7.2 Reponses regarding preparedness for donation from donors donating pre and post 
January 2012 
 
7.3.4 DO DONORS EXPERIENCE STRESS ABOUT THE PROCEDURE AND IF 
SO WHY? 
Most donors experienced some stress regarding donation, and 32% reported the 
process as very stressful or quite stressful.   When donors were asked about sources 
of stress 17% stated this was due to concerns about their own health (including all 
donors who found the procedure ‘very stressful’), 21% reported anxiety about the 
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stated ‘other’ reasons, which in most cases was concern about the recipient’s outcome 
including: “concerns about the long term/short term effects on the health of the patient 
if I were to be sick”, “concerns about whether it would work or not” and “concerns that 
patient would have adverse reaction to receiving it”.  
Regarding questions exploring difficulties with the logistics of donation, 48 (91%) 
donors described having to make significant arrangements in order to donate including 
education or work in 78%, and 26% suffering loss of earnings.  70% of donors had to 
meet costs, which included flights in 17% of cases. Two overseas donors mentioned 
additional difficulties in being away from their family for the donation period.  
Regarding the physical experience, 21% stated that they experienced more pain or 
side effects than expected, of which three donors (6%) made additional comments that 
suggested a much worse reaction than expected. Each of these donors also 
commented that a more extensive discussion of the side effects would have been 
helpful.  
Figure 7.3 Responses regarding how stressful donors found the donation experience 
 
11% of donors stated that they had experienced negative emotions or psychological 
difficulties as a result of donation, which in all donors who elaborated, were due to the 
recipient’s health. Two donors described very difficult psychological experiences, with 
one stating, “[the transplant] not working and having a lot of guilt as a result which has 
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taken a lot of counselling to clear”. The other described a difficult dynamic with his 
sister following donation. In both of these cases the recipients developed extensive 
chronic GvHD.  
Figure 7.4 Sources of stress described by the related donors  
 
Figure 7.5 Responses regarding the physical experience of donation
 
Donors were asked where they would have preferred to donate; only one donor stated 
that they would have preferred to be treated in a separate centre to their relative. Other 
donors were equally split between those actively preferring to be at the same centre as 
their relative and those who either didn’t mind or who preferred the most convenient 
option.  
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Figure 7.6 Responses regarding where donors would have preferred to donate 
 
7.3.5  DO DONORS FEEL THAT THEY ARE OFFERED ADEQUATE SUPPORT? 
Although 92% felt the hospital provided enough support at the time of donation, 17% 
felt that not enough post-donation support was available. This was reiterated when 
donors were asked the final open ended question, “Are there any other ways in which 
you feel your donation or post-donation care could have been improved?”. Although 38 
(72%) donors stated that no improvements were needed, the remaining donors who 
suggested improvements felt that the post-donation support was inadequate, including 
the following statements: 
•  “I feel counselling should be available, my sister cut me out of her life….she 
sees GVHD as a personal attack from me… I telephoned in tears and received 
a very negative response…Living with her death would be easier”  
• “The hospital could have seen me after the procedure, as I had a lot of health 
issues but there was no support”  
• “Yes, after care. I felt like I was on a conveyor belt and once I had donated I 
was forgotten”  
• “From my experience if it doesn’t work it is awful for the donor. I don't know 
what anyone can do to help the donor” 
Same	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Don't	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This study uniquely describes the experience of related donors who underwent a 
donation pathway in which care was delivered according to current regulatory 
standards and consensus recommendations. The response rate of 52% was very 
satisfactory, particularly considering that the survey was administered using postal 
questionnaires, and with 53 participants, this represents one of the largest studies of 
related donor experience to date.  
I was able to demonstrate a reassuringly positive experience for the majority of donors 
who reported feeling well informed, non-coerced, well prepared, and experienced little 
or no stress, and little physical pain.  However, I identified two donors (4%) who 
experienced very negative psychological consequences of donation, both in cases 
where the recipient had developed severe GvHD. Both of these donors commented on 
the lack of post-donation support that was available. A further three donors (6%) found 
the donation procedure stressful or difficult for reasons relating to their own health, and 
again, all felt that post-donation care was lacking.  
I found very good results regarding the information donors receive about the donation 
procedure, particularly prior to HLA typing, which was an area highlighted as 
inadequate in several studies of donor care, including those I described in Chapters 4 
and 5. This study reassuringly demonstrates that it is possible to provide donors with 
information before HLA typing, and that donors appreciate receiving information in 
different formats, and discussing the procedure with more than one health care 
professional. Nonetheless, I found that donors may benefit from further information 
regarding potential outcomes for their recipient.  During the period studied, the written 
information supplied to donors did not explain the health complications of 
transplantation for the recipient, and while the potential for an adverse outcome was 
briefly touched upon in the donor consent discussions, and donors were not given 
specific details of the possible complications for their relative.  




The findings of this study confirm previous reports (Pillay et al, 2012) of low 
ambivalence regarding the decision to donate. This was more evident here than in 
previous studies, with 85% of donors describing ‘no consideration’ which may reflect 
efforts to provide donors with adequate information prior to HLA typing. I was also able 
to show that males were more likely to require some consideration prior to deciding to 
donate. Although I did not demonstrate a difference in sources of information sought or 
provided to male or female donors, it may be that the additional consideration in male 
donors resulted in closer attention to the information provided, which may explain the 
increased preparedness described by male donors. Interestingly, I was also able to 
show an improvement over time with donors in the more recent donation era being 
more likely to describe themselves as totally prepared for donation.  I did not find any 
difference in the sources of information that donors reported receiving between earlier 
and later time periods, however the written information booklets about donation were 
updated several times over the study period, which may explain this finding.  
In accordance with earlier studies I found that the two donors who described severe 
psychological difficulties were cases where the recipient had developed severe GvHD. 
Both of these donors commented on the lack of post-donation support that was 
available.  The three donors who commented on severe physical side effects also 
remarked that more post-donation support should be available. Current consensus 
guidelines recommend long-term donor follow-up, but focus on capturing specific health 
information to exclude an increased incidence of autoimmune or malignant disorders 
following donation. This information is most easily captured using a standard health 
questionnaire, however such follow-up will not provide the required support for the 
small proportion of donors who develop severe physical or emotional difficulties after 
donation.  
Acute physical events associated with donation almost invariably occur within 30 days, 
and donors at the centre studied are given contact details for the transplant team in 
case they develop such events. In light of the findings of this study, it may be advisable 
to contact donors in writing at 30 days, asking them to make contact if they have any 




health issues and providing written information of who to contact in the future if they 
develop physical or psychological health issues.   
The retrospective nature of this study limited the potential to provide an in-depth 
analysis of the physical or psychological experience of donation, in particular to 
determine whether the closeness of the sibling relationships influenced the donor 
experience. Notwithstanding, the main objective was to assess the adequacy of a 
donor pathway adhering to current recommendations, and I was able to achieve this.   
Preventing a potential conflict of interest has been a major focus of the initiatives in 
donor care to date, and this study reassuringly affirmed that providing current 
recommendations are adhered to, donors do not feel pressurised to donate.   
In summary, I have shown that providing donors with information both about the 
donation experience and the potential complications for the recipient is vital. While 90% 
of donors report a positive experience, current pathways do not provide adequate post-
donation support for the minority that have a difficult experience, and efforts should 
next focus on addressing this issue.  




CHAPTER	  8:	  UK	  NATIONAL	  GUIDELINES	  FOR	  HPC	  
RELATED	  DONOR	  CARE	  
8.1 INTRODUCTION 
In Chapter 4 I demonstrated diversity between UK transplant centres at several stages 
of the related donor care pathway. This variation included the presence of an 
assessment of the health of a potential related donor before HLA typing, the duration of 
post-donation follow-up and the method by which this is conducted. In addition, I 
showed that transplant centres use differing criteria to determine the medical suitability 
of related donors and differing investigations during assessment. The result of these 
differences is that donors who would be accepted by some transplant centres would be 
deemed unsuitable by others. 
This variation is not surprising, given that mandatory regulations in related donor care 
are largely focused on ensuring that donors undergo informed consent. Although the 
WMDA and WBMT have produced consensus statements which endeavour to fill a gap 
by providing recommendations for the principles of related donor care, differences in 
regulations and in the set-up of RD care between nations have prevented the creation 
of detailed and specific universal recommendations. As part of the study described in 
Chapter 4 I therefore sought the views of transplant physicians in the UK regarding the 
potential for development of national guidelines in related donor care, which >80% of 
transplant physicians feel would improve related donor care nationally.   
This chapter describes the process of formulating UK guidelines for related donor care, 
endorsed by the British Committee for Standards in Haematology and the BSBMT.  
The objectives of the guidelines were:  
• To review the literature regarding the safety and experience of adult and 
paediatric HPC donors and to define evidence-based guidance for the entire 
donation pathway from the initial point of contact with donors through to donor 
follow-up  




• To incorporate requirements of national competent authority, JACIE, and 
consider previously published expert consensus guidelines 
• To use the findings of the study described in Chapter 4 to ensure that the 
proposed guidance is logistically possible for transplant centres to meet  
• To create a set of ‘tools’ that allow efficient, standardised assessment of RDs 
aiming both to improve adherence to the guidelines, and to improve efficiency of 
the donor pathway in transplant centre  
• To provide guidance for decision-making in difficult ‘grey areas’ where a 
potential or minor increase in risk is apparent 
• To determine a process for counselling of donors who do not meet medical 
suitability criteria  
 
8.2 METHODS AND MATERIALS 
I established a working group comprising experts in the fields of adult and paediatric 
donor health, medical ethics, allogeneic haematopoietic cell transplantation and stem 
cell collection (see Table 8.1). Systematic literature searches using PUBMED for 
relevant publications in English were conducted up to April 2015 using the following 
keywords: related donor; family donor; stem cell donor; stem cell mobilisation and other 
search terms pertinent to subsections. After reviewing the literature the group 
considered a number of questions outlined below, and made recommendations based 
on responses to these. The draft guideline was reviewed by British Haematologists, the 
BSCH and the BSBMT. Where possible, these guidelines are based on published 
evidence, with the ‘GRADE’ system used to quote levels and grades of evidence, 










Table 8.1 Roles of experts in the guideline working group 
Name Job title Role in guideline group 
Dr Chloe 
Anthias 
Medical Officer Anthony 
Nolan 





Ex-Chief Medical Officer 
Anthony Nolan 





Deputy Medical Director of 
the BBMR 




Transplant Director, The 
Royal Marsden  
Clinical expert in HPC transplantation 





Scottish National Blood 
Transfusion Service 




Professor of Clinical and 
Biomedical Ethics, 
University of Sussex 
Expert in medical ethics and consent 
Prof Rob 
Wynn 




Clinical expert in paediatric HPC 






Clinical expert in HPC donation and 
transplantation 
Mrs Louise  
Mcnamara 
Divisional Nurse Director, 
The Royal Marsden  
Expert in clinical apheresis and HPC 
donation 










8.3 DISCUSSIONS WITHIN THE GUIDELINE GROUP TO 
FORMULATE RECOMMENDATIONS 
8.3.1 EVALUATION OF THE RISKS OF DONATION 
8.3.1.1 What are the risks of donation for the donor? 
The common short-term side effects of GCSF are well documented and include bone 
pain, flu-like symptoms, headaches, insomnia, and gastrointestinal symptoms (Miller et 
al, 2008; Hölig et al, 2009). The apheresis procedure is associated with symptomatic 
hypocalcaemia, hypovolaemia and bruising, or nerve injury related to venepuncture.  
 
Reported serious adverse reactions include splenic rupture, cardiovascular events, 
cerebrovascular events, thrombotic events, anaphylaxis and complications related to 
central venous catheter (CVC) placement. GCSF may unmask or exacerbate pre-
existing autoimmune conditions (Parkkali et al, 1996; Nasilowska-Adamska et al, 2010; 
Lee et al, 2015). 
8.3.1.2 What are the risks for the recipient?  
Donation of HPCs can result in the transmission of infectious, malignant or hereditary 
or autoimmune diseases. HPC recipients are at risk of the same infectious agents as 
recipients of blood products, but are also at risk of cellular pathogen transfer.  
Transmission of a wide variety of bacteria, viruses, fungi and parasitic infections is well 
documented, as detailed in Table 1.4 in the introduction to this thesis.  
 
Transmission of malignancies can occur either due to engraftment of malignant HPCs 
causing haematological cancers, or through transfer of solid organ malignant cells 
leading to metastatic cancer in the recipient.  Reported cases of malignancies 
transmitted by HPC transplantation have to date been limited to those of 
haematological origin, however transmission of solid organ cancers have been 
observed in recipient of organ transplants. Proven donor-derived malignancies have 
also been reported following solid organ transplantation. Details of these cases are 
provided in Table 1.5 of the introduction to this thesis.  
 




Any hereditary diseases that originate from HPCs can potentially be transmitted, 
including haemoglobinopathies, Gaucher’s disease, enzyme deficiencies (Au et al, 
2002) and cyclic neutropenia (Krance et al, 1982).  The most commonly reported 
transmissions of autoimmune disease are psoriasis and autoimmune thyroid disease, 
but in theory any autoimmune disease could be transmitted.  
 
8.3.1.3 How can we identify donors at risk?  
Careful evaluation of HPC donors is essential to minimise the risks to both the donor 
and recipient.   In Chapter 4, I demonstrated variation in the investigations undertaken 
for RDs, which in general are less extensive than those performed in healthy UDs.  
Even if RDs are finally accepted with conditions with which a UD would be deferred, 
identification of such conditions is equally important and the group therefore agreed 
that screening procedures should as far as possible mirror those for unrelated donors. 
This should ideally include completion of a formal health history questionnaire, a full 
evaluation with a health care professional with expertise in donor health, and screening 
investigations similar to those used as standard in UDs.   
8.3.1.4 Should the suitability criteria applied to RDs differ from those used in UDs? 
Large studies in unrelated donors who are assessed against strict medical criteria have 
shown the incidence of SAEs to be around 1% (Pulsipher et al, 2009; 2014; Miller et al, 
2008; Hölig et al, 2009). A study in PBSC donors in Japan (Kodera et al, 2013) and the 
study I described in Chapter 3 both suggest that acceptance of donors who do not 
meet UD suitability criteria is linked to a greater risk during donation. However, most 
experts, including the guideline group, agree that it is inappropriate to apply the same 
stringent UD medical criteria to RDs who have a much greater psychological 
investment in the transplant.  The group agreed that it is wrong to expose any donor to 
a known substantial health risk, but there are grey areas where the risks are theoretical 
or inadequately defined. In the UD context, such donors would rightly be deferred but in 
the RD situation, the group agreed that a ‘protocol exception’ system could be used. 
This involves gaining specific consent from the donor regarding a potential increased 
risk.   There was consensus agreement that any conditions posing a potential risk to 




the recipient should be discussed with the recipient’s transplant physician prior to 
acceptance of the donor.  
 
8.3.1.5 Should screening be different in older donors? 
Older donors are more likely to suffer from occult morbidities, which may increase 
either donor risk (e.g. cardiovascular disease) or recipient risk (e.g. malignant disease). 
The most important screening tool is a careful medical history and examination, aiming 
to exclude evidence of cardiovascular or malignant disease. The group agreed that all 
RDs over the age of 50 should have a chest x-ray, serum electrophoresis and prostate 
specific antigen (PSA) (male donors) performed.  Specific additional investigations are 
also prudent in family donors who are donating to a recipient with a disease that may 
have a familial association, such as chronic lymphocytic leukaemia.   
8.3.2 THE PROCEDURE FOR INFORMED CONSENT  
8.3.2.1 How do we ensure donors are adequately counselled prior to HLA typing? 
As described in Chapter 4, 36% of UK centres do not assess the health of RDs prior to 
HLA typing.  Ensuring that a donor is fit and willing to proceed before determining 
whether they are a match is advantageous to the transplant centre, the donor and the 
recipient by preventing transplant delays while an alternative donor is sought, saving 
unnecessary typing costs and preventing distress/guilt for a RD who is deferred after 
they are known to be a match.  The group agreed that donors must be adequately 
informed about donation in order to make a decision to proceed with HLA typing and 
that written information should be provided at this point. However, there were concerns 
that this may not be achievable in 100% of cases, and the final recommendation was 
therefore that written information should be provided where possible. The group 
reviewed the national information for related donors currently produced by charities and 
agreed it to be fit for purpose (Anthony Nolan, 2014; Bloodwise, 2012). 
 
There was unanimous agreement that donors should be informed about their HLA 
matching status and given time to consider before giving permission to disclose results 
to their potential recipient.  





The guideline group agreed that an assessment of donor health should be conducted 
prior to HLA typing, but felt that it is difficult to achieve this universally, particularly since 
RDs may be identified by a referring hospital rather than a transplant centre. The 
decision was made to include a brief health questionnaire tool with the guidelines to 
promote a thorough assessment and to highlight the Anthony Nolan RD donor 
information that provides a checklist for RDs with health conditions that may preclude 
donation and encourages them to discuss any such conditions with their transplant 
centre contact.  
 
8.3.2.2 How can we prevent a potential conflict of interest in the context of current 
transplant centre set up where the recipient’s transplant team are responsible for 
RDs? 
It is widely accepted that donor and recipient care should be completely separated to 
prevent any potential conflict of interest, which would ideally be achieved by separate 
teams caring for the donor and recipient. However, in Chapter 4 I showed that donor 
consent in the UK is provided by transplant physicians in 50% of centres, who due to 
the size of transplant centres, are likely to be members of the same team caring for the 
recipient.   
 
FACT-JACIE Standards, to which all UK transplant centres must conform, require that 
the clinician evaluating the donor should not be the primary physician of the recipient. 
However, we felt that ideally the physician managing the donor should ensure that they 
do not simultaneously have direct care of the transplant recipient. Since transplant 
clinicians are not uniquely able to evaluate donors the group decided to describe 
successful alternative models of donor evaluation, for example, involving blood 










8.3.3 THE PROCEDURE FOR HPC DONATION 
8.3.3.1 How should RDs be mobilised for PBSC harvest? 
Granocyte® (lenograstim) and Neupogen® (filgrastim) are both licensed for stem cell 
mobilisation of healthy donors in the UK and have equivalent efficacy and safety 
profiles. There was felt to be no evidence of an improved yield using a dose above the 
10mcg/kg/day used by UD registries and recommended in the summary of product 
characteristics.  The group felt that although a small number of studies suggest 
equivalent efficacy for biosimilar GCSF, its used in RDs should not be recommended 
until further follow-up data are available (Shaw et al, 2011).  Plerixafor is not currently 
licensed for use in healthy donors, and likewise, insufficient data are currently available 
to recommend its use routinely to mobilise RDs.  However, the group agreed that in the 
setting of a failed mobilisation with GCSF, Plerixafor could be considered as an 
alternative to an emergency BM harvest following informed consent.  
Since higher rates of complications are seen in donors who require central venous 
catheters, (Anderlini et al, 2001) the group agreed that their use should be limited to 
cases where they are absolutely necessary, which occurs in 1-2% unrelated donors  
(Anthony Nolan data, unpublished). In line with BCSH guidelines for central venous 
catheter insertion (Bishop et al, 2007), these should be inserted by a skilled operator 
under ultrasound guidance.  
8.3.3.2 What is the best approach to donors who fail to harvest sufficient stem cells 
for engraftment? 
While transplant physicians routinely request ≥4x106 CD34+ cells/kg recipient weight, 
and yields of <2x106 CD34+ cells/kg are generally considered suboptimal, engraftment 
is possible with lower CD34 doses, and as such, UD registries do not offer a 
supplementary emergency BM harvest unless the yield following two procedures is less 
than 1x106 CD34+ cells/kg recipient weight. The group noted that fewer than 1% of 
healthy donors fail to reach 1x106 CD34+ cells/kg following 2 apheresis procedures 
(Hölig et al, 2009; Billen et al, 2014), and that female donors, older donors and donors 
weighing less than their recipients are more likely to harvest lower doses (Teipel et al, 
2015; Al-Ali et al, 2010; Billen et al, 2014; Richa et al, 2009). 





As demonstrated in the study described in Chapter 4, some centres allow donors to 
undergo three apheresis procedures. The group did not feel there should be an 
absolute recommendation against this, providing that a third procedure was considered 
by the local apheresis expert likely to result in a total stem cell yield compatible with 
engraftment. The most common contraindication to a third procedure is the donor 
platelet count, which is <100x109/l in almost 40% donors after two procedures 
(Pulsipher et al, 2009). The authors agreed that donor fitness to proceed with a third 
procedure should be assessed against local apheresis donor thrombocytopenic 
thresholds. In donors with a platelet count close to the donor thresholds (commonly 
80x109/l), a smaller volume (<2.5 blood volumes) should be processed. 
There was agreement that donors in whom a third day is deemed inappropriate, or who 
fail to achieve a yield considered adequate for engraftment after three procedures, 
could be considered for an emergency BM harvest in the absence of contraindications, 
and following appropriate discussion and consent.  
8.3.3.3 Should limits to BM harvest volume be recommended? 
Studies in UDs confirm a low incidence of adverse reactions using a maximum of 
20mls/kg, following which only 5% of healthy donors have a post-procedure 
haemoglobin of <100g/l (Anthony Nolan data, unpublished), and allogeneic transfusion 
should not be necessary. Providing this limit is adhered to, evidence does not support 
the practice of autologous blood collection and infusion (Parkkali et al, 2005; Mijovic et 
al, 2006; Gouëzec et al, 2015). The group therefore recommended adhering to a limit 
of 20mls/kg and against the use of autologous unit collection beforehand. In practice, 
as discussed in Chapter 4, all but one UK centre that specified a limit already adhered 
to a maximum of 20mls/kg and only 9% of centres perform autologous collections. The 
group agreed that prophylactic iron supplementation should be considered peri-harvest 
in females of childbearing potential or those on low iron diets to speed recovery.  
 
 




8.3.4 SPECIAL CONSIDERATIONS IN PAEDIATRIC DONORS 
8.3.4.1 How do we ensure ethical use of paediatric donors? 
Since there are associated risks and no direct medical benefit to the paediatric donor 
from donating, the accepted justification for permitting minor siblings to donate stem 
cells is that the donor will benefit from the greater likelihood of survival and reduced 
suffering of their sibling. This justification is supported by results of some studies, 
describing psychosocial benefits experienced by paediatric sibling donors, including 
increased self-esteem, pride, and worth of life and independence (Wiener et al, 2008; 
van Walraven et al, 2013; Packman et al, 2010; MacLeod et al, 2003). However, in 
some of these studies, the donation experience was linked to recipient transplant 
outcome with some donors of unsuccessful transplants reporting predominantly 
negative experiences (van Walraven et al, 2013).  
Internationally, it is ethically considered appropriate to allow minors to donate, 
(American Academy of Pediatrics, 2010; Bitan et al, 2015), and children have served 
as stem cell donors for >30 years. Based on ensuring benefit and limiting harm, most 
experts consider donation to be justifiable only provided that there is a strong positive 
link (or anticipated strong positive link in very young children) and a reasonable chance 
of a successful transplant outcome (Pentz et al, 2008).  
In view of the greater potential for placing undue pressure on the donor in the 
paediatric setting, it is crucial that the donor’s care is separated from that of the 
recipient by ensuring that the physician responsible for the donor is not involved in the 
care of the recipient. For this reason HTA regulations also require that all cases of 
minors who are not competent to consent are reviewed by an independent assessor 
who interviews the donor and submits a report to the HTA (HTA, 2014).  
Consent for the donation procedure in minors is provided by parents, however it is 
widely agreed that children should be given information in an age appropriate fashion 
and should participate in the decision-making process by giving their assent. Although 
the legal position is that parents can consent for their child, it is recognised that a 




conflict of interest exists for parents of a child donating to their sibling. If the child 
objects, the independent assessor must explore the reasons and as far as possible 
explain consequences of not donating.  
 
There was unanimous agreement that children should be permitted to serve as HPC 
donors but suggested definite criteria should be met, including evidence of a positive 
relationship with the recipient and that no medically equivalent older related donor is 
available. 
8.3.4.2 Is BM harvesting safe in paediatric donors? 
The safety profile of BM donation in children appears to be excellent, with the risk of 
life-threatening events of less than 0.5% (Buckner et al, 1984). A recent EBMT 
paediatric diseases working party study (Styczynski et al, 2012) in 313 BM donors 
confirmed historical reports of low incidence of adverse reactions; the main risk being 
that allogeneic transfusion is likely to be necessary in very young donors donating to an 
older sibling. However, providing that a maximum 20mls/kg donor weight is aspirated, 
allogeneic blood products are rarely required (Styczynski et al, 2012).  
8.3.4.3. Is PBSC donation safe in paediatric donors? 
The EBMT paediatric diseases working party study (Styczynski et al, 2012) included 
140 PBSC donors, with the only serious adverse event recorded in a donor who 
developed a pneumothorax as a result of CVC insertion. The Paediatric Blood and 
Marrow Transplant Consortium conducted a retrospective analysis on the safety and 
efficacy of PBSCs donation by 201 paediatric sibling donors from 22 institutions. This 
study showed good yields in all age groups and few side effects (Pulsipher et al, 2004). 
Further analyses suggest that children report fewer side effects during GCSF 
mobilisation than adults (Karakukcu & Unal, 2015; Duong et al, 2014; Volker, 2013; 
Pulsipher et al, 2006).  
While autologous collection of PBSCs in children is routine practice, there are several 
potential issues with allogeneic PBSC collection in children under 16 years, which 
potentially carries greater risks than BM donation. First, in donors weighing less than 
20kg, priming of the apheresis circuit is almost always required, exposing the donor to 




allogeneic blood products. Second, central venous access is required in smaller 
donors, with investigations showing that while it is possible to collect 80% of 13-16 year 
olds peripherally, this is only possible in a third of 7-12 year olds (Pulsipher et al, 2004). 
In children, central venous catheter insertion is likely to cause more pain and risk than 
the mobilisation or collection. The third issue is that in the UK, filgrastim is not licensed 
for stem cell mobilisation in donors under 16 years, and although lenograstim is 
licensed in children >2 years, including for mobilisation, the summary of product 
characteristics does not recommended its use, due to a lack of specific studies of 
mobilisation in children. Data from the severe chronic neutropenia international registry 
are reassuring in that no malignancies have been reported, and there are no reports of 
splenic rupture occurring in children.  
8.3.4.4 Is PBSC mobilisation effective in paediatric donors? 
A number of studies have included donors <18 years in assessments of PBSC yield 
following GCSF and concluded favourable efficacy in younger donors. In 2002, a 
Japanese group published a study examining factors associated with successful 
mobilisation with GCSF in PBSC donor and found a negative correlation between stem 
cell yield and age (Shimizu et al, 2002), These findings were echoed in a more recent 
Italian multi-centre study (Bertani et al, 2014) which investigated donor variables 
correlating with HPC mobilisation in 360 donors aged 13+ treated with GCSF and 
noted that younger age was associated with better mobilisation following GCSF.  
A study  examining the factors associated with successful mobilisation in 400 donors 
aged 12+ receiving lenograstim (Ings et al, 2006) demonstrated successful mobilisation 
in all younger donors, with poor mobilisation occurring exclusively in donors 54 years or 
older.  Mobilisation has been directly compared between adults and paediatric donors, 
Kawano et al reported the CD34 yield of 25 adult and 19 paediatric donors mobilised 
with GCSF, finding no difference in the CD34 yield per unit of blood processed 
(Kawano et al, 1999).   
A further study included 101 donors aged 16-63 years, who underwent PBSC donation 




Satisfactory mobilisation occurred in both groups, and no long-term adverse events 
were recorded (Martino et al, 2005). 
8.3.4.5 Summary of discussions regarding the optimal donation route in paediatric 
donors  
The group agreed that the available evidence confirms the safety of BM donation in 
donors <16 years, providing that the aforementioned limit of 20ml/kg aspirated volume 
is adhered to.  The evidence regarding PBSC donation is less clear. The group agreed 
that CVC insertion in paediatric donors should be avoided, and that BM should be the 
only donation route recommended in donors aged 12 years or younger. There was felt 
to be no evidence for an increased risk of PBSC donation over BM donation in donors 
aged 13-15 with good venous access, however the group were not certain that there 
are adequate data regarding the long-term safety of GCSF in this group. Following 
discussion with additional members of the paediatric subgroup of the BSBMT, the 
decision was made to recommend BM as the only donation route in donors <16 years. 
 
8.3.4.6 Can 16-17 year old donors be treated as adults? 
Since 2012, 16-year olds have been permitted to join the Anthony Nolan donor register 
and to donate PBSC or BM as unrelated donors. The evidence and licensing data used 
to make this decision were reviewed by the guideline group before formulating 
recommendations for RDs in this age range.  
Lenograstim is used for HPC mobilisation by all UK UD registries, and is more 
commonly used by UK transplant centres than filgrastim, but the license in donors <18 
years was unclear stating: “Granocyte is indicated in adults, adolescents and children 
older than 2 years for…. the mobilisation of peripheral blood progenitor cells (PBPCs), 
for patients as well as healthy donors”. 
 
However, under the subsection ‘Special warnings and precautions for use’ the use of 
lenograstim in minors is cautioned, stating: ”Based on some local regulations and lack 
of studies, minor donors should not be considered”. 




To clarify the situation regarding minors the manufacturers, Chugai, were approached 
who confirmed that the term ‘minor’ in this context refers to the age of consent for 
medical treatment, which differs between European countries. (S Long, Medical 
Director, personal communication).  Lenograstim and filgrastim are therefore both 
licensed in allogeneic donors in 16 and 17 year olds. 
Chugai also provided the following summary of adverse events reported in paediatric 
healthy donors aged 16-18 years old treated with lenograstim, as of 30 April 2014, from 
their Global Argus Database detailing adverse events: “8 children aged 16-18 year olds 
received lenograstim. Of those 8, serious event (pneumothorax) was reported in 1 
case, but causality between lenograstim and pneumothorax was ruled out both by the 
reporter and company. The remaining 6 cases were non-serious, whilst no adverse 
event was reported in the remaining 1 case.” 
On review of prospective and retrospective studies that have included donors 16-17 
years of age, no increased incidence of SAEs has been observed in comparison to 
older donors (Bertani et al, 2014; Kawano et al, 1999; Basara et al, 2000; Martino et al, 
2009). 
Under the provisions of the HT (Scotland) Act, children are defined as being under 16 
years of age, therefore those over 16 may consent to donation in the same way as 
older adults. In England and Wales, children are defined as less than 18 years of age, 
however donation of bone marrow and PBSC by children who are Gillick competent to 
consent can be approved locally.  
The group agreed that there is sufficient evidence for the safety and efficacy of PBSC 
mobilisation in donors aged 16-17. Donors in this age group can undergo the same 
evaluation procedure as older adults, with no need for additional investigations. In 
Scotland these donors may provide their own consent and in England those who are 
deemed Gillick competent may do so.  
 





8.3.5 FOLLOW-UP OF RELATED DONORS  
8.3.5.1 What is the most efficient method of RD follow-up? 
The objectives of donor follow-up are twofold; firstly to capture any short-term adverse 
events occurring in the first 30 days after donation, and secondly, to provide long-term 
surveillance to exclude an increased incidence of health issues in donors compared to 
the normal population. Reporting of donor adverse reactions is an HTA requirement, 
and, although not legally required in the UK, long-term donor follow-up is a mandatory 
requirement of FACT-JACIE (FACT-JACIE, 2011) and is also recommended by the 
WBMT (Halter et al, 2013), and WHO guiding principles (WHO, 2010).   
Greater than 50% of BM donors and 80% of PBSC donors report full recovery at one 
week post-donation (Pulsipher et al, 2013). Most transplant centres and donor 
registries provide follow-up within 7 days to ensure donors are recovering, often by 
telephone. The group agreed that provisions should be made for further follow-up of 
donors who have not recovered by this point to ensure that donor health events 
occurring within 30 days of donation are captured.  
Current evidence, which has reassuringly demonstrated no increase in incidence of 
autoimmune disease or malignancies in donors, is based predominantly on data from 
large unrelated donor cohorts. RDs tend to be older and are more likely to have pre-
existing health problems, but follow-up data on remain scarce, partly due to an 
historical lack of a centralised database to allow reporting. This has been addressed by 
the EBMT donor outcome committee and donor follow-up data can now be reported 
using specific EBMT donor outcome forms, which link this data to recipient records. In 
the UK, 17/22 centres surveyed provide follow-up to 30 days, allowing adverse event 
reporting, but currently only 23% follow donors to 5 years and 14% to 10 years. 23% of 
UK centres already submit donor to EBMT. 




The group agreed that promotion of both short-term and long-term data collection on 
RDs is essential, and that ideally this data should be analysed centrally by EBMT. The 
authors agreed that data collection should be limited to the minimum data set 
recommended by WBMT, and that this could be collected by administrative rather than 
clinical staff (but reviewed if any concerns were raised).  
8.3.5.2. Should RDs routinely be offered psychological support post-donation?  
Several studies (including the study described in Chapter 7), have shown that poor 
recipient outcomes are linked to a very negative psychological experience for their 
related donor in a small proportion of cases (Switzer et al, 1998; van Walraven et al, 
2010a; Wolcott et al, 1986). The emotions most commonly described are guilt and 
anxiety (Pillay et al, 2012).   
It is clear that education of related donors regarding the possible outcomes for their 
recipient is important, but the use of additional psychological interventions has not 
been studied.  The guideline group recognised the need for psychological evaluation as 
part of the donor medical procedure. Some members of the group felt that a formal 
separate psychological evaluation should be offered, but this was not finally formulated 
into a recommendation because this service is simply not available in some transplant 
centres.  As an alternative approach it was suggested that clinicians contact the 
donor’s GP to discuss any concerns identified.  
The group agreed that there is currently inadequate psychological support for RDs 
post-donation, however, in the absence of interventional studies describing a benefit, it 
was difficult to make a specific recommendation, particularly because it was felt that 
these would prove impossible for transplant centres to fulfil.  
8.3.5.3 What guidance should be offered regarding subsequent donations? 
With a growing proportion of patients undergoing reduced intensity transplants, a 
parallel increase in donors undergoing multiple therapeutic cell donations is seen. 
Currently, at least 5-10% of unrelated donors provide a subsequent donation of stem 




cells or lymphocytes, and probably a higher proportion of RDs, and it is conceivable 
that this proportion will rise further with the advent of novel cellular therapies. Providing 
that the initial donation is uncomplicated, there is evidence that healthy donors can 
safely donate HPCs on at least two occasions, with similar side effects and similarly 
low incidence of SARs (la Rubia et al, 2002; Lown et al, 2013). Second donations are 
therefore permitted by most unrelated donor stem cell registries and are in accordance 
with WMDA guidelines (Confer et al, 2011). The reported yield of subsequent donations 
is similar to initial donations, although some studies have demonstrated slightly lower 
CD34 doses in subsequent HPC donations (la Rubia et al, 2002; Platzbecker et al, 
2008).   
Lymphocyte collection is associated with very few short-term side effects (McLeod et 
al, 1998). Repeated collections can lead to prolonged lymphopenia in up to 50% 
donors, which is likely to be a greater risk in older donors (Nicolini et al, 2004), but 
there is no evidence that persistent lymphopenia in these donors is associated with 
significant infective risks.  
The guideline group agreed that available evidence suggests that donors can safely 
donate HPCs on two occasions and that UDs are in some situations permitted to make 
a third HPC donation. In considering this issue we decided against making a definite 
limit for the number of subsequent donations allowed, but instead recommended that 
greater than two HPC donations should be considered exceptional. In the absence of 
lymphopenia the group agreed that donors can be permitted to donate lymphocytes on 
at least two occasions. All members of the group agreed that it is important that 
transplant centres have a policy in this regard, and that donors are re-evaluated for 
fitness to donate prior to any subsequent donation. 
 
 




8.4 FINAL RECOMMENDATIONS  
8.4.1   DONOR CARE PRIOR TO HLA TYPING 
The health of related donors should be assessed before conducting HLA typing to 
allow early deferral of unfit donors. (1B) 
Sufficient information for allogeneic donors should be provided before the potential 
donor undergoes HLA typing, so as to protect the potential donor from undue pressure 
should he/she be the only suitable donor. (1C) 
It is suggested that this includes written information. (2D)  
Donors should be informed of their HLA matching status and offered time to consider 
before giving permission to disclose results to their potential recipient. (1C) 
8.4.2 EVALUATION OF RELATED DONORS 
Donor suitability should be evaluated by a licensed health care professional who is not 
the primary transplant physician or health care professional overseeing care of the 
recipient. (1C) 
Donors should be evaluated in a confidential setting. (1C) 
Defined medical suitability/eligibility criteria should be used to determine acceptability of 
related donors. (1B) 
Related donors should be carefully evaluated for the presence of any health issues that 
may present a risk to their health or the health of their intended recipient, including the 









Table 8.2 Recommended evaluation for related HPC donors at the donor 
medical 
Procedure Information to record 
Medical history Autoimmune symptoms/disease 
Inflammatory eye disease 
Cardiovascular symptoms/disease 
Neurological symptoms/disease 
Malignancy: to include symptoms of malignancy in 
donors >50 years, and adherence to national 
cervical/bowel/breast screening programmes 
Allergy history 
Anaesthetic history 
Blood transfusion history 
Thrombotic and bleeding history 
Vaccination history 
Back problems 











Venous access in PBSC donors 
Skin for suspicious lesions 
Cardiorespiratory system 
Lymph nodes  
Thyroid 
Abdominal system 
Neurological exam if indicated 

























type I and II, 
Treponema 
pallidum CMV IgG 
antibodies,   




HCV, HIV, HBV viral 
PCRs 











Haematology Full blood count 
Blood group and 
antibody screen 
Coagulation screen   
G6PD screening Males originating from 





At risk ethnicity or 
suggestive 
haematological indices 
Blood film and 
peripheral blood 
immunophenotyping 
MDS (blood film only) 
Sibling donors of 
patients with CLL 
Biochemistry Urea and 
electrolytes 







Males >50 years 
Serum protein 
electrophoresis 





Urine analysis for 
blood and protein 
Pregnancy test  in 
females of 
childbearing age 
 (urine or serum) 
Chest X-ray  
 
Donor >50 years, and 
all donors with a 
respiratory history or 
significant smoking 
history 





Donor evaluation should focus on identification of psychological as well as physical 
risks. (1C) 
There should be a procedure for managing relatives who are deemed to be unsuitable 
as donors following evaluation. (2C) 
Medical follow-up of any health issues identified during evaluation should be arranged, 
usually via the donor’s family doctor. (2C) 
8.4.3 TAKING INFORMED CONSENT FROM RELATED DONORS 
Donor counselling should include a clear explanation of the risks of donation, including 
the risks for the recipient, and the possibility of a subsequent donation request. (1C) 
Donors who are ineligible due to risks to the recipient, should only be permitted to 
proceed following discussion with the recipient’s transplant physician and documented 
acceptance by the physician and recipient. (1C) 
Acceptance of donors who do not meet standard medical suitability criteria requires 
additional consent and documentation for the rationale of proceeding with donation. 
(1C) 
The donor’s permission must be obtained prior to discussion of any confidential 
medical or lifestyle information with other health professionals or the recipient. (2C) 
8.4.4 THE DONATION PROCEDURE 
8.4.4.1 PBSC 
Filgrastim or lenograstim at a dose of 10mcg/kg/day for four to five days is 
recommended for mobilisation of RDs (1A) 
Full blood count monitoring during the mobilisation period is not required providing 
standard doses of GCSF are administered. (2B) 




Central venous catheters should be used only when absolutely necessary and should 
be inserted by a skilled operator under ultrasound guidance (1B)  
The use of biosimilar GCSF or alternative mobilisation agents for related donors cannot 
be recommended outside the context of a clinical study where follow-up is performed 
(2D) 
It is suggested that related donors usually undergo up to two apheresis procedures as 
standard practice.  (2C) 
In donors with a platelet count close to the centre’s donor thresholds (commonly 
80x109/l), a smaller volume (<2.5 blood volumes) should be processed. (2C) 
PBSC donors in whom an adequate harvest for engraftment is not achieved following 
two apheresis procedures could undergo a third apheresis procedure or a bone marrow 
harvest in the absence of contraindications and following appropriate consent. (1B) 
8.4.4.2 Bone marrow donation  
A maximum aspiration volume of 20ml/kg donor weight is recommended at bone 
marrow harvest. (1B) 
Health care professionals performing BM harvests should undergo specific training and 
continued exposure to the procedure to ensure their skill is maintained. (1B) 
The collection of autologous blood prior to BM harvest is not recommended. (2B) 
Iron supplementation should be considered peri-harvest in females of childbearing 
potential or those on low iron diets. (2C) 
8.4.5 SUBSEQUENT DONATIONS 
It is recommended that centres define limits for the frequency and total number of 
donations that RDs may undergo. (1C) 
The donation of HPCs on more than two occasions should be considered as 
exceptional. (2C) 




Donors should be re-evaluated and consented before any subsequent donation. (1C) 
It is suggested that all blood tests are repeated for donations occurring >3 months from 
the initial donation. (2C) 
As with initial donations, subsequent donations are only recommended when there is a 
reasonable probability of a successful outcome for the recipient. (2C) 
8.4.6 SPECIAL CONSIDERATIONS IN PAEDIATRIC DONORS 
In England and Wales, donors aged 16 or 17 may be considered for either PBSC or 
BM donation as per older adults, and if deemed to be Gillick competent by the 
assessing physician, they may consent to this procedure. (1C) 
In Scotland, donors aged 16 or 17 are considered adults and standard adult consent 
procedures apply. (1C) 
Children <16 may serve as haematopoietic progenitor cell donors providing the 
following criteria are fulfilled (1C): 
1. There is no medically equivalent older relative who is willing and able to donate 
2. There is a strong and emotionally positive relationship with the recipient 
3. There is a reasonable likelihood of a successful outcome for the recipient 
4. The procedure should be explained using age-appropriate materials and assent 
of the child should be obtained where appropriate  
5. An independent donor advocate provides an assessment as per HTA 
requirements 
6. Parental consent is obtained if the child is not Gillick competent 
Medical evaluation of paediatric donors should be performed by a health care 
professional who is not involved in the care of the intended recipient. (1C) 
BM donation is the only donation method recommended in children <16 years old. As 
with adults, a maximum of 20mls/kg is recommended to avoid the need for allogeneic 
transfusion. (1C) 
Bone marrow donation is not recommended in babies of less than six months old. (1B) 




8.4.7 DONOR FOLLOW-UP 
It is suggested that related donors are contacted within 2-7 days from donation to 
ensure they are recovering as expected. (2C) 
It is suggested that donors who have not recovered at 7 days receive further follow-up, 
or are provided with contact details to report any remaining symptoms which have not 
subsided within the expected timeframe.  (2D) 
It is suggested that related donors are requested to report any morbidities occurring in 
the first 30 days post-donation to a designated contact in the transplant centre to allow 
adverse event recording. (2D) 
Provision of psychological or emotional support post-donation should be considered 
where necessary (2C) 
Long-term donor follow-up should include parameters suggested in the WBMT 
minimum data set and should be performed biannually to 10 years from the last 
donation. (1C) 
It is suggested that centres report long-term RD follow-up data to EBMT to allow 
centralised data collection. (2D) 
8.5 NATIONAL MEDICAL SUITABILITY AND ELIGIBILITY CRITERIA 
FOR RELATED DONORS 
The above guidelines were designed to outline best practice in the management and 
assessment of RDs, but purposefully focused on educating those involved in donor 
care about how these procedures should ideally be conducted and the principles 
behind donor evaluation. The guideline group had decided not to make specific 
recommendations about which medical conditions should and should not be accepted 
in related donors, in part because it would be impossible to do so thoroughly within the 
scope of a guideline document. A second reason for this was that there are many 
areas where it is impossible to provide definitive guidance and the final decision should 




be based on determination of the severity of a condition (possibly including input from 
other medical specialists) and frank discussion of any increased risks with the donor.  
During preparation of the guidelines, it became apparent that although defining medical 
criteria for related donors would not be possible within the scope of the guidelines, 
such criteria would nevertheless be hugely valuable to the community and would 
complement the guidelines perfectly.  The Scottish National Blood Transfusion Service 
(SNBTS) already produce very extensive medical criteria for related HPC donors 
(Douglas, 2014), originally adapted from their guidelines for acceptance of blood 
donors. As per all UK national blood donor guidelines, these criteria categorise the 
guidance as follows: obligatory deferral; protocol exception (where additional consent 
must be sought); discretionary acceptance; acceptance. However, these criteria are an 
internal SNBTS document, which is not widely used by transplant centres, and as a 
word document with >150 pages, it is not in a user-friendly format.  
With permission from SNBTS, the group reviewed and revised this comprehensive 
document to create BCSH/BSBMT endorsed national medical criteria for acceptance of 
related HPC donors. In view of the success of the online WMDA medical suitability tool 
(https://wiki.wmda.info/index.php?title=Main_Page) which has been accessed >1.5 
million times in the last 2 years, I decided to create a wiki-site with a similar format for 
our national medical RD criteria. This wiki-site is in the final stages of creation.  
8.6 CONCLUSIONS   
Although allogeneic HPC donation has an excellent safety record, with very low rates of 
serious adverse reactions in healthy donors it is critical that all HPC donors are 
thoroughly evaluated to determine any conditions or characteristics that increase their 
risk. Evaluation of RDs must consider the psychological risks and benefits to the donor, 
and in some situations the potential psychological benefit to a donor who wishes to 
donate must be balanced against a degree of physical risk. It may be appropriate to 
accept relatives as donors with medical conditions or characteristics that somewhat 
increase their risk, but specific informed consent regarding such risk is crucial.  




These guidelines are designed to offer specific recommendations for the optimal 
process for donor evaluation and management at each stage of the donor care 
pathway. The intention was to provide clinicians with the available evidence regarding 
the physical and psychological risks of donation and the donor factors known to 
influence these, to aid decision-making in difficult areas.   
It was beyond the scope of the guideline format to try to address individual medical 
conditions and thus I decided to create a separate paired resource for medical 
suitability criteria.  I hope that in combination these projects will fill a much-needed gap 
in related donor care nationally.  
 
 




CHAPTER	  9.	  	  CONCLUSIONS	  
9.1 SUMMARY 
In this thesis I have presented an in-depth investigation of the pathway of adult related 
donor care internationally and have been able to identify several areas where current 
practice is suboptimal with respect to the health or interests of related donors. After 
designing and undertaking three studies to determine practice patterns in related donor 
care (all of which resulted in publications in peer-reviewed journals) and one study 
evaluating the related donor care pathways from the perspective of RDs, I was able to 
draw my findings together to formulate national guidelines in related donor care. I also 
used these findings as a basis to prospectively evaluate potential novel models of 
related donor care, in an effort to overcome the current issues in the care pathway.  
The study I conducted in Chapter 3 demonstrated the value of FACT-JACIE as a 
regulatory body in driving change in the field of related donor care. This study also 
added to current evidence regarding the increased incidence of SARs in donors not 
meeting UD medical suitability criteria, which led to the recommendation for a thorough 
evaluation of cardiovascular risk factors in older RDs in the BCSH/BSBMT guidelines.  
In Chapters 4 and 5 I highlighted that despite FACT-JACIE recommendations, donor 
follow-up is absent in the US and is infrequently performed to the recommended 
duration in other regions. This finding served as a basis for the pilot study I carried out  
(Chapter 6) where I successfully demonstrated an alternative model of donor care 
where an UD registry provided RD follow-up. Other findings from the international 
donor care surveys served as a basis for the development of the BSCH guidelines 
(Chapter 8). This included the need to prevent coercion of related donors by ensuring 
they are fully informed prior to HLA typing, that donor permission is sought before their 
HLA results are disclosed to the intended recipient, and that their evaluation and 
consent should be by a clinician who is not involved in the care of their recipient.  




In Chapter 7, I demonstrated the importance of fully informing related donors of the 
possible consequences of donation, both for themselves and their recipient. I identified 
post-donation psychological support as an area which is lacking in current donor care 
set-ups. Following the study in Chapter 6 the Anthony Nolan registry decided to 
consider providing such support, which would directly address this issue.  
9.2 CHALLENGES 
The greatest challenges I encountered during the studies described in this thesis 
occurred during attempts to set up pilot studies for alternative models of related donor 
care in UK centres. Although I confirmed initial interest from transplant centres, once I 
had determined all the logistics and costs for the first two models described in Chapter 
6, the centres I was working with were unable to accept proposals for the pilot studies. 
In the case of the first model this was due to concerns with meeting the costs of such a 
model after the initial pilot study. In the case of the second model the concerns were 
logistical because the model would have required onsite support, which was unable to 
be guaranteed.   
The other area in which I faced challenges was regarding collection of data for the 
international surveys of related donor care. In order to achieve a reasonable response 
rate I decided not to insist that transplant centres enter their own CIBMTR or EBMT 
centre number (which many clinicians would not know off the top of their head). 
However, despite specifically requesting that respondents enter their centre name in 
full, many centres used abbreviations  (e.g. U of M) which I then had to match to the 
centre names held by the EBMT or CIBMTR alongside the centre numbers. This was a 
very time consuming process but was I think, a necessary hurdle to overcome to 
achieve satisfactory response rates. 
9.3 FUTURE PROJECTS 




9.3.1 AN INTERNATIONAL SURVEY OF PAEDIATRIC PRACTICE PATTERNS 
IN RD CARE 
During the process of writing up publications for the two studies examining international 
donor care in the US and EBMT transplant centres (Chapter 5), several members of 
the donor health and safety working committee of the CIBMTR commented that no 
such studies have explored practice patterns in paediatric centres.  I therefore 
suggested that this should be proposed as a subsequent study, and have been working 
with other members of the committee to formulate a study questionnaire. A proposal for 
this study (for which I am a primary investigator) has been accepted by the CIBMTR 
donor health and safety working committee.  
9.3.2  UK RD FOLLOW-UP BY THE ANTHONY NOLAN 
Following the successful pilot study of related donor follow-up I described in Chapter 6, 
the Anthony Nolan are planning to offer a related donor follow-up service to transplant 
centres. Before this point, the options for additional staff training are being reviewed to 
ensure that donors with psychological problems post-donation are adequately 
supported. This service will initially be offered without charge to transplant centres 
using the Anthony Nolan graft identification and advisory service, but if successful, will 
then be offered nationwide. This service will be audited to ensure donor and transplant 
centre satisfaction.  
9.3.3 AN AUDIT OF UK CENTRE PRACTICE AGAINST THE BSCH RELATED 
DONOR CARE GUIDELINES 
The BCSH process requires that guideline authors submit a template for proposed 
audit of UK centres. I plan to lead a re-audit of UK centre practice approximately 18-24 
months after introduction of the guidelines.  




9.3.4 UPDATING AND EXPANSION OF THE WIKI-PAGE FOR MEDICAL 
CRITERIA FOR RELATED HPC DONORS 
The wiki-site for national related HPC donor medical criteria that I am creating (Chapter 
8) has the provision for users to make requests or comments. As has been the case for 
the WMDA unrelated donor criteria, it is envisaged that users are likely to request 
criteria to be created for additional medical conditions. Furthermore it will be necessary 
to periodically update these criteria to bring them in line with new recommendations 
from regulatory bodies. I will lead a small group of experts in updating these criteria on 
an annual basis and additional recommendations will also be added on an ‘as needed’ 
basis where urgent changes to guidance are needed (for example situations such as 
the recent Ebola virus outbreak).  
9.4 CONCLUSION 
Although allogeneic HPC donation has an excellent safety record, this thesis has 
outlined several areas in which current pathways do not adequately protect the health 
and wellbeing of related donors. Through the studies described in this thesis I have 
been able both to define these areas in detail, and to determine where and how 
improvements are needed.  These improvements I have suggested are most likely to 
be most realised if driven by further augmentation of FACT-JACIE Standards, and 
through the use of the national evidence-based guidelines and medical criteria I led on 
creating.   This will I hope ultimately result in greater standardisation of related donor 









Abanyie, F.A., Gray, E.B., Delli Carpini, K.W., Yanofsky, A., McAuliffe, I., Rana, M., Chin-Hong, 
P.V., Barone, C.N., Davis, J.L., Montgomery, S.P. & Huprikar, S. (2015) Donor-derived 
Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 
2009-2013. American Journal of Transplantation, 15, 1369–1375. 
Ahmed, K., Safdar, K., Kemmer, N., Atiq, M., Wang, J. & Neff, G.W. (2007) Intestinal 
Schistosomiasis Following Orthotopic Liver Transplantation: A Case Report. 
Transplantation proceedings, 39, 3502–3504. 
Al-Ali, H.K., Bourgeois, M., Krahl, R., Edel, E., Leiblein, S., Poenisch, W., Basara, N., Lange, T. 
& Niederwieser, D. (2010) The impact of the age of HLA-identical siblings on mobilization 
and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow 
Transplantation, 46, 1296–1302.  
American Academy of Pediatrics Committee on Bioethics (2010) Children as Hematopoietic 
Stem Cell Donors. Pediatrics, 125, 392–404. 
Anasetti, C., Logan, B.R., Lee, S.J., Waller, E.K., Weisdorf, D.J., Wingard, J.R., Cutler, C.S., 
Westervelt, P., Woolfrey, A., Couban, S., Ehninger, G., Johnston, L., Maziarz, R.T., 
Pulsipher, M.A., Porter, D.L., Mineishi, S., McCarty, J.M., Khan, S.P., Anderlini, P., 
Bensinger, W.I., et al (2012) Peripheral-blood stem cells versus bone marrow from 
unrelated donors. The New England journal of medicine, 367, 1487–1496. 
Anderlini, P., Donato, M., Lauppe, M.J., Huh, Y.O., Martin, T.G., Chan, K.W., Champlin, R.E. & 
Körbling, M. (2000) A comparative study of once-daily versus twice-daily filgrastim 
administration for the mobilization and collection of CD34+ peripheral blood progenitor cells 
in normal donors. British Journal of Haematology, 109, 770–772. 
Anderlini, P., Rizzo, J.D., Nugent, M.L., Schmitz, N., Champlin, R.E., Horowitz, M.M., IBMTR 
Statistical Center of the International Bone Marrow Transplant Registry, Medical College of 
Wisconcin, Milwaukee, WI, USAEBMT, Kiel, Germany (2001) Peripheral blood stem cell 
donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and 
European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow 
Transplantation, 27, 689–692. 
Anthias, C., Billen, A., Arkwright, R., Alejandro Madrigal, J. & Shaw, B.E. (2015) Harvests from 
bone marrow donors who weigh less than their recipients are associated with a significantly 
increased probability of a suboptimal harvest yield. Transfusion, in press  
Anthony Nolan, (2014) Donating to your relative. Available at: http//www.anthonynolan.org 
Au, W.Y., Ma, S.K., Lie, A.K.W., Liang, R., Cheng, T. & Kwong, Y.L. (2002) Glucose-6-
phosphate dehydrogenase deficiency and hematopoietic stem cell transplantation. Bone 
Marrow Transplantation, 29, 399–402. 
Bacigalupo, A., Tong, J., Podesta, M., Piaggio, G., Figari, O., Colombo, P., Sogno, G., Tedone, 
E., Moro, F. & Van Lint, M.T. (1992) Bone marrow harvest for marrow transplantation: effect 






Baron, F., Dresse, M.-F. & Beguin, Y. (2003) Transmission of chronic myeloid leukemia through 
peripheral-blood stem-cell transplantation. The New England journal of medicine, 349, 
913–914. 
Barrett, A.J., Ringdén, O., Zhang, M.J., Bashey, A., Cahn, J.Y., Cairo, M.S., Gale, R.P., 
Gratwohl, A., Locatelli, F., Martino, R., Schultz, K.R. & Tiberghien, P. (2000) Effect of 
nucleated marrow cell dose on relapse and survival in identical twin bone marrow 
transplants for leukemia. Blood, 95, 3323–3327. 
Basara, N., Schmetzer, B., Blau, I.W., Bischoff, M., Günzelmann, S., Kirsten, D. & Fauser, A.A. 
(2000) Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an 
open label randomized split dose escalating study. Bone Marrow Transplantation, 25, 371–
376. 
Batinić, D., Marusić, M., Pavletić, Z., Bogdanić, V., Uzarević, B., Nemet, D. & Labar, B. (1990) 
Relationship between differing volumes of bone marrow aspirates and their cellular 
composition. Bone Marrow Transplantation, 6, 103–107. 
Bellou, A., Kanny, G., Fremont, S. & Moneret-Vautrin, D.A. (1997) Transfer of atopy following 
bone marrow transplantation. Annals of allergy, asthma & immunology : official publication 
of the American College of Allergy, Asthma, & Immunology, 78, 513–516. 
Bensinger, W.I., Martin, P.J., Storer, B., Clift, R., Forman, S.J., Negrin, R., Kashyap, A., 
Flowers, M.E., Lilleby, K., Chauncey, T.R., Storb, R. & Appelbaum, F.R. (2001) 
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical 
relatives in patients with hematologic cancers. The New England journal of medicine, 344, 
175–181. 
Berg, K.D., Brinster, N.K., Huhn, K.M., Goggins, M.G., Jones, R.J., Makary, A., Murphy, K.M., 
Griffin, C.A., Rosenblum-Vos, L.S., Borowitz, M.J., Nousari, H.C. & Eshleman, J.R. (2001) 
Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation. The New 
England journal of medicine, 345, 1458–1463. 
Bertani, G., Santoleri, L., Martino, M., Fedele, R., Moscato, T., Marenco, P., Grillo, G., Zucchetti, 
E., Lotesoriere, I., Lando, G., Cesana, C., Cairoli, R. & Rossini, S. (2014) Identification of 
hematopoietic progenitor cell donor characteristics predicting successful mobilization: 
results of an Italian multicenter study. Transfusion, 54, 2028–2033. 
Billen, A., Madrigal, J.A., Szydlo, R.M. & Shaw, B.E. (2014) Female donors and donors who are 
lighter than their recipient are less likely to meet the CD34+ cell dose requested for 
peripheral blood stem cell transplantation. Transfusion. 54, 2953-2960. 
Bishop, L., Dougherty, L., Bodenham, A., Mansi, J., Crowe, P., Kibbler, C., Shannon, M. & 
Treleaven, J. (2007) Guidelines on the insertion and management of central venous access 
devices in adults. International Journal of Laboratory Hematology, 29, 261–278. 
Bitan, M., van Walraven, S.M., Worel, N., Ball, L.M., Styczynski, J., Torrabadella, M., Witt, V., 
Shaw, B.E., Seber, A., Yabe, H., Greinix, H.T., Peters, C., Gluckman, E., Rocha, V., Halter, 
J. & Pulsipher, M.A. (2015) Determination of Eligibility in Related Pediatric Hematopoietic 
Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group 
of the Worldwide Network for Blood and Marrow Transplantation Association. Biology of 
Blood and Marrow Transplantation, 1–7. 





Marolleau, J.-P., Garnier, F., Ribaud, P. & Gluckman, E. (2002) Association of CD34 cell 
dose with hematopoietic recovery, infections, and other outcomes after HLA-identical 
sibling bone marrow transplantation. Blood, 99, 2726–2733. 
Blaise, D., Kuentz, M., Fortanier, C., Bourhis, J.H., Milpied, N., Sutton, L., Jouet, J.P., Attal, M., 
Bordigoni, P., Cahn, J.Y., Boiron, J.M., Schuller, M.P., Moatti, J.P. & Michallet, M. (2000) 
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic 
transplantation in patients with early-stage leukemia: a report from the Société Française 
de Greffe de Moelle. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology, 18, 537–546. 
Bloodwise (2012) Donating stem cells. 1–24 Available at bloodwise.org.uk 
Braun-Parvez, L., Charlin, E., Caillard, S., Ducloux, D., Wolf, P., Rolle, F., Golfier, F., Flicoteaux, 
H., Bergerat, J.-P. & Moulin, B. (2010) Gestational choriocarcinoma transmission following 
multiorgan donation. American Journal of Transplantation, 10, 2541–2546. 
Bredeson, C., Leger, C., Couban, S., Simpson, D., Huebsch, L., Walker, I., Shore, T., Howson-
Jan, K., Panzarella, T., Messner, H., Barnett, M. & Lipton, J. (2004) An evaluation of the 
donor experience in the canadian multicenter randomized trial of bone marrow versus 
peripheral blood allografting. Biology of Blood and Marrow Transplantation, 10, 405–414. 
Buckner, C.D., Clift, R.A., Sanders, J.E., Stewart, P., Bensinger, W.I., Doney, K.C., Sullivan, 
K.M., Witherspoon, R.P., Deeg, H.J. & Appelbaum, F.R. (1984) Marrow harvesting from 
normal donors. Blood, 64, 630–634. 
Buckner, C.D., Epstein, R.B., Rudolph, R.H., Clift, R.A., Storb, R. & THOMAS, E.D. (1970) 
Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. 
Blood, 35, 741–750. 
Butterworth, V.A., Simmons, R.G. & Bartsch, G. (1993) Psychosocial effects of unrelated bone 
marrow donation: experiences of the National Marrow Donor Program. Blood, 81, 1947-
1959. 
Champlin, R.E., Schmitz, N., Horowitz, M.M., Chapuis, B., Chopra, R., Cornelissen, J.J., Gale, 
R.P., Goldman, J.M., Loberiza, F.R., Hertenstein, B., Klein, J.P., Montserrat, E., Zhang, 
M.J., Ringdén, O., Tomany, S.C., Rowlings, P.A., Van Hoef, M.E. & Gratwohl, A. (2000) 
Blood stem cells compared with bone marrow as a source of hematopoietic cells for 
allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working 
Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood, 
95, 3702–3709. 
Chang, G., McGarigle, C., Spitzer, T.R., McAfee, S.L., Harris, F., Piercy, K., Goetz, M.A. & 
Antin, J.H. (1998) A Comparison of Related and Unrelated Marrow Donors. Psychosomatic 
Medicine, 60, 163. 
Christopher, K.A. (2000) The experience of donating bone marrow to a relative. Oncology 
nursing forum, 27, 693–700. 
Clare, S., Mank, A., Stone, R., Davies, M., Potting, C. & Apperley, J.F. (2010) Management of 
related donor care: a European survey. Bone Marrow Transplantation, 45, 97–101. 
Cleaver, S.A. (1993) The Anthony Nolan Research Centre. Bone Marrow Transplantation, 11 





Collier, A.C., Miller, R.A. & Meyers, J.D. (1984) Cryptosporidiosis after marrow transplantation: 
person-to-person transmission and treatment with spiramycin. Annals of internal medicine, 
101, 205–206. 
Coluccia, P., Crovetti, G., Del Fante, C., Dallavalle, F.M., Laszlò, D., Ferremi, P., Marenchino, 
D., Santoleri, L., De Filippo, C., Mattana, F., Mariani, L., Perseghin, P. & Ravagnani, F. 
(2012) Screening of related donors and peripheral blood stem cell collection practices at 
different Italian apheresis centres. Blood transfusion, 10, 440–447. 
Confer, D.L., Shaw, B.E. & Pamphilon, D.H. (2011) WMDA guidelines for subsequent donations 
following initial BM or PBSCs. Bone Marrow Transplantation, 46, 1409–1412. 
Copelan, E.A. (2006) Hematopoietic stem-cell transplantation. The New England journal of 
medicine, 354, 1813–1826. 
Cornelissen, J.J., van Putten, W.L.J., Verdonck, L.F., Theobald, M., Jacky, E., Daenen, S.M.G., 
van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P.C., van der Lelie, H., Fey, 
M., Ferrant, A., Maertens, J., Gratwohl, A. & Lowenberg, B. (2007) Results of a 
HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem 
cell transplantation in first remission acute myeloid leukemia in young and middle-aged 
adults: benefits for whom? Blood, 109, 3658–3666. 
Daikeler, T., Günaydin, I., Einsele, H., Kanz, L. & Kötter, I. (1999) Transmission of psoriatic 
arthritis by allogeneic bone marrow transplantation for chronic myelogenous leukaemia 
from an HLA-identical donor. Rheumatology (Oxford, England), 38, 89–90. 
Dausset, J. (1958) Iso-leuko-antibodies. Acta haematologica, 20, 156–166. 
de Lavallade, H., Ladaique, P., Lemarié, C., Fürst, S., Faucher, C., Blaise, D., Chabannon, C. & 
Calmels, B. (2009) Older age does not influence allogeneic peripheral blood stem cell 
mobilization in a donor population of mostly white ethnic origin. Blood, 113, 1868–1869. 
Dharmasena, F. & Gordon-Smith, E.C. (1986) Transmission of malaria by bone marrow 
transplantation. Transplantation, 42, 228. 
Donor choice according to age for allo-SCT for AML in complete remission (2013) Donor choice 
according to age for allo-SCT for AML in complete remission. 48, 1028–1032.  
Douglas K., (2014) SNBTS Donor acceptance criteria for related allogeneic HPC donors. 
Unpublished. 
Duong, H.K., Savani, B.N., Copelan, E., Devine, S., Costa, L.J., Wingard, J.R., Shaughnessy, 
P., Majhail, N., Perales, M.-A., Cutler, C.S., Bensinger, W., Litzow, M.R., Mohty, M., 
Champlin, R.E., Leather, H., Giralt, S. & Carpenter, P.A. (2014) Peripheral Blood Progenitor 
Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: 
Guidelines from the American Society for Blood and Marrow Transplantation. Biology of 
Blood and Marrow Transplantation, 20, 1262–1273. 
Eapen, M., Horowitz, M.M., Klein, J.P., Champlin, R.E., Loberiza, F.R., Ringdén, O. & Wagner, 
J.E. (2004) Higher mortality after allogeneic peripheral-blood transplantation compared with 
bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell 
Source Working Committee of the International Bone Marrow Transplant Registry. Journal 






Ertem, M., Kürekçi, A.E., Aysev, D., Unal, E. & Ikincioğullari, A. (2000) Brucellosis transmitted 
by bone marrow transplantation. Bone Marrow Transplantation, 26, 225–226. 
FACT-JACIE (2011) International Standards fir cellular therapy product collection, processing 
and administration 4th Edition, Available at: www.Jacie.org 
FACT-JACIE (2012) International Standards fir cellular therapy product collection, processing 
and administration 5th Edition,. Available at: www.Jacie.org 
Favre, G., Beksac, M., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., Russell, N., 
Apperley, J., Szer, J., Bradstock, K., Buzyn, A., Matcham, J., Gratwohl, A. & Schmitz, N. 
(2003) Differences between graft product and donor side effects following bone marrow or 
stem cell donation. Bone Marrow Transplantation, 32, 873–880. 
Ferrand, C., Garnache-Ottou, F., Collonge-Rame, M.A., Larosa, F., Blanc, M., Behar, C., 
Giannoli, C., Garnier, F., Tiberghien, P., Deconinck, E. & Rohrlich, P.S. (2012) Systematic 
donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL 
transmission after unrelated hematopoietic stem cell transplantation. European journal of 
haematology, 88, 269–272. 
Ferreira, G.F., de Oliveira, R.A., Jorge, L.B., Nahas, W.C., Saldanha, L.B., Ianhez, L.E. & 
Srougi, M. (2010) Urothelial carcinoma transmission via kidney transplantation. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association, 25, 641–643. 
Fischer, J.C., Frick, M., Wassmuth, R., Platz, A., Punzel, M. & Wernet, P. (2005) Superior 
mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not 
female unrelated stem cell donors. British Journal of Haematology, 130, 740–746. 
Flandrin-Gresta, P., Callanan, M., Nadal, N., Jaubert, J., Cornillon, J., Guyotat, D. & Campos, L. 
(2010) Transmission of leukemic donor cells by allogeneic stem cell transplantation in a 
context of familial CLL: should we screen donors for MBL? Blood, 116, 5077–5078. 
Fortanier, C., Kuentz, M., Sutton, L. & Milpied, N. (2002) Healthy sibling donor anxiety and pain 
during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: 
results of a randomised study. Bone marrow Transplantation, 29. 145-149 
Frank, S., Müller, J., Bonk, C., Haroske, G., Schackert, H.K. & Schackert, G. (1998) 
Transmission of glioblastoma multiforme through liver transplantation. Lancet, 352, 31. 
Garrido, G. & Matesanz, R. (2008) The Spanish National Transplant Organization (ONT) tumor 
registry. Transplantation, 85, S61–3. 
Gerstenkorn, C. & Thomusch, O. (2003) Transmission of a pancreatic adenocarcinoma to a 
renal transplant recipient. Clinical transplantation, 17, 473–476. 
Giessing, M., Reuter, S., Schönberger, B., Deger, S., Tuerk, I., Hirte, I., Budde, K., Fritsche, L., 
Morgera, S., Neumayer, H.H. & Loening, S.A. (2004) Quality of Life of Living Kidney Donors 
in Germany: A Survey with the Validated Short Form-36 and Giessen Subjective 
Complaints List-24 Questionnaires. Transplantation, 78, 864–872. 
Gomez-P, C.F., Mantilla-H, J.C. & Rodriguez-Morales, A.J. (2014) Fatal Chagas Disease 






Gouëzec, H., Ferré, N., Hervé, F., Lapart, C., Leberre, C., Bernard, M., Dauriac, C. & 
Nimubona, S. (2015) Pertinence du prélèvement sanguin autologue et de sa transfusion 
lors d’un don de moelle osseuse. Transfusion clinique et biologique, 22, 71–75. 
Griffiths, P.D. (2010) Transmission of swine influenza through organ transplantation. Reviews in 
medical virology, 20, 65–67. 
Halter, J., Kodera, Y., Ispizua, A.U., Greinix, H.T., Schmitz, N., Favre, G., Baldomero, H., 
Niederwieser, D., Apperley, J.F., Gratwohl, A.for the European Group for Blood and Marrow 
Transplantation (EBMT) activity survey office (2009) Severe events in donors after 
allogeneic hematopoietic stem cell donation. Haematologica, 94, 94–101. 
Halter, J.P., van Walraven, S.M., Worel, N., Bengtsson, M., Hägglund, H., Nicoloso-de Faveri, 
G., Shaw, B.E., Schmidt, A.H., Fechter, M., Madrigal, A., Szer, J., Aljurf, M.D., Weisdorf, D., 
Horowitz, M.M., Greinix, H., Niederwieser, D., Gratwohl, A., Kodera, Y. & Confer, D. (2013) 
Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome 
data: a consensus statement from the Worldwide Network for Blood and Marrow 
Transplantation (WBMT). Bone Marrow Transplantation, 48, 220–225. 
Hart, J., Turner, A.R., Larratt, L., Russell, J., Franko, B., Frantz, C., Paonessa, T., Mansoor, A. 
& Lai, R. (2007) Transmission of a follicular lymphoma by allogeneic bone marrow 
transplantation--evidence to support the existence of lymphoma progenitor cells. British 
Journal of Haematology, 136, 166–167. 
Heegaard, E.D. & Laub Petersen, B. (2000) Parvovirus B19 transmitted by bone marrow. British 
Journal of Haematology, 111, 659–661. 
Horowitz, M.M. & Confer, D.L. (2005) Evaluation of Hematopoietic Stem Cell Donors. ASH 
Education Program Book, 2005, 469–475. 
Hölig, K. (2013) G-CSF in Healthy Allogeneic Stem Cell Donors. Transfusion Medicine and 
Hemotherapy, 40, 225–235. 
Hölig, K., Kramer, M., Kroschinsky, F., Bornhäuser, M., Mengling, T., Schmidt, A.H., Rutt, C. & 
Ehninger, G. (2009) Safety and efficacy of hematopoietic stem cell collection from 
mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 
3928 donors. Blood, 114, 3757–3763. 
Human Tissue Authority, (2014) Code of practice 6-Donation of allogeneic bone marrow and 
peripheral blood stem cells. Available at www.hta.gov.uk 
Ings, S.J., Balsa, C., Leverett, D., Mackinnon, S., Linch, D.C. & Watts, M.J. (2006) Peripheral 
blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating 
factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. British Journal of 
Haematology, 134, 517–525. 
Ison, M.G., Hager, J., Blumberg, E., Burdick, J., Carney, K., Cutler, J., Dimaio, J.M., Hasz, R., 
Kuehnert, M.J., Ortiz-Rios, E., Teperman, L. & Nalesnik, M. (2009)Donor-derived disease 
transmission events in the United States: data reviewed by the OPTN/UNOS Disease 
Transmission Advisory Committee. In pp 1929–1935. Blackwell Publishing Inc. 
Kao, R.-H., Li, C.-C., Shaw, C.-K., Wang, T.-F., Chu, S.-C., Chen, S.-H., Yao, C.-Y., Huang, K.-
P. & Wu, Y.-F. (2009) Correlation between characteristics of unrelated bone marrow donor 





hematology, 89, 227–230. 
Karakukcu, M. & Unal, E. (2015) Stem cell mobilization and collection from pediatric patients 
and healthy children. Transfusion and apheresis science : official journal of the World 
Apheresis Association : official journal of the European Society for Haemapheresis, 1–6. 
Kawano, Y., Takaue, Y., Watanabe, T., Abe, T., Okamoto, Y., Iwai, A., Iwai, T., Watanabe, A., 
Ito, E., Makimoto, A., Nakagawa, R., Watanabe, H., Sato, J., Suenaga, K., Suzuya, H., 
Ohnishi, T., Kanamaru, S., Kaneko, M. & Kuroda, Y. (1999) Efficacy of the mobilization of 
peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors. 
Cancer research, 59, 3321–3324. 
Kim, J.K., Carmody, I.C., Cohen, A.J. & Loss, G.E. (2009) Donor transmission of malignant 
melanoma to a liver graft recipient: case report and literature review. Clinical 
transplantation, 23, 571–574. 
Kodera, Y., Yamamoto, K., Harada, M., Morishima, Y., Dohy, H., Asano, S., Ikeda, Y., 
Nakahata, T., Imamura, M., Kawa, K., Kato, S., Tanimoto, M., Kanda, Y., Tanosaki, R., 
Shiobara, S., Kim, S.W., Nagafuji, K., Hino, M., Miyamura, K., Suzuki, R., et al (2013) 
PBSC collection from family donors in Japan: a prospective survey. Bone Marrow 
Transplantation, 49, 195–200. 
Kollman, C., Howe, C.W., Anasetti, C., Antin, J.H., Davies, S.M., Filipovich, A.H., Hegland, J., 
Kamani, N., Kernan, N.A., King, R., Ratanatharathorn, V., Weisdorf, D. & Confer, D.L. 
(2001) Donor characteristics as risk factors in recipients after transplantation of bone 
marrow from unrelated donors: the effect of donor age. Blood, 98, 2043–2051. 
Koreth, J., Schlenk, R., Kopecky, K.J., Honda, S., Sierra, J., Djulbegovic, B.J., Wadleigh, M., 
DeAngelo, D.J., Stone, R.M., Sakamaki, H., Appelbaum, F.R., Döhner, H., Antin, J.H., 
Soiffer, R.J. & Cutler, C. (2009) Allogeneic stem cell transplantation for acute myeloid 
leukemia in first complete remission: systematic review and meta-analysis of prospective 
clinical trials. JAMA, 301, 2349–2361. 
Krance, R.A., Spruce, W.E., Forman, S.J., Rosen, R.B., Hecht, T., Hammond, W.P. & Blume, 
K.G. (1982) Human cyclic neutropenia transferred by allogeneic bone marrow grafting. 
Blood, 60, 1263–1266. 
Kusne, S. & Smilack, J. (2005) Transmission of rabies virus from an organ donor to four 
transplant recipients. Liver transplantation : official publication of the American Association 
for the Study of Liver Diseases and the International Liver Transplantation Society, 11, 
1295–1297. 
la Rubia, De, J., Arbona, C., Del Cañizo, C., Arrieta, R., De Arriba, F., Pascual, M.J., Sanjuan, 
I., Díaz, M.A., Brunet, S., Alegre, A., Insunza, A., Espigado, I., Zamora, C., la Serna, De, J., 
Serrano, D., Bargay, J., Petit, J., Martínez, D., Verdeguer, A., Ribera, J.M., et al (2002) 
Second mobilization and collection of peripheral blood progenitor cells in healthy donors is 
associated with lower CD34(+) cell yields. Journal of hematotherapy & stem cell research, 
11, 705–709. 
la Rubia, de, J., de Arriba, F., Arbona, C., Pascual, M.J., Zamora, C., Insunza, A., Martinez, D., 
Paniagua, C., Diaz, M.A. & Sanz, M.A. (2008) Follow-up of healthy donors receiving 
granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and 





la Rubia, de, J., Diaz, M.A., Verdeguer, A., Pascual, M.J., Arbona, C., Arrieta, R., Brunet, S., 
Bargay, J., Martínez, C., Espigado, I., Serrano, D., Alegre, A., de Arriba, F., La Serna, de, 
J., Zamora, C., Benlloch, L. & Sanz, M.A. (2001) Donor age-related differences in PBPC 
mobilization with rHuG-CSF. Transfusion, 41, 201–205. 
Labott, S. & Pfammatter, A. (2014) The influence of the donor-recipient relationship on related 
donor reactions to stem cell donation. Nature Publishing Group, 49, 831–835. 
Lampeter, E.F., McCann, S.R. & Kolb, H. (1998) Transfer of diabetes type 1 by bone-marrow 
transplantation. Lancet (London, England), 351, 568–569. 
Lee, J., Billen, A., Lown, R.N., Potter, M.N., Craddock, C.F., de Lavallade, H., Shaw, B.E. & 
Sharpe, C.C. (2015) Exacerbation of IgA nephropathy following G-CSF administration for 
PBSC collection: suggestions for better donor screening. Bone Marrow Transplantation, In 
press. 
Lee, S.J., Klein, J., Haagenson, M., Baxter-Lowe, L.A., Confer, D.L., Eapen, M., Fernandez-
Vina, M., Flomenberg, N., Horowitz, M., Hurley, C.K., Noreen, H., Oudshoorn, M., 
Petersdorf, E., Setterholm, M., Spellman, S., Weisdorf, D., Williams, T.M. & Anasetti, C. 
(2007) High-resolution donor-recipient HLA matching contributes to the success of 
unrelated donor marrow transplantation. Blood, 110, 4576–4583. 
Lefrère, F., Besson, C., Datry, A., Chaibi, P., Leblond, V., Binet, J.L. & Sutton, L. (1996) 
Transmission of Plasmodium falciparum by allogeneic bone marrow transplantation. Bone 
Marrow Transplantation, 18, 473–474. 
Li, X., Li, J., Wang, L., Niu, X., Hou, R., Liu, R., Hao, Z., Wang, C., Yin, G. & Zhang, K. (2015) 
Transmission of psoriasis by allogeneic bone marrow transplantation and blood transfusion. 
Blood cancer journal, 5, e288. 
Lipshutz, G.S., Baxter-Lowe, L.A., Nguyen, T., Jones, K.D., Ascher, N.L. & Feng, S. (2003) 
Death from donor-transmitted malignancy despite emergency liver retransplantation. Liver 
transplantation : official publication of the American Association for the Study of Liver 
Diseases and the International Liver Transplantation Society, 9, 1102–1107. 
Lipshutz, G.S., Mihara, N., Wong, R., Wallace, W.D., Allen-Auerbach, M., Dorigo, O., Rao, P.N., 
Pham, P.-C.T. & Pham, P.-T.T. (2009) Death from metastatic donor-derived ovarian cancer 
in a male kidney transplant recipient. American Journal of Transplantation, 9, 428–432. 
Ljungman, P. (2014) The role of cytomegalovirus serostatus on outcome of hematopoietic stem 
cell transplantation. Current opinion in hematology, 21, 466–469. 
Ljungman, P., Brand, R., Hoek, J., la Camara, de, R., Cordonnier, C., Einsele, H., Styczynski, 
J., Ward, K.N., Cesaro, S.Infectious Diseases Working Party of the European Group for 
Blood and Marrow Transplantation (2014) Donor cytomegalovirus status influences the 
outcome of allogeneic stem cell transplant: a study by the European group for blood and 
marrow transplantation. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America, 59, 473–481. 
Ljungman, P., Lawler, M., Asjö, B., Bogdanovic, G., Karlsson, K., Malm, C., McCann, S.R., 
Ringdén, O. & Gahrton, G. (1994) Infection of donor lymphocytes with human T 
lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for 





Loh, E., Couch, F.J., Hendricksen, C., Farid, L., Kelly, P.F., Acker, M.A., Tomaszewski, J.E., 
Malkowicz, S.B. & Weber, B.L. (1997) Development of donor-derived prostate cancer in a 
recipient following orthotopic heart transplantation. JAMA, 277, 133–137. 
Lown, R.N., Philippe, J., Navarro, W., van Walraven, S.M., Philips-Johnson, L., Fechter, M., 
Pawson, R., Bengtsson, M., Beksac, M., Field, S., Yang, H. & Shaw, B.E. (2014) Unrelated 
adult stem cell donor medical suitability: recommendations from the World Marrow Donor 
Association Clinical Working Group Committee. Bone Marrow Transplantation, 49, 880–
886. 
Lown, R.N., Tulpule, S., Russell, N.H., Craddock, C.F., Roest, R., Madrigal, J.A. & Shaw, B.E. 
(2013) Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell 
donors are associated with bone marrow harvest. Haematologica, 98, 1956–1963. 
Lysák, D., Kořístek, Z., Gašová, Z., Skoumalová, I. & Jindra, P. (2010) Efficacy and safety of 
peripheral blood stem cell collection in elderly donors; does age interfere? Journal of 
Clinical Apheresis, 26, 9–16. 
MacKie, R.M., Reid, R. & Junor, B. (2003) Fatal melanoma transferred in a donated kidney 16 
years after melanoma surgery. The New England journal of medicine, 348, 567–568. 
MacLeod, K.D., Whitsett, S.F., Mash, E.J. & Pelletier, W. (2003) Pediatric Sibling Donors of 
Successful and Unsuccessful Hematopoietic Stem Cell Transplants (HSCT): A Qualitative 
Study of Their Psychosocial Experience. Journal of Pediatric Psychology, 28, 223–230. 
Martino, M., Callea, I., Condemi, A., Dattola, A., Irrera, G., Marcuccio, D., Messina, G., Pontari, 
A., Pucci, G., Console, G. & Lacopino, P. (2006) Predictive factors that affect the 
mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte 
colony-stimulating factor (G-CSF). Journal of Clinical Apheresis, 21, 169–175. 
Martino, M., Console, G., Dattola, A., Callea, I., Messina, G., Moscato, T., Massara, E., Irrera, 
G., Fedele, R., Gervasi, A., Bresolin, G. & Iacopino, P. (2009) Short and long-term safety of 
lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a 
single centre experience. Bone Marrow Transplantation, 44, 163–168. 
Martino, M., Console, G., Irrera, G., Callea, I., Condemi, A., Dattola, A., Messina, G., Pontari, A., 
Pucci, G., Furlò, G., Bresolin, G., Iacopino, P. & Morabito, F. (2005) Harvesting peripheral 
blood progenitor cells from healthy donors: retrospective comparison of filgrastim and 
lenograstim. Journal of Clinical Apheresis, 20, 129–136. 
Martino, M., Moscato, T., Barillà, S., Dattola, A., Pontari, A., Fedele, R., Furlò, G., Marzia Stilo, 
C., Alberto Gallo, G. & Tripepi, G. (2015) Mobilization of hematopoietic progenitor stem 
cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily 
dosing: a single-center prospective study with historical control. Transfusion, 55, 2032–
2038. 
Massoud, M.R., William, B.M., Harrill, K., Cooper, B.W., de Lima, M. & Schmaier, A.H. (2014) 
Transmission of lupus anticoagulant by allogeneic stem cell transplantation. Revista 
brasileira de hematologia e hemoterapia, 36, 287–289. 
McLeod, B.C., Price, T.H., Owen, H., Ciavarella, D., Sniecinski, I., Randels, M.J. & Smith, J.W. 
(1998) Frequency of immediate adverse effects associated with apheresis donation. 





Mellouli, F., Ksouri, H., Torjmen, L., Abdelkefi, A., Ladeb, S., Ben Othman, T., Ben Hassen, A. & 
Béjaoui, M. (2009) Transmission of type 1 diabetes by bone marrow transplantation: a case 
report. Pediatric transplantation, 13, 119–122. 
Mijovic, A., Britten, C., Regan, F. & Harrison, J. (2006) Preoperative autologous blood donation 
for bone marrow harvests: Are we wasting donors' time and blood? Transfusion Medicine, 
16, 57–62. 
Miller, J.P., Perry, E.H., Price, T.H., Bolan, C.D., Jr., Karanes, C., Boyd, T.M., Chitphakdithai, P. 
& King, R.J. (2008) Recovery and safety profiles of marrow and PBSC donors: experience 
of the National Marrow Donor Program. Biology of Blood and Marrow Transplantation, 14, 
29–36. 
Minchinton, R.M., Waters, A.H., Kendra, J. & Barrett, A.J. (1982) Autoimmune 
thrombocytopenia acquired from an allogeneic bone-marrow graft. Lancet (London, 
England), 2, 627–629. 
Miyoshi, I., Murata, N., Machida, H. & Taguchi, H. (1995) Transmission of human T-
lymphotrophic virus type 1 by bone marrow transplantation. British Journal of Haematology, 
89, 690–691. 
Munzenberger, N. & Fortanier, C. (1999) Psychosocial aspects of haematopoietic stem cell 
donation for allogeneic transplantation: How family donors cope with this experience. 
Psycho‐Oncology, 8, 55-63  …. 
Nair, B.T., Bhat, S.H., Narayan, U.V., Sukumar, S., Saheed, M., Kurien, G. & Sudhindran, S. 
(2007) Donate organs not malignancies: postoperative small cell lung carcinoma in a 
marginal living kidney donor. Transplantation proceedings, 39, 3477–3480. 
Naparstek, E., Block, C.S. & Slavin, S. (1982) Transmission of brucellosis by bone marrow 
transplantation. Lancet, 1, 574–575. 
Nasilowska-Adamska, B., Perkowska-Ptasinska, A., Tomaszewska, A., Serwacka, A. & 
Marianska, B. (2010) Acute glomerulonephritis in a donor as a side effect of allogeneic 
peripheral blood stem cell mobilization with granulocyte colony-stimulating factor. 
International journal of hematology, 92, 765–768. 
Nicolini, F.E., Wattel, E., Michallet, A.-S., Bourgeot, J.-P., Tremisi, J.-P., Hequet, O. & Michallet, 
M. (2004) Long-term persistent lymphopenia in hematopoietic stem cell donors after 
donation for donor lymphocyte infusion. Experimental Hematology, 32, 1033–1039. 
Niederwieser, D., Gentilini, C., Hegenbart, U., Lange, T., Moosmann, P., Pönisch, W., Al-Ali, H., 
Raida, M., Ljungman, P., Tyndall, A., Urbano-Ispizua, A., Lazarus, H.M. & Gratwohl, A. 
(2004) Transmission of donor illness by stem cell transplantation: should screening be 
different in older donors? Bone Marrow Transplantation, 34, 657–665. 
Niederwieser, D.W., Appelbaum, F.R., Gastl, G., Gersdorf, E., Meister, B., Geissler, D., 
Tratkiewicz, J.A., Thaler, J. & Huber, C. (1990) Inadvertent transmission of a donor's acute 
myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. The New 
England journal of medicine, 322, 1794–1796. 
Nishimori, M., Yamada, Y., Hoshi, K., Akiyama, Y., Hoshi, Y., Morishima, Y., Tsuchida, M., 
Fukuhara, S. & Kodera, Y. (2002) Health-related quality of life of unrelated bone marrow 





O'Donnell, J., Goldman, J.M., Wagner, K., Ehinger, G., Martin, N., Leahy, M., Kariuki, N., Dokal, 
I. & Roberts, I. (1998) Donor-derived Plasmodium vivax infection following volunteer 
unrelated bone marrow transplantation. Bone Marrow Transplantation, 21, 313–314. 
O'Donnell, P.V., Pedersen, T.L., Confer, D.L., Rizzo, J.D., Pulsipher, M.A., Stroncek, D., 
Leitman, S., Anderlini, P.on behalf of the Donor Health and Safety Working Committee from 
the Center for International Blood and Marrow Transplant Research (CIBMTR) (2010) 
Practice patterns for evaluation, consent, and care of related donors and recipients at 
hematopoietic cell transplantation centers in the United States. Blood, 115, 5097–5101. 
O'Reilly, R.J., Dupont, B., Pahwa, S., Grimes, E., Smithwick, E.M., Pahwa, R., Schwartz, S., 
Hansen, J.A., Siegal, F.P., Sorell, M., Svejgaard, A., Jersild, C., Thomsen, M., Platz, P., 
L'Esperance, P. & Good, R.A. (1977) Reconstitution in severe combined immunodeficiency 
by transplantation of marrow from an unrelated donor. The New England journal of 
medicine, 297, 1311–1318. 
Ottinger, H.D., Beelen, D.W., Scheulen, B., Schaefer, U.W. & Grosse-Wilde, H. (1996) Improved 
immune reconstitution after allotransplantation of peripheral blood stem cells instead of 
bone marrow. Blood, 88, 2775–2779. 
Packman, W. (2004) Psychosocial Adjustment of Adolescent Siblings of Hematopoietic Stem 
Cell Transplant Patients. Journal of Pediatric Oncology Nursing, 21, 233–248. 
Packman, W., Weber, S., Wallace, J. & Bugescu, N. (2010) Psychological effects of 
hematopoietic SCT on pediatric patients, siblings and parents: a review. Bone Marrow 
Transplantation, 45, 1134–1146. 
Parkkali, T., Juvonen, E., Volin, L., Partanen, J. & Ruutu, T. (2005) Collection of autologous 
blood for bone marrow donation: how useful is it? Bone Marrow Transplantation, 35, 1035–
1039. 
Parkkali, T., Volin, L., Sirén, M.K. & Ruutu, T. (1996) Acute iritis induced by granulocyte colony-
stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor 
cell donor. Bone Marrow Transplantation, 17, 433–434. 
Pasquini, M.C. & Zhu, X.Current uses and outcomes of hematopoietic stem cell transplantation: 
2014 CIBMTR Summary Slides. 
Passweg, J., Baldomero, H., Bregni, M., Cesaro, S., Dreger, P., Duarte, R.F. & Falkenburg, J. 
(2013) Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow 
Transplantation, 1–7. 
Passweg, J.R., Baldomero, H., Peters, C., Gaspar, H.B., Cesaro, S., Dreger, P., Duarte, R.F., 
Falkenburg, J.H.F., Farge-Bancel, D., Gennery, A., Halter, J., Kröger, N., Lanza, F., Marsh, 
J., Mohty, M., Sureda, A., Velardi, A., Madrigal, A.European Society for Blood and Marrow 
Transplantation EBMT (2014) Hematopoietic SCT in Europe: data and trends in 2012 with 
special consideration of pediatric transplantation. Nature Publishing Group, 49, 744–750. 
Pavletic, Z.S., Bishop, M.R., Tarantolo, S.R., Martin-Algarra, S., Bierman, P.J., Vose, J.M., 
Reed, E.C., Gross, T.G., Kollath, J., Nasrati, K., Jackson, J.D., Armitage, J.O. & Kessinger, 
A. (1997) Hematopoietic recovery after allogeneic blood stem-cell transplantation compared 
with bone marrow transplantation in patients with hematologic malignancies. Journal of 






Pentz, R.D., Haight, A.E., Noll, R.B., Barfield, R., Pelletier, W., Davies, S., Alderfer, M.A. & 
Hinds, P.S. (2008) The Ethical Justification for Minor Sibling Bone Marrow Donation: A 
Case Study. The Oncologist, 13, 148–151. 
Petropoulou, A.D., Robin, M., Socié, G. & Galicier, L. (2010) Transmission of familial 
Mediterranean fever mutation after bone marrow transplantation and successful treatment 
with anakinra. Transplantation, 90, 102–103. 
Pillay, B., Lee, S.J., Katona, L., De Bono, S., Warren, N., Fletcher, J. & Burney, S. (2012) The 
psychosocial impact of haematopoietic SCT on sibling donors. Bone Marrow 
Transplantation, 47, 1361–1365. 
Platzbecker, U., Binder, M., Schmid, C., Rutt, C., Ehninger, G. & Bornhäuser, M. (2008) Second 
donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft 
failure after allogeneic transplantation. Haematologica, 93, 1276–1278. 
Pruett, T.L., Tibell, A., Alabdulkareem, A., Bhandari, M., Cronin, D.C., Dew, M.A., Dib-Kuri, A., 
Gutmann, T., Matas, A., McMurdo, L., Rahmel, A., Rizvi, S.A.H., Wright, L. & Delmonico, 
F.L. (2006) The Ethics Statement of the Vancouver Forum on the Live Lung, Liver, 
Pancreas, and Intestine Donor. Transplantation, 81, 1386–1387. 
Pulsipher, M.A., Chitphakdithai, P. & Logan, B.R. (2010) Peripheral blood stem cell (PBSC) 
donors experience higher levels of pain and toxicities early on, while bone marrow (BM) 
donors experience slower recovery and  Blood (ASH Annual Meeting Abstracts 2010).  
Pulsipher, M.A., Chitphakdithai, P., Logan, B.R., Navarro, W.H., Levine, J.E., Miller, J.P., Shaw, 
B.E., O'Donnell, P.V., Majhail, N.S. & Confer, D.L. (2014) Lower risk for serious adverse 
events and no increased risk for cancer after PBSC vs BM donation. Blood, 123, 3655–
3663. 
Pulsipher, M.A., Chitphakdithai, P., Logan, B.R., Shaw, B.E., Wingard, J.R., Lazarus, H.M., 
Waller, E.K., Seftel, M., Stroncek, D.F., Lopez, A.M., Maharaj, D., Hematti, P., O'Donnell, 
P.V., Loren, A.W., Leitman, S.F., Anderlini, P., Goldstein, S.C., Levine, J.E., Navarro, W.H., 
Miller, J.P., et al (2013) Acute toxicities of unrelated bone marrow versus peripheral blood 
stem cell donation: results of a prospective trial from the National Marrow Donor Program. 
Blood, 121, 197–206. 
Pulsipher, M.A., Chitphakdithai, P., Miller, J.P., Logan, B.R., King, R.J., Rizzo, J.D., Leitman, 
S.F., Anderlini, P., Haagenson, M.D., Kurian, S., Klein, J.P., Horowitz, M.M. & Confer, D.L. 
(2009) Adverse events among 2408 unrelated donors of peripheral blood stem cells: results 
of a prospective trial from the National Marrow Donor Program. Blood, 113, 3604–3611. 
Pulsipher, M.A., Levine, J.E., Hayashi, R.J., Chan, K.W., Anderson, P., Duerst, R., Osunkwo, I., 
Fisher, V., Horn, B. & Grupp, S.A. (2004) Safety and efficacy of allogeneic PBSC collection 
in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium 
Experience (PBMTC) 1996–2003. Bone Marrow Transplantation, 35, 361–367. 
Pulsipher, M.A., Nagler, A., Iannone, R. & Nelson, R.M. (2006) Weighing the risks of G-CSF 
administration, leukopheresis, and standard marrow harvest: Ethical and safety 
considerations for normal pediatric hematopoietic cell donors. Pediatric Blood & Cancer, 
46, 422–433. 
Remberger, M., Ringdén, O. & Mattsson, J. (2015) Bone marrow aspiration technique has 






Richa, E., Papari, M., Allen, J., Martinez, G., Wickrema, A., Anastasi, J., Van Besien, K. & Artz, 
A. (2009) Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-
Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization. Biology of Blood and 
Marrow Transplantation, 15, 1394–1399. 
Rinaldi, C., Savignano, C., Pasca, S., Sperotto, A., Patriarca, F., Isola, M., Fanin, R. & De 
Angelis, V. (2012) Efficacy and safety of peripheral blood stem cell mobilization and 
collection: a single-center experience in 190 allogeneic donors. Transfusion, 52, 2387–
2394. 
Ringdén, O., Labopin, M., Solders, M., Beelen, D., Arnold, R., Ehninger, G., Milpied, N., 
Niederwieser, D., Hamladji, R.-M., Kyrcz-Krzemien, S., Ganser, A., Socié, G., Stelljes, M., 
Volin, L., Craddock, C., Mohty, M.Acute Leukaemia Working Party of the European Group 
for Blood and Marrow Transplantation (2014) Who is the best hematopoietic stem-cell 
donor for a male patient with acute leukemia? … transplantation, 98, 569–577. 
Ritchie, D.S., Sainani, A., D'Souza, A. & Grigg, A.P. (2005) Passive donor-to-recipient transfer 
of antiphospholipid syndrome following allogeneic stem-cell transplantation. American 
journal of hematology, 79, 299–302. 
Roseman, D.A., Kabbani, D., Kwah, J., Bird, D., Ingalls, R., Gautam, A., Nuhn, M. & Francis, 
J.M. (2013) Strongyloides stercoralis transmission by kidney transplantation in two 
recipients from a common donor. American Journal of Transplantation, 13, 2483–2486. 
Saigal, S., Choudhary, N.S., Saraf, N., Kataria, S., Mohanka, R. & Soin, A.S. (2013) 
Transmission of dengue virus from a donor to a recipient after living donor liver 
transplantation. Liver transplantation : official publication of the American Association for 
the Study of Liver Diseases and the International Liver Transplantation Society, 19, 1413–
1414. 
Shaw, B.E. (2008) The clinical implications of HLA mismatches in unrelated donor 
haematopoietic cell transplantation. International journal of immunogenetics, 35, 367–374. 
Shaw, B.E., Confer, D.L., Hwang, W. & Pulsipher, M.A. (2015) A review of the genetic and long-
term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the 
development of haematological malignancies. 50, 334–340. 
Shaw, B.E., Confer, D.L., Hwang, W.Y., Pamphilon, D.H. & Pulsipher, M.A. (2011) Concerns 
about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of 
stem cells in normal donors: position of the World Marrow Donor Association. 
Haematologica, 96, 942–947. 
Shimizu, N., Asai, T., Hashimoto, S., Narita, M., Kobayashi, M., Ito, M., Onoda, M., Yokota, A., 
Cho, R., Nakaseko, C., Nishimura, M. & Saito, Y. (2002) Mobilization factors of peripheral 
blood stem cells in healthy donors. Therapeutic apheresis : official journal of the 
International Society for Apheresis and the Japanese Society for Apheresis, 6, 413–418. 
Shuhart, M.C., Myerson, D., Spurgeon, C.L., Bevan, C.A., Sayers, M.H. & McDonald, G.B. 
(1996) Hepatitis C virus (HCV) infection in bone marrow transplant patients after 






Siddiq, S., Pamphilon, D., Brunskill, S., Dorée, C., Hyde, C. & Stanworth, S. (2009) Bone 
marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation 
in healthy donors. The Cochrane database of systematic reviews, CD006406. 
Smith, C.I., Aarli, J.A., Biberfeld, P., Bolme, P., Christensson, B., Gahrton, G., Hammarström, 
L., Lefvert, A.K., Lönnqvist, B. & Matell, G. (1983) Myasthenia gravis after bone-marrow 
transplantation. Evidence for a donor origin. The New England journal of medicine, 309, 
1565–1568. 
Spitzer, T.R., Areman, E.M., Cirenza, E., Yu, M., Dickerson, S., Kotula, P.L., Sacher, R.A. & 
Cottler-Fox, M. (1994) The impact of harvest center on quality of marrows collected from 
unrelated donors. Journal of hematotherapy, 3, 65–70. 
Stanley, E., Ratard, R., Staples, J.E. & Royce, R. (2009) West Nile virus transmission via organ 
transplantation and blood transfusion-Louisiana, 2008. Morbidity and Mortality Weekly 
Report, 58. 1263-1267. 
Storek, J., Vliagoftis, H., Grizel, A., Lyon, A.W., Daly, A., Khan, F., Bowen, T., Game, M., 
Larratt, L., Turner, R. & Huebsch, L. (2011) Allergy transfer with hematopoietic cell 
transplantation from an unrelated donor. Bone Marrow Transplantation, 46, 605–606. 
Strenger, V., Caselli, E., Lautenschlager, I., Schwinger, W., Aberle, S.W., Loginov, R., Gentili, 
V., Nacheva, E., DiLuca, D. & Urban, C. (2014) Detection of HHV-6-specific mRNA and 
antigens in PBMCs of individuals with chromosomally integrated HHV-6 (ciHHV-6). Clinical 
microbiology and infection : the official publication of the European Society of Clinical 
Microbiology and Infectious Diseases, 20, 1027–1032. 
Styczynski, J., Balduzzi, A., Gil, L., Labopin, M., Hamladji, R.M., Marktel, S., Yesilipek, M.A., 
Fagioli, F., Ehlert, K., Matulova, M., Dalle, J.H., Wachowiak, J., Miano, M., Messina, C., 
Diaz, M.A., Vermylen, C., Eyrich, M., Badell, I., Dreger, P., Gozdzik, J., et al (2012) Risk of 
complications during hematopoietic stem cell collection in pediatric sibling donors: a 
prospective European Group for Blood and Marrow Transplantation Pediatric Diseases 
Working Party study. Blood, 119, 2935–2942. 
Switzer, G.E., Dew, M.A., Magistro, C.A., Goycoolea, J.M., Twillman, R.K., Alter, C. & Simmons, 
R.G. (1998) The effects of bereavement on adult sibling bone marrow donors' psychological 
well-being and reactions to donation. Bone Marrow Transplantation, 21, 181–188. 
Teipel, R., Schetelig, J., Kramer, M., Schmidt, H., Schmidt, A.H., Thiede, C., Oelschlägel, U., 
Kroschinsky, F., Bornhäuser, M., Ehninger, G. & Hölig, K. (2015) Prediction of 
hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in 
healthy unrelated donors. Transfusion, n/a–n/a. 
The Consensus Statement of the Amsterdam Forum on the Care of the Live Kidney Donor 
(2004) The Consensus Statement of the Amsterdam Forum on the Care of the Live Kidney 
Donor. … transplantation, 78, 491–492. 
Thomas, E.D., Lochte, H.L. & Ferrebee, J.W. (1959) Irradiation of the entire body and marrow 
transplantation: some observations and comments. Blood, 14, 1–23. 
Thomas, E.D., Lochte, H.L., Jr., Lu, W.C. & Ferrebee, J.W. (1957) Intravenous Infusion of Bone 
Marrow in Patients Receiving Radiation and Chemotherapy. The New England journal of 





Thomson, J.A., Wilson, R.M. & Franklin, I.M. (1995) Transmission of thyrotoxicosis of 
autoimmune type by sibling allogeneic bone marrow transplant. European journal of 
endocrinology / European Federation of Endocrine Societies, 133, 564–566. 
van Walraven, S.M., Ball, L.M., Koopman, H.M., Switzer, G.E., Ropes-de Jong, C.M.H., de 
Jong, A., Bredius, R.G.M. & Egeler, R.M. (2010a) Managing a dual role-experiences and 
coping strategies of parents donating haploidentical G-CSF mobilized peripheral blood 
stem cells to their children. Psycho-Oncology, 21, 168–175. 
van Walraven, S.M., Faveri, G.N.-D., Axdorph-Nygell, U.A.I., Douglas, K.W., Jones, D.A., Lee, 
S.J., Pulsipher, M., Ritchie, L., Halter, J. & Shaw, B.E. (2010b) Family donor care 
management: principles and recommendations. Bone Marrow Transplantation, 45, 1269–
1273. 
van Walraven, S.M., Straathof, L.M., Switzer, G.E., Lankester, A., Korthof, E.T., Brand, A. & 
Ball, L.M. (2013) Immediate and long-term somatic effects, and health-related quality of life 
of BM donation during early childhood. A single-center report in 210 pediatric donors. Bone 
Marrow Transplantation, 48, 40–45. 
Vasu, S., Leitman, S.F., Tisdale, J.F., Hsieh, M.M., Childs, R.W., Barrett, A.J., Fowler, D.H., 
Bishop, M.R., Kang, E.M., Malech, H.L., Dunbar, C.E., Khuu, H.M., Wesley, R., Yau, Y.Y. & 
Bolan, C.D. (2008) Donor demographic and laboratory predictors of allogeneic peripheral 
blood stem cell mobilization in an ethnically diverse population. Blood, 112, 2092–2100. 
Volker (2011) Transmission of chromosomally integrated HHV-6 by bone marrow 
transplantation. Pediatric Blood Cancer, 56 171. 
VWM Chuang, Wong T.Y., Leung, Y.H. Edmund, S.K., Law, Y.L., Owen. T/Y., Chan, K.M., Iris, 
H.L., Que, T.L. Yung, W.H., Lui, S.H. (2008) Review of dengue fever cases in Hong Kong 
during 1998 to 2005. Hong Kong Medical Journal, 4, 1–8. 
Wang, Q., Yuan, L., Li, H.-H., Zhao, Y., Huang, W.-R., Bo, J., Wang, S.-H., Zhu, H.-Y., Dou, L.-
P., Wang, Q.-S., Yu, L. & Jing, Y. (2013) [Analysis of influence factors on G-CSF-mobilized 
hematopoietic stem cells of 191 healthy donors in a mono center]. Journal of experimental 
hematology / Chinese Association of Pathophysiology, 21, 169–172. 
Wang, T.-F., Chu, S.-C., Chen, S.-H., Huang, K.-P., Su, Y.-C., Li, D.-K., Shyr, M.-H., Chang, C.-
Y., Tsai, H.-H. & Kao, R.-H. (2011) The effect of different harvest strategies on the 
nucleated cell yields of bone marrow collection. Biology of blood and marrow 
transplantation, 17, 351–355. 
Watanabe, T., Takaue, Y., Kawano, Y., Koike, K., Kikuta, A., Imaizumi, M., Watanabe, A., 
Eguchi, H., Ohta, S., Horikoshi, Y., Iwai, A., Makimoto, A., Kuroda, Y.Peripheral Blood 
Stem Cell Transplantation Study Group of Japan (2002) HLA-identical sibling peripheral 
blood stem cell transplantation in children and adolescents. Biology of Blood and Marrow 
Transplantation, 8, 26–31. 
WHO (2010) WHO guiding principles on human cell, tissue and organ transplantation. Available 
at http://www.who.int/transplantation/Guiding_PrinciplesTransplantation_WHA63.22en.pdf. 
Wiener, L.S., Steffen-Smith, E., Battles, H.B., Wayne, A., Love, C.P. & Fry, T. (2008) Sibling 
stem cell donor experiences at a single institution. Psycho‐Oncology, 17, 304–307. 





Bom, J.G. & Brand, A. (2013) Clinical outcomes after peripheral blood stem cell donation by 
related donors: a Dutch single‐center cohort study. Transfusion, 53, 96–103. 
Winston, D.J., Vikram, H.R., Rabe, I.B., Dhillon, G., Mulligan, D., Hong, J.C., Busuttil, R.W., 
Nowicki, M.J., Mone, T., Civen, R., Tecle, S.A., Trivedi, K.K., Hocevar, S.N.West Nile Virus 
Transplant-Associated Transmission Investigation Team (2014) Donor-derived West Nile 
virus infection in solid organ transplant recipients: report of four additional cases and review 
of clinical, diagnostic, and therapeutic features. … transplantation, 97, 881–889. 
WMDA. International Standards for Unrelated Hematopoietic Progenitor Cell Donor Registries 
standards W. International Standards for Unrelated Hematopoietic Progenitor Cell Donor 
Registries. Available at:  
http://www.worldmarrow.org/fileadmin/Committees/STDC/20140101-STDC-
WMDA_Standards.pdf 
Wolcott, D.L., Wellisch, D.K., Fawzy, F.I. & Landsverk, J. (1986) Psychological adjustment of 




















APPENDIX	  1.	  SUPPLEMENTARY	  MATERIALS	  
Figure S1. Survey of related donor care in UK transplant centres 
 















































































Figure S2. Survey of related donor care in US and EBMT transplant centres 
 









































Figure S3. Proposal for pilot study of related donor management by Anthony Nolan and The 
London Clinic 
Proposal	  for	  pilot	  of	  related	  donor	  management	  by	  Anthony	  Nolan	  	  	  
Background	  International	  standards	  ensure	  uniformity	  in	  assessment	  and	  care	  of	  volunteer	  unrelated	  donors	  (UDs)	  and	  guarantee	  the	  quality	  of	  stem	  cells	  for	  UD	  transplant	  recipients.	  In	  contrast,	  the	  care	  of	  related	  donors	  is	  more	  varied	  and	  less	  well	  regulated.	  Several	  parties	  (Clare1,	  O’Donnell2,	  van	  Walraven3)	  have	  highlighted	  the	  discrepancies	  between	  unrelated	  and	  related	  donor	  care,	  particularly	  with	  respect	  to	  the	  heterogeneity	  of	  medical	  eligibility	  criteria	  used,	  potential	  conflicts	  of	  interest	  when	  the	  same	  team	  is	  involved	  in	  the	  care	  of	  the	  donor	  and	  recipient,	  and	  the	  lack	  of	  related	  donor	  follow	  up.	  	  As	  a	  result,	  JACIE	  standards4	  now	  stipulate	  that	  “allogeneic	  donor	  suitability	  should	  be	  evaluated	  by	  a	  physician	  who	  is	  not	  the	  physician	  of	  the	  recipient”	  and,	  regulations	  are	  likely	  to	  become	  more	  specific	  in	  the	  future	  with	  respect	  to	  the	  independent	  evaluation	  of	  donors.	  	  	  Recent	  studies	  have	  shown	  an	  increased	  incidence	  of	  adverse	  reactions	  in	  both	  a)	  related	  donors	  compared	  to	  unrelated	  donors5,	  and	  b)	  related	  donors	  who	  do	  not	  meet	  UD	  eligibility	  criteria	  compared	  to	  those	  who	  do6,	  7.	  	  Consequently,	  it	  has	  been	  suggested	  that	  practice	  of	  caring	  for	  related	  donors	  should	  be	  in	  line	  with	  that	  of	  unrelated	  donors,	  and	  that	  ideally	  suitability	  criteria	  and	  evaluation	  of	  family	  donors	  should	  be	  standardised.	  At	  present,	  data	  regarding	  the	  risks	  of	  donation	  in	  older	  donors	  (>65	  years)	  are	  lacking,	  and	  it	  is	  unclear	  whether	  older	  donor	  who	  pass	  a	  thorough	  medical	  assessment	  are	  more	  likely	  to	  experience	  adverse	  events	  related	  to	  donation	  compared	  to	  younger	  donors.	  	  There	  are	  logistical	  obstacles	  to	  implementing	  independent	  and	  standardised	  evaluation	  of	  related	  donor	  in	  the	  setting	  of	  transplant	  centres,	  where	  related	  donors	  have	  traditionally	  been	  assessed	  and	  managed	  by	  the	  same	  team	  of	  transplant	  physicians	  involved	  in	  the	  care	  of	  the	  HSCT	  recipient.	  This	  has	  raised	  the	  question	  of	  whether	  there	  is	  a	  role	  for	  HPC	  donor	  registries	  in	  assuming	  responsibility	  for	  part,	  or	  all,	  of	  the	  RD	  care	  pathway.	  When	  this	  issue	  was	  discussed	  at	  a	  joint	  WMDA-­‐EBMT	  debate	  in	  April	  2013,	  there	  was	  unanimous	  enthusiasm	  from	  the	  transplant	  community	  to	  explore	  alternative	  models	  of	  related	  donor	  care.	  	  	  A	  further	  consideration,	  is	  the	  potential	  for	  a	  large	  increase	  in	  the	  number	  of	  related	  donors	  undergoing	  donation.	  Patient	  outcomes	  following	  haplo-­‐identical	  transplants	  have	  vastly	  improved	  in	  recent	  years,	  and	  some	  countries	  are	  seeing	  a	  significant	  increase	  in	  the	  number	  of	  these	  transplants	  being	  performed.	  Assessment	  of	  stem	  cell	  donors	  is	  a	  very	  time	  consuming	  process	  for	  transplant	  centres,	  and	  an	  increased	  proportion	  of	  related	  donors	  may	  prove	  challenging	  in	  terms	  of	  donor	  capacity	  for	  many	  centres.	  	  
Pilot	  study	  proposal	  To	  begin	  to	  develop	  an	  alternative	  pathway	  of	  related	  donor	  care,	  we	  hope	  to	  pilot	  a	  process	  where	  the	  assessment	  and	  donation	  and	  follow-­‐up	  of	  RDs	  is	  provided	  by	  a	  separate	  organization.	  	  	  	  Given	  extensive	  joint	  experience	  The	  London	  Clinic/AN	  in	  facilitating	  HPC	  donations	  and	  strong	  existing	  links	  between	  AN	  and	  transplant	  centres,	  we	  propose	  to	  test	  the	  logistics	  of	  an	  alternative	  model	  of	  related	  donor	  care,	  where	  related	  donors	  are	  seen	  by	  an	  




independent	  physician	  and	  receive	  care	  equivalent	  to	  that	  of	  an	  unrelated	  donor,	  at	  The	  London	  Clinic.	  	  	  
Aims	  1.	  To	  explore	  whether	  an	  alternative	  model	  of	  donor	  care	  where	  donors	  are	  evaluated	  and	  donate	  is	  acceptable	  to:	  	  a) Transplant	  physicians	  b) Related	  stem	  cell	  donors	  	  2.	  To	  prospectively	  investigate	  the	  proportion	  of	  family	  donors	  who	  would	  fail	  donor	  medical	  if	  the	  suitability	  criteria	  for	  UDs	  were	  used,	  and	  determine	  where	  these	  criteria	  could	  be	  relaxed	  (eg	  for	  upper	  age	  limit)	  providing	  a	  thorough	  medical	  assessment	  is	  performed.	  	  	  	  
Logistics	  HPC	  transplant	  directors	  at	  the	  largest	  London-­‐based	  centres	  would	  be	  contacted	  and	  asked	  to	  participate	  by	  referring	  their	  related	  donors	  for	  assessment	  and	  donation	  at	  TLC.	  We	  would	  hope	  to	  facilitate	  a	  total	  of	  20	  related	  donations	  over	  a	  1	  year	  period.	  	  Related	  donors	  would	  be	  seen	  and	  assessed	  at	  The	  London	  Clinic	  in	  the	  same	  manner	  as	  unrelated	  volunteer	  stem	  cell	  donors.	  	  	  Following	  the	  donor	  medical	  assessment,	  all	  investigations,	  the	  donation	  process,	  and	  post-­‐donation	  follow	  up	  would	  	  be	  performed	  according	  to	  the	  same	  procedures	  used	  for	  unrelated	  donors.	  One	  month	  after	  donation,	  a	  short	  evaluation	  form	  about	  the	  donor	  experience	  would	  be	  sent.	  	  	  Service	  level	  agreements	  already	  exist	  between	  AN	  and	  participating	  transplant	  centres,	  and	  between	  AN	  and	  The	  London	  Clinic,	  which	  would	  be	  adapted	  to	  include	  related	  donors.	  	  	  
Costs	  The	  London	  Clinic	  would	  offer	  equivalent	  fees	  for	  donor	  investigations	  and	  the	  donation	  process	  to	  those	  currently	  offered	  to	  AN	  for	  unrelated	  donors.	  	  AN	  is	  providing	  funding	  for	  this	  project	  for	  the	  duration	  of	  the	  pilot	  study.	  	  
	  	  
Expected	  outcomes	  of	  pilot	  study	  1. The	  data	  collected	  in	  this	  pilot	  study	  would	  form	  the	  basis	  for	  a	  publication	  discussing	  alternative	  pathways	  of	  related	  donor	  care.	  	  2. Following	  a	  successful	  pilot	  study	  we	  hope	  to	  be	  able	  to	  offer	  this	  pathway	  of	  related	  donor	  care	  to	  transplant	  centres	  nationwide.	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Figure S4. Proposal for assessment of related donors at King’s College Hospital  
Proposal	  for	  assessment	  of	  related	  donors	  at	  King’s	  College	  
Hospital	  
Background	  As	  part	  of	  my	  MD	  in	  the	  assessment	  and	  care	  of	  related	  HPC	  donors	  at	  Anthony	  Nolan,	  I	  am	  in	  the	  process	  of	  setting	  up	  pilot	  studies	  to	  trial	  alternative	  pathways	  of	  related	  donor	  care.	  	  	  	  	  The	  background	  to	  this	  project	  is	  that	  several	  studies	  have	  drawn	  attention	  to	  discrepancies	  between	  the	  aspects	  of	  related	  and	  unrelated	  donor	  care,	  particularly	  with	  respect	  to	  potential	  conflicts	  of	  interest	  when	  the	  same	  team	  is	  involved	  in	  the	  care	  of	  the	  donor	  and	  recipient,	  and	  the	  lack	  of	  related	  donor	  follow	  up.	  Although	  the	  most	  recent	  JACIE	  standards	  have	  addressed	  these	  issues,	  in	  many	  transplant	  centres	  independent	  donor	  assessment	  and	  donor	  follow-­‐up	  are	  logistically	  difficult	  to	  achieve.	  We	  are	  therefore	  looking	  at	  alternative	  pathways	  that	  could	  both	  enhance	  related	  donor	  care,	  and	  enable	  transplant	  centres	  to	  comply	  with	  JACIE	  standards.	  	  	  
Potential	  pilot	  study	  at	  King’s	  	  The	  proposal	  for	  a	  pilot	  study	  at	  King’s	  would	  be	  for	  an	  independent	  physician	  (me)	  to	  perform	  the	  medical	  assessment	  of	  related	  donors	  onsite	  at	  King’s.	  All	  other	  aspects	  of	  donor	  care	  would	  be	  performed	  at	  King’s	  as	  per	  current	  practice,	  but	  follow-­‐up	  post-­‐donation	  would	  be	  provided	  by	  Anthony	  Nolan.	  	  
Aims	  The	  aims	  of	  this	  pilot	  study	  are	  to	  explore	  an	  alternative	  model	  of	  donor	  care	  and	  determine	  acceptability	  of	  this	  model	  to	  	  a) transplant	  teams	  b) related	  donors	  
Logistics	  (these	  are	  flexible	  and	  subject	  to	  discussion	  with	  
King’s	  team)	  
We	  would	  plan	  to	  conduct	  this	  pilot	  study	  over	  a	  6-­‐9	  month	  period.	  When	  matched	  related	  donors	  were	  identified,	  the	  King’s	  transplant	  coordinators	  would	  contact	  me	  and	  (where	  feasible	  with	  respect	  to	  timing)	  I	  would	  perform	  the	  donor	  medical	  assessment	  at	  King’s.	  All	  other	  aspects	  of	  donor	  work-­‐up	  would	  be	  arranged	  as	  per	  current	  practice	  at	  Kings.	  Following	  donor	  medical	  I	  would	  arrange	  donor	  clearance	  either	  electronically	  or,	  if	  necessary,	  by	  returning	  in	  person.	  We	  propose	  that	  I	  would	  use	  current	  Anthony	  Nolan	  suitability	  criteria	  for	  unrelated	  donors	  with	  exception	  to	  certain	  agreed	  deviations	  eg	  age.	  If	  related	  donors	  do	  not	  meet	  these	  criteria,	  I	  would	  discuss	  individual	  cases	  with	  the	  transplant	  team	  at	  Kings	  to	  reach	  a	  decision	  regarding	  acceptance	  of	  the	  donor.	  




GCSF	  prescription	  and	  administration	  and	  the	  donation	  procedure	  would	  be	  performed	  as	  per	  current	  practice	  at	  Kings,	  and	  the	  King’s	  team	  would	  be	  responsible	  for	  donor	  care	  over	  this	  period.	  	  
Donor	  Follow	  up	  Following	  donation,	  we	  propose	  donors	  would	  be	  followed	  up	  by	  Anthony	  Nolan,	  receiving	  identical	  follow	  up	  to	  unrelated	  donors.	  This	  would	  include	  a	  phone	  call	  at	  2-­‐3	  days	  post-­‐donation,	  a	  survey	  monkey	  health	  questionnaire	  at	  7	  days	  post	  donation,	  and	  then	  a	  health	  questionnaire	  annually	  for	  the	  next	  five	  years,	  one	  at	  year	  six	  and	  eight	  and	  finally	  at	  year	  ten.	  	  
At	  the	  time	  of	  donor	  medical,	  donors	  would	  be	  given	  a	  one-­‐page	  information	  sheet/consent	  form	  outlining	  the	  follow	  up	  process.	  By	  signing	  this	  consent	  they	  would	  agree	  to	  data	  transfer	  and	  follow	  up	  by	  Anthony	  Nolan.	  	  
Related	  donors	  would	  not	  receive	  any	  other	  type	  of	  communication	  from	  Anthony	  Nolan	  such	  as	  fundraising	  information.	  	  
Any	  medical	  issues	  identified	  during	  follow	  up	  would	  be	  discussed	  within	  the	  medical	  team	  at	  Anthony	  Nolan.	  In	  the	  event	  of	  donors	  reporting	  any	  complications	  felt	  to	  be	  directly	  related	  to	  stem	  cell	  donation,	  the	  Anthony	  Nolan	  medical	  officers	  would	  liaise	  with	  the	  clinical	  team	  at	  King’s	  to	  discuss	  whether	  any	  further	  action	  is	  required.	  	  










Figure S5. Proposal for follow-up of Nottingham University Hospital related HPC donors by 
Anthony Nolan 
PROPOSAL	  FOR	  FOLLOW	  UP	  OF	  NUH	  RELATED	  DONORS	  BY	  ANTHONY	  NOLAN	  	  
Introduction/Background	  In	  order	  to	  identify	  health	  issues	  related	  to	  donation	  procedures	  or	  stem	  cell	  mobilization,	  it	  is	  vital	  to	  monitor	  the	  health	  of	  stem	  cell	  donors	  post-­‐donation.	  Donor	  follow	  up	  has	  now	  become	  a	  JACIE	  requirement,	  but	  it	  can	  be	  logistically	  difficult	  for	  transplant	  centres	  to	  achieve	  follow	  up	  measures.	  Furthermore,	  centralised	  recording	  of	  this	  follow	  up	  data	  for	  both	  related	  and	  unrelated	  donors	  is	  necessary	  if	  we	  are	  to	  improve	  our	  understanding	  of	  donation	  risks.	  	  	  	  Anthony	  Nolan	  has	  an	  established	  process	  of	  donor	  follow	  up	  for	  unrelated	  donors,	  and	  we	  propose	  to	  undertake	  a	  pilot	  study	  extending	  this	  process	  to	  related	  donors.	  	  	  	  
Aims	  of	  pilot	  study	  To	  explore	  the	  logistics	  of	  related	  donor	  follow	  up	  by	  Anthony	  Nolan	  and	  ensure	  acceptability	  to	  transplant	  teams	  and	  related	  donors.	  	  	  
Logistics	  Related	  donors	  would	  be	  seen	  and	  undergo	  assessment	  and	  donation	  as	  per	  current	  practice	  at	  Nottingham	  University	  Hospitals	  NHS	  Trust.	  At	  the	  time	  of	  donor	  medical,	  donors	  would	  be	  given	  an	  information	  sheet/consent	  form	  outlining	  this	  pilot	  study	  and	  the	  follow	  up	  process.	  By	  signing	  this	  consent	  they	  would	  agree	  to	  data	  transfer	  and	  follow	  up	  by	  Anthony	  Nolan.	  	  	  Following	  donation,	  the	  transplant	  coordinator	  from	  the	  NUH	  would	  contact	  the	  donor	  once	  at	  2-­‐3	  days	  post-­‐donation	  to	  ensure	  no	  immediate	  complications	  have	  occurred.	  The	  ‘referral	  for	  family	  donor	  follow	  up’	  form	  would	  then	  be	  completed	  and	  sent	  with	  the	  consent	  to	  follow	  up	  to	  Anthony	  Nolan	  Team	  Support	  on	  the	  day	  of,	  or	  after	  donation.	  	  	  After	  this	  point,	  related	  donors	  would	  receive	  identical	  follow	  up	  to	  Anthony	  Nolan	  unrelated	  donors,	  with	  a	  survey	  monkey	  health	  questionnaire	  at	  7	  days	  post	  donation,	  a	  further	  questionnaire	  at	  1	  month,	  and	  then	  a	  health	  questionnaire	  annually	  for	  the	  next	  five	  years,	  one	  at	  year	  six	  and	  eight	  and	  finally	  at	  year	  ten.	  The	  follow	  up	  questionnaires	  would	  include	  asking	  whether	  the	  donor	  would	  be	  willing	  to	  undergo	  a	  further	  donation	  to	  their	  relative	  if	  requested.	  	  	  Related	  donors	  would	  not	  receive	  any	  other	  type	  of	  communication	  from	  Anthony	  Nolan	  such	  as	  fundraising	  information.	  	  	  Any	  medical	  issues	  identified	  during	  follow	  up	  would	  be	  discussed	  within	  the	  medical	  team	  at	  Anthony	  Nolan.	  In	  the	  event	  of	  donors	  reporting	  any	  complications	  felt	  to	  be	  directly	  related	  to	  stem	  cell	  donation,	  the	  Anthony	  Nolan	  medical	  officers	  would	  report	  complications	  to	  the	  clinical	  team	  at	  NUH	  with	  a	  joint	  discussion	  regarding	  any	  further	  action	  required.	  	  	  
Study	  period	  




We	  propose	  to	  undertake	  recruitment	  to	  this	  pilot	  study	  over	  a	  one-­‐year	  period	  to	  begin	  at	  a	  mutually	  agreed	  time-­‐point.	  All	  related	  donors	  donating	  at	  NUH	  within	  this	  period	  would	  be	  invited	  to	  participate	  and	  each	  of	  these	  donors	  would	  receive	  follow	  up	  by	  Anthony	  Nolan	  for	  the	  full	  ten-­‐year	  follow	  up	  period.	  	  	  If	  successful,	  this	  follow	  up	  pathway	  could	  in	  the	  future	  be	  offered	  to	  transplant	  centres	  nationally.	  	  	  
























Figure S6. Request for family donor follow up at Anthony Nolan 
 




Figure S7. Donor information and consent for related donor follow-up pilot study 
 











Figure S8. Standard operating procedure for family donor follow-up at Anthony Nolan 
 
 



























Figure S9. Day 7 follow-up questionnaire for pilot study of related donors followed up by 
Anthony Nolan
 
























Figure S10. Annual follow-up questionnaire for pilot study of related donors followed up by 
Anthony Nolan
 















Figure S11.  Survey questionnaire sent to related donors to evaluate experience of the donation 
pathway at The Royal Marsden
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